Document:

EX-10.13

 Exhibit 10.13 
  

 
  

***Text Omitted and Filed Separately with the Securities and Exchange Commission 

Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 

EXECUTION VERSION 

LICENSE AGREEMENT 

THIS LICENSE AGREEMENT (the
“Agreement”) is made and entered into as of September 27th , 2012 (the “Effective Date”) by and between LUMENA
PHARMACEUTICALS, INC, a company with limited liability organized under the laws of Delaware, USA, having a place of business at 2520 Meridian Parkway, Suite 400, Durham, NC 27713, USA
(“Lumena”), and SANOFI-AVENTIS DEUTSCHLAND GMBH, a company organized under the laws of Germany with its principal place of business at 65926 Frankfurt am Main,
Germany (“Sanofi”). Lumena and Sanofi are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. 

RECITALS 

A.        Sanofi controls certain intellectual property related to its BARI (Bile Acid
Reabsorption Inhibitor) program and, in particular, a proprietary compound designated as SAR-548304. 

B.        Lumena is a privately-held biotechnology company focused on developing treatments for
metabolic diseases. 
 C.        Lumena desires to acquire an exclusive worldwide license
under Sanofi’s intellectual property related to SAR-548304 to develop, manufacture and commercialize Licensed Products containing SAR-548304 for the treatment or prevention of metabolic disease(s), and Sanofi is willing to grant such a license
to Lumena, on the terms and conditions set forth herein. 
 NOW, THEREFORE, in
consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties agree as follows: 
  

	1.	DEFINITIONS 

 Capitalized terms used in this Agreement (other than the headings of the
Sections or Articles) have the following meanings set forth in this Article 1, or, if not listed in this Article 1, the meanings as designated in the text of this Agreement. 

1.1      “Affiliate” means, with respect to a particular Party, a
person, corporation, partnership, or other entity that controls, is controlled by or is under common control with such Party. For the purposes of the definition in this Section 1.1, the word “control” (including, with
correlative meaning, the terms “controlled by” or “under the common control with”) means the actual power, either directly or indirectly through one (1) or more intermediaries, to direct or cause the direction
of the management and policies of such entity, whether by the ownership of at least fifty percent (50%) of the voting stock of such entity, or by contract or otherwise. 

1.2      “CMC Activities” means the activities necessary or useful for
generating the Information related to the chemistry, manufacturing and controls of Compound or Licensed Product, required for the Regulatory Approval of Licensed Products, as specified by the FDA or other applicable Regulatory Authority. 

1.3      “Combination Product” means either: (a) any pharmaceutical
product that consists of a Compound and at least one other active ingredient that is not a Compound; or (b) any combination of a Licensed Product and another pharmaceutical product that contains at least one other active ingredient that is not
a Compound where such products are not formulated together but are sold together and invoiced as one product. 

 1.4      “Commercialize”
means to promote, market, distribute, sell, offer for sale, contract to sell or import Compound and Licensed Product. For clarity, “Commercializing” and “Commercialization” have a correlative meaning. 

1.5      “Compound” means SAR-548304 and [...***...]. 

1.6      “Confidential Information” of a Party means any and all
Information of such Party that is disclosed to the other Party under this Agreement, whether in oral, written, graphic, or electronic form. 

1.7      “Controlled” means, with respect to any compound, material,
Information or intellectual property right, that the Party owns or has a license to such compound, material, Information or intellectual property right and has the ability to grant to the other Party access, a license or a sublicense (as applicable)
to such compound, material, Information or intellectual property right as provided for herein without violating the terms of any agreement or other arrangements with any Third Party existing at the time such Party would be first required hereunder
to grant the other Party such access, license or sublicense. 

1.8      “Develop” or “Development” means, with respect
to Compounds and Licensed Products, all activities relating to preparing and conducting non-clinical studies and other analyses, clinical studies, and regulatory activities (e.g., preparation and submission of regulatory applications) that
are necessary or useful to obtain or maintain Regulatory Approval of Licensed Products, excluding the CMC Activities, the manufacture of Compound and the Manufacture of Licensed Product. 

1.9      “Diligent Efforts” means, with respect to Lumena’s
obligations under this Agreement, the carrying out of such obligations or tasks with a level of efforts and resources consistent with the commercially reasonable practices of a similarly situated company in the pharmaceutical industry for the
research, development or commercialization of a similarly situated pharmaceutical product as the Licensed Product at a similar stage of development or commercialization, taking into account efficacy, safety, patent and regulatory exclusivity,
anticipated or approved labeling, present and future market potential, competitive market conditions, the profitability of the Licensed Product in light of pricing and reimbursement issues, and all other relevant factors. Diligent Efforts shall be
determined on a market-by-market and indication-by-indication basis, and it is anticipated that the level of efforts required shall be different for different markets and indications and shall change over time, reflecting changes in the status of
the Licensed Product and markets involved. 
 1.10      “Dollars” or
“$” means the legal tender of the U.S. 

1.11      “EMA” means the European Medicines Agency or any successor
entity. 
 1.12      “EU” means the European Union, as its membership
may be altered from time to time, and any successor thereto. 

1.13      “Executive Officers” means the Chief Executive Officer of
Lumena and the President of Global Research & Development for Sanofi, or such other person (of similar seniority within Sanofi) designated by Sanofi from time to time. 

1.14      “FDA” means the United States Food and Drug Administration,
and any successor thereto. 

  
 2 

 1.15     “Field” means any
therapeutic or prophylactic application in human (but not animal) health. 

1.16     “First Commercial Sale” means, with respect to a Licensed Product in
a particular country, the first commercial sale of such Licensed Product in such country after all needed Regulatory Approvals have been obtained in such country. 

1.17     “GAAP” means United States generally accepted accounting principles
consistently applied. 
 1.18     “Governmental Authority” means any
multi-national, federal, state, local, municipal, provincial or other government authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court or other
tribunal). 
 1.19     “IFRS” means International Financial Reporting
Standards, as they exist from time to time, consistently applied. 

1.20     “Indication” means any disease or condition which could be listed
under the header “INDICATIONS AND USAGE” or described under the header “CLINICAL STUDIES” of a Licensed Product’s label upon Regulatory Approval in the United States, or equivalent thereof. 

1.21     “Initiation” of a clinical trial means the first randomization of a
subject enrolled in such clinical trial. 
 1.22     “Information” means
all information, techniques, technology, practices, trade secrets, inventions (whether patentable or not), methods, knowledge, know-how, skill, experience, data, results (including pharmacological, toxicological and clinical test data and results),
analytical and quality control data, results or descriptions, software and algorithms. 

1.23     “Knowledge” means, with respect to a Party, the good faith
understanding of the facts and information in the possession of an officer of such Party, or any in-house legal counsel of, or in-house patent agents employed by, such Party or its Affiliates, without any duty to conduct any additional investigation
with respect to such facts and information by reason of the execution of this Agreement. For purposes of this definition, an “officer” means any person in the position of vice president, senior vice president, president or chief
executive officer of a Party. 
 1.24     “Laws” means all laws, statutes,
rules, regulations, ordinances and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision, domestic or foreign. 

1.25     “Licensed Product” means any pharmaceutical product in any dosage
strength or formulation containing a Compound, either alone or in combination with other agents. 

1.26     “Major Markets” means [...***...]. 

1.27     “Manufacturing” means all activities related to Licensed Product
manufacture, formulation, processing, filling, finishing, packaging, labeling, inspection, receiving, including holding and shipping of Compound, Licensed Products, or any raw materials or packaging materials with respect thereto, or any
intermediate of any of the foregoing, and including process and cost optimization, process development, qualification and validation, equipment and facility qualification and validation, 

  
 3 

 
commercial manufacture of Licensed Product, stability and release testing, quality assurance and quality control, and CMC Activities with respect to Licensed Product, but excluding the
manufacture of Compound and CMC Activities with respect to the Compound. For clarity, “Manufacture” has a correlative meaning. 

1.28     “Marketing Authorization Application” or “MAA”
means: (a) in the United States, a New Drug Application (as defined in Title 21, Section 314.50 et seq. of the U.S. Code of Federal Regulations) or any supplement to a New Drug Application, and (b) in any other country or regulatory
jurisdiction, an equivalent application for regulatory approval required before commercial sale or use of a Licensed Product (or with respect to a subsequent indication) in such country or regulatory jurisdiction. 

1.29     “MHLW” means the Japanese Ministry of Health, Labour and Welfare or
any successor entity. 
 1.30     “MTA” means that Material Transfer
Agreement between Sanofi-Aventis Deutschland GmbH and Lumena dated January 24, 2012. 

1.31     “Net Sales” means, with respect to a given period of time, the gross
amount invoiced by Lumena and its Affiliates and their sublicensees and subcontractors to Third Party purchasers from the sale or distribution to such Third Parties of the Licensed Product, less the following deductions and offsets that are actually
incurred, allowed, accrued and/or taken and are specifically allocated with respect to such sale or distribution, but solely to the extent that such deductions or offsets are not otherwise recovered by or reimbursed to Lumena or its Affiliates, and
their sublicensees and subcontractors: 
 (a)     [...***...] 

(b)     [...***...] 

(c)     [...***...] 

(d)     [...***...] 

(e)     [...***...] 

The methodology for calculating (a) – (e), on a country-by-country basis, shall conform to GAAP or IFRS consistently
applied by Lumena. 
 Net Sales shall also include the fair market value of all consideration received by Lumena and its

  
 4 

 
Affiliates and their sublicensees and subcontractors in respect of any sale of Licensed Product to Third Party end-users, whether such consideration is in cash, payment in kind, exchange for
value or another form. 
 If any discounts or other deductions or rebates are made in connection with sales of a Licensed
Product that is bundled or sold together with other products of Lumena, its Affiliates or their sublicensees and subcontractors, then the discount, deduction or rebate applied to the Licensed Product shall not exceed the discount, deduction or
rebate applied to any of the other products of Lumena, its Affiliates or their sublicensees and subcontractors in such arrangement based upon the respective list prices of the Licensed Product and such other products prior to applying the discount,
unless Lumena provides evidence reasonably satisfactory to Sanofi that such difference is commercially reasonable and does not unfairly prejudice the Licensed Product in favor of such other products. 

For Licensed Products which are sold as Combination Products, the Net Sales for such Combination Products shall be adjusted by
multiplying the actual Net Sales by the fraction A/(A+B) where A is [...***...], and B is [...***...], if such other active product or product component is sold separately. If the other product or product component is not sold
separately, then the actual Net Sales shall be adjusted by multiplying the actual Net Sales by the fraction A/C where A is [...***...], and C is [...***...]. If neither of the foregoing applies, then the Parties shall determine the Net
Sales of the Combination Product in good faith based on the respective values of the components of such Combination Product. In the event the Parties are not able to reach agreement, Net Sales for such Combination Product shall be determined by an
expert jointly appointed by the parties, with such determination to be based on the respective values of the components of such Combination Product. The decision of the expert shall be final and binding on the Parties and the fees of the expert
shall be equally shared between the Parties. 
 1.32     “Patent” means
all: (a) unexpired letters patent (including inventor’s certificates) which have not been held invalid or unenforceable by a court of competent jurisdiction from which no appeal can be taken or has been taken within the required time
period (and which have not been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise, or been abandoned in accordance with or as permitted by the terms of this Agreement or by mutual written agreement), including any
substitution, extension, registration, confirmation, validation, reissue, re-examination, supplementary protection certificates, confirmation patents, patent of additions, renewal or any like filing thereof; (b) pending applications for letters
patent which have not been canceled, withdrawn from consideration, finally determined to be unallowable by the applicable governmental authority or court for whatever reason (and from which no appeal is or can be taken), and/or abandoned in
accordance with or as permitted by the terms of this Agreement or by mutual written consent, including any continuation, division or continuation-in-part thereof and any provisional applications; and (c) any United States and international
counterparts to any of (a) and (b) above. 
 1.33     “Phase 2b Clinical
Trial” means a study of a Licensed Product in the Field in human patients to determine initial efficacy, pharmacological effect, or dose range and/or regimen finding before embarking on Phase 3 Clinical Trial, as further defined in 21
C.F.R. 312.21(b), as amended from time to time, or the corresponding foreign regulations. 

1.34     “Phase 3 Clinical Trial” means a pivotal study (whether or not
denominated a “Phase 3” 

  
 5 

 
clinical study under applicable regulations) in the Field in human patients with a defined dose or a set of defined doses of a Licensed Product designed to ascertain efficacy and safety of such
Licensed Product for the purpose of enabling the preparation and submission of Marketing Authorization Applications to the competent Regulatory Authorities in a country of the Territory, as further defined in 21 C.F.R. 312.21(c), as amended from
time to time, or the corresponding foreign regulations. 
 1.35     “Phase 4
Clinical Trial” means a Licensed Product support clinical trial of a Licensed Product that is commenced after receipt of Regulatory Approval in the country where such trial is conducted. A Phase 4 Clinical Trial may include epidemiological
studies, modeling and pharmacoeconomic studies, “post-marketing surveillance trials” and investigator-sponsored clinical trials, but excludes clinical trials conducted for the purposes of label expansion or Regulatory Approval. 

1.36     “Regulatory Approval” means any and all approvals (including
supplements, amendments, pre- and post-approvals, pricing and reimbursement approvals), licenses, registrations or authorizations of any national, supra-national (e.g., the European Commission or the Council of the EU), regional, state or
local regulatory agency, department, bureau, commission, council or other governmental entity, that are necessary for the manufacture, distribution, use or sale of a Licensed Product in a regulatory jurisdiction. 

1.37     “Regulatory Authority” means the applicable national (e.g.,
the FDA), supra-national (e.g., the European Commission or the Council of the EU), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity that, in each case, governs the approval of a
Licensed Product in such applicable regulatory jurisdiction. 
 1.38     “Regulatory
Materials” means regulatory applications, submissions, notifications, registrations, Regulatory Approvals and/or other filings made to or with, or other approvals granted by, a Regulatory Authority that are necessary or reasonably desirable
in order to Develop, Manufacture, market, sell or otherwise Commercialize a Licensed Product in a particular country or regulatory jurisdiction. 

1.39     “Sanofi Know-How” means (i) all documents and materials listed
on Exhibit 1.39 or not listed but subsequently provided by Sanofi or its Affiliates to Lumena, and in each case, the Information Controlled by Sanofi or its Affiliates contained or embodied in such documents and materials, (ii) the
Initial Manufacturing Know-How which Sanofi provides to Lumena in accordance with Section 4.2, and (iii) all Information generated by Lumena under the MTA which is owned by Sanofi or its Affiliates pursuant to the terms of such MTA. For
clarity, the Sanofi Know-How does not include any Sanofi Manufacturing Know-How or other Information not contained or embodied in the documents and materials listed on Exhibit 1.39, including Information contained in any document referred to or
cited in a document listed on Exhibit 1.39 (unless such Information is also contained in a document listed on Exhibit 1.39). 

1.40     “Sanofi Patents” means, (i) those Patents listed on Exhibit
1.40 and (ii) any Patents Controlled by Sanofi or its Affiliates, claiming inventions within Sanofi Know-How, and for each of (i) and (ii) above, any foreign counterparts, continuations, divisionals, provisionals, extensions,
reissues, registrations, patents, registrations and/or confirmations of such Patents. Exhibit 1.40 may be updated from time-to-time during the Term upon the mutual written agreement of the Parties. 

1.41     “Sanofi Manufacturing Know-How” means any written documentation and
the Information contained therein, that is (i) Controlled by Sanofi or its Affiliates and (ii) related to CMC Activities with respect to Compound and/or manufacture of Compound (and for clarity, not also related to Manufacture), in each
case to the extent Sanofi considers, in its discretion, that such documentation and 

  
 6 

 
Information is necessary or reasonably useful for Lumena to manufacture Compound for the purposes of using, Developing, Manufacturing, having Manufactured and Commercializing Compounds and
Licensed Products in accordance with this Agreement. 
 1.42     “Sanofi
Technology” means the Sanofi Patents and the Sanofi Know-How. 

1.43     “Series A-1 Preferred Stock” means the class of preferred stock of
Lumena having the rights set forth on Exhibit 1.43. 
 1.44     “Series A
Preferred Stock Financing” means Lumena’s first issuance of Series A Preferred Stock in an equity financing transaction. 

1.45     “Territory” means all countries in the world. 

1.46     “Third Party” means any person or entity other than:
(a) Lumena; (b) Sanofi; or (c) an Affiliate of either Party. 

1.47     “U.S.” means the United States of America, including all possessions
and territories thereof. 
 1.48     “Valid Claim” means (a) a claim
in an issued Patent that has not: (i) expired or been canceled; (ii) been declared invalid by an unreversed and unappealable or unappealed decision of a court or other appropriate body of competent jurisdiction; (iii) been admitted to
be invalid or unenforceable through reissue, disclaimer or otherwise; or (iv) been abandoned in accordance with or as permitted by the terms of this Agreement or by mutual written agreement of the Parties; or (b) a claim under an
application for a Patent that has been pending for not more than [...***...] and has not been canceled, withdrawn from consideration, finally determined to be unallowable by the applicable governmental authority or court for whatever reason
(and from which no appeal is or can be taken), or abandoned. 
 1.49     Additional
Definitions. Each of the following definitions is set forth in the section of the Agreement indicated below: 
  

			
	 Definition

 
	  	
Section
  

	“Acquiror”	  	12.4
	“Additional Existing Materials”	  	4.3(a)
	“Additional New Materials”	  	5.1
	“Agreement”	  	Preamble
	“Alliance Manager”	  	4.1
	“Change in Control”	  	2.8(d)
	“Charter”	  	9.2(a)
	“Claims”	  	10.1(a)
	“Commercial Supply Agreement”	  	5.2
	“Commercialization Plan”	  	4.8
	“Competing Product”	  	2.9
	“Compound Manufacturing Option”	  	2.2
	“Development Candidate”	  	2.8(a)
	“Development Plan”	  	4.4

  
 7 

			
	“Effective Date”	  	Preamble        
	“Evaluation Period”	  	2.8(a)
	“Expression of Interest”	  	2.8(a)
	“FCPA”	  	4.10
	“Generic Entry”	  	3.5(e)
	“ICC”	  	11.3
	“Indemnified Party”	  	10.1(b)
	“Indemnifying Party”	  	10.1(b)
	“Initial Manufacturing Know-How”	  	4.2
	“Initial Materials”	  	4.2
	“Lumena”	  	Preamble        
	“Lumena Intellectual Property”	  	6.1
	“Lumena Patents”	  	6.2(b)
	“Lumena Witholding Tax Action”	  	3.10(c)
	“Manufacturing Notice”	  	2.2
	“Market Share”	  	3.5(e)
	“Negotiation Period”	  	2.8(b)
	“Party” and “Parties”	  	Preamble
	“Pre-Commercial Supply Agreement”	  	5.2
	“Product Infringement”	  	6.3(a)
	“Product Marks”	  	4.9
	“Program Transaction”	  	2.8(a)
	“Proposal”	  	2.8(a)
	“RFP”	  	2.7
	“Right of First Negotiation”	  	2.8
	“Royalty Term”	  	3.5(b)
	“Safety Failure”	  	8.5
	“Sanofi”	  	Preamble
	“Sanofi Indemnitees”	  	10.1(a)
	“SEC”	  	7.4(b)
	“Second Negotiation”	  	2.8(b)
	“Securities Act”	  	9.3(c)
	“Series A Agreements”	  	3.2(a)
	“Specifications”	  	4.2
	“Supply Agreements”	  	5.2
	“Term”	  	8.1
	“Third Party License”	  	3.5(d)
	“Third Party Compound Claim”	  	3.5(d)

  

	2.	LICENSES AND RELATED RIGHTS 

2.1     License Grant.  Subject to the terms and conditions of this Agreement,
Sanofi and its Affiliates hereby grant Lumena during the Term an exclusive (even as to Sanofi, but subject to Section 2.4), worldwide, royalty-bearing license, with the right to sublicense through multiple tiers as provided in Section 2.3,
under the Sanofi Technology to: (i) use, Develop and Commercialize Compounds and Licensed Products; (ii) Manufacture and, subject to Section 2.3, have Manufactured Licensed Products 

  
 8 

 
and (ii) to perform Lumena’s obligations under this Agreement, in each case in the Field and in the Territory. For clarity, the license granted to Lumena under this Section 2.1
does not include the right to manufacture Compound or perform CMC Activities with respect to Compound. 

2.2     Compound Manufacturing Option.  Subject to the terms and conditions of this
Agreement, Sanofi and its Affiliates hereby grant Lumena during the Term the exclusive option to obtain an exclusive license to manufacture Compound (the “Compound Manufacturing Option”). The Compound Manufacturing Option may be
exercised by Lumena at any time during the Term upon written notice to Sanofi (the “Manufacturing Notice”). Upon Lumena’s exercise of the Compound Manufacturing Option in accordance with this Section 2.2, Sanofi
(i) shall and hereby does grant to Lumena an exclusive (even as to Sanofi except as provided in any Supply Agreement still in effect at such time, but subject to Section 2.4), worldwide, royalty-bearing license, with the right to
sublicense as provided in Section 2.3, under the Sanofi Technology and Sanofi Manufacturing Know-How, to manufacture Compound and perform CMC Activities with respect to Compound in the Field in the Territory and (ii) will provide Lumena
with the Sanofi Manufacturing Know-How in accordance with Section 5.3. 

2.3     Sublicensing; Subcontracting.  Lumena shall have the right to grant
sublicenses of the license granted to it under Section 2.1 and any license granted to it under Section 2.2, or otherwise subcontract its activities with respect to Compounds or Licensed Products, to its Affiliates and, subject to
Sanofi’s Right to Bid under Section 2.7 and Right of First Negotiation under Section 2.8 below, any Third Party, provided that: (i) Lumena shall remain responsible for the compliance with this Agreement by any such sublicensee
and subcontractor; (ii) each such sublicense and subcontract agreement shall be consistent with the terms and conditions of this Agreement; (iii) Lumena shall ensure that it obtains ownership and/or licenses and/or rights to all inventions
and Information (including all data, know-how, inventions, Regulatory Materials and Regulatory Approvals) generated by such sublicensee or subcontractor under such agreement that are related to the Licensed Product and are necessary or reasonably
useful to Develop or Commercialize Licensed Products, sufficient to enable Lumena to grant the rights granted to Sanofi hereunder, including Sanofi’s rights under Section 8.6; and (iv) if this Agreement terminates other than for
breach by Sanofi, upon request by Sanofi, Lumena will either assign its rights and obligations under such sublicense or subcontract agreement to Sanofi or terminate such sublicense or subcontract agreement. 

2.4     Retained Rights.  It is understood that at all times Sanofi and its
Affiliates retain the right to: (i) practice the Sanofi Technology outside the scope of the license granted to Lumena in Section 2.1 and any license granted to Lumena under Section 2.2; and (ii) make and use Compounds as tool
compounds for internal research purposes, provided that Sanofi shall, upon Lumena’s written request (which requests shall be made no more than once per calendar year), provide to Lumena a reasonably detailed written summary of the results of
any such internal research, to the extent such results relate to the use of Compounds as inhibitors of Apical Sodium Dependent Bile Acid Transporter (ASBT). It is further understood that at all times prior to Lumena’s exercise of the Compound
Manufacturing Option, Sanofi and its Affiliates retain the exclusive right to manufacture Compound and to perform CMC Activities with respect to Compound, for the benefit of Lumena. 

2.5     Negative Covenant.  Lumena covenants that it will not and will not permit
any of its Affiliates or sublicensees or subcontractors to use or practice any Sanofi Technology outside the scope of the license granted to it under Section 2.1 and any license granted to it under Section 2.2. Except as permitted under
Section 2.4, Sanofi covenants that it will not and will not permit any of its Affiliates (i) to use or practice Sanofi Technology to Develop or Commercialize Compounds or Licensed Products, or to manufacture Compound other than for the
benefit of Lumena or for use by Sanofi as permitted under Section 2.4(ii), Manufacture Licensed Products (other than for the benefit of Lumena), or (ii) if Lumena 

  
 9 

 
exercises its Compound Manufacturing Option, to use or practice Sanofi Technology to manufacture Compound, or (iii) assign or license to any Third Party any rights under Sanofi Technology to
Develop or Commercialize Compounds or Licensed Products, or to develop or commercialize [...***...], in each case in the Field in the Territory. 

2.6     No Implied Licenses.  Except as explicitly set forth in this Agreement,
neither Party shall be deemed by estoppel or implication to have granted the other Party any license or other right to any intellectual property of such Party. 

2.7     Right to Bid.  If at any time after Initiation of the first Phase 3 Clinical
Trial of a Licensed Product, Lumena or any of its Affiliates wishes to subcontract any rights granted to Lumena under Section 2.1 to Manufacture Licensed Products, then Lumena shall deliver to Sanofi a request for proposal containing a written
description of the activities intended to be subcontracted (the “RFP”). If Sanofi wishes to enter into negotiations with Lumena regarding the terms on which Sanofi might provide the services described in the RFP, then, within
[...***...] after Sanofi’s receipt of the RFP, or within any longer period mutually agreed in writing between the Parties, Sanofi shall so notify Lumena in writing and in Lumena’s discretion, Lumena and Sanofi may enter into
negotiations of the terms under which Sanofi may provide such services. For clarity, nothing in this Section 2.7 will obligate Lumena to negotiate with Sanofi or enter into an agreement with Sanofi for the services described in the RFP. 

2.8     Right of First Negotiation.  During the Term, neither Lumena nor any of its
Affiliates shall assign or sublicense any rights granted to Lumena under Section 2.1 to Commercialize Licensed Products, to any Third Party, without first providing Sanofi with the opportunity, in accordance with this Section 2.8, to
assume such assignment or sublicense (the “Right of First Negotiation”). 

(a)     Evaluation Period.  If at any time during the Term Lumena or any of its
Affiliates wishes to enter into a Program Transaction then Lumena shall deliver to Sanofi (i) a reasonably detailed written description of the proposed Program Transaction (the “Proposal”) and (ii) a reasonably detailed
written summary of all data and results produced by Lumena or its Affiliates, sublicensees or subcontractors, as applicable, with respect to the Licensed Products which would be necessary or reasonably useful for Sanofi’s evaluation of the
Proposal. If Sanofi wishes to enter into negotiations with Lumena regarding the terms on which Sanofi might assume any such Proposal, then, within [...***...] after Sanofi’s receipt of such Proposal, or within any longer period mutually
agreed in writing between the Parties (the “Evaluation Period”), Sanofi shall so notify Lumena in writing (the “Expression of Interest”). For the purposes of this Section 2.8, a “Program
Transaction” means an assignment, transfer or sublicense to a Third Party (or the grant of an option to a Third Party to obtain an assignment, transfer or sublicense) of any rights granted to Lumena under Section 2.1 to Commercialize
Licensed Products, either alone or as part of an assignment of all of Lumena’s rights and obligations under this Agreement wherein the assignment of all of Lumena’s rights and obligations under this Agreement comprises substantially all of
the assets of the transaction. For clarity and by way of example, a transaction which includes an assignment by Lumena of all of its rights and obligations under this Agreement and rights with respect to a Lumena Development Candidate is not a
Program Transaction. “Development Candidate” means a compound in development by or on behalf of Lumena which is undergoing or has undergone GLP toxicology studies. 

(b)     Negotiation Period.  If Lumena receives Sanofi’s Expressions of
Interest with respect to a Proposal within the Evaluation Period in accordance with Section 2.8(a), then the Parties shall promptly enter into good faith negotiations on the principal terms of a separate written agreement under which Sanofi
would assume such Proposal. Such negotiations shall include at least [...***...] negotiation [...***...] (held in person, or by video conference or telephone conference), in which the Parties shall identify and attempt in good faith to
resolve any points of disagreement on such principal terms. If (i) 

  
 10 

 
Lumena does not receive Sanofi’s Expression of Interest with respect to a Proposal within the Evaluation Period or (ii) the Parties fail to reach agreement on the principal terms under
which Sanofi would assume such Proposal within [...***...] after Sanofi’s Expressions of Interest, or within any longer period mutually agreed in writing between the Parties (the “Negotiation Period”), then Lumena may
enter into a definitive agreement with any Third Party with respect to such Proposal, provided, however, that, Lumena may not, for a period of [...***...] immediately following expiry of the Negotiation Period, enter into a definitive
agreement with respect to such Proposal with any Third Party containing terms which when taken together are materially more favorable to such Third Party than the principal terms last proposed to Sanofi pursuant to this Section 2.8(b) without
first notifying Sanofi in writing of such more favorable terms. If, after receiving notice of such more favorable terms, Sanofi wishes to assume such Proposal on such more favorable terms, then Sanofi shall so notify Lumena in writing and the
Parties shall promptly enter into good faith negotiations on the principal terms of a separate written agreement under which Sanofi would assume such Proposal (the “Second Negotiation”), which negotiations shall include at least
[...***...] negotiation [...***...] (held in person, or by video conference or telephone conference). If Sanofi and Lumena fail to enter into an agreement under which Sanofi would assume such Proposal within [...***...] after the
start of the Second Negotiation, Lumena will be free to enter into a definitive agreement with any Third Party with respect to the subject matter of the Proposal on any terms without further obligation to Sanofi. 

(c)     Due Diligence.  At any time during the Evaluation Period or the Negotiation
Period, Sanofi may request that Lumena provide Sanofi with Information relating to Compounds and Licensed Products produced by Lumena or its Affiliates or sublicensees, as applicable, which is necessary for Sanofi’s evaluation of the Proposal,
and Lumena shall, at Lumena’s cost and expense, promptly provide such Information to Sanofi. 

(d)     Application of First Right of Negotiation.  Sanofi’s Right of First
Negotiation shall apply on a Proposal-by-Proposal basis and Lumena shall deliver to Sanofi a Proposal pursuant to Section 2.8(a) each time during the Term Lumena or any of its Affiliates wishes to enter into a Program Transaction.
Notwithstanding the above, in the event of a Change in Control of Lumena, Sanofi’s Right to Bid under Section 2.7 shall [...***...] and this Section 2.8 shall be [...***...]. For the purposes of this Agreement,
“Change in Control” means (a) a sale, lease, license or other disposition of all or substantially all of the assets of Lumena (other than pursuant to a Program Transaction); (b) any consolidation or merger of Lumena with
or into any other corporation or other entity or person, or any other corporate reorganization, in which the capital stock of Lumena immediately prior to such consolidation, merger or reorganization represents less than fifty percent (50%) of
the voting power of the surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such consolidation, merger or reorganization; or (c) any transaction or series of related transactions to which
Lumena is a party in which in excess of fifty percent (50%) of Lumena voting power is transferred; provided that a change of control will not include (i) any consolidation or merger effected exclusively to change the domicile of Lumena, or
(ii) any transaction or series of transactions principally for bona fide equity financing purposes in which cash is received by Lumena or any successor, or indebtedness of Lumena is cancelled or converted, or a combination thereof. 

(e)     Proposed Change in Control.  In the event that Lumena’s board of
directors determines to explore a potential Change in Control transaction and engages in an internally led or investment banker (or similar advisor) led process with respect thereto, Lumena will provide Sanofi with the opportunity to participate in
such process. In the event that Lumena, other than pursuant to the process described in the preceding sentence, receives a Third Party proposal regarding a Change in Control transaction, Lumena will, as soon as reasonably practicable, inform Sanofi
of such Third Party proposal and afford Sanofi, prior to the proposed Change in Control, an opportunity, reasonable in the 

  
 11 

 
circumstances, to provide a proposal with respect to such Change in Control. For clarity, the Parties agree that a period of [...***...] would be a reasonable opportunity in any
circumstance. 
 2.9     Exclusivity. 

(a)     Lumena agrees that for the three (3) year period after the First Commercial Sale
of a Licensed Product, on a Licensed Product-by-Licensed Product basis, except for the Commercialization of Licensed Products pursuant to this Agreement, Lumena and its Affiliates (excluding any Acquirer or Acquirer Affiliates as provided in
Section 2.9(b)) shall not (either through its own efforts or with an Affiliate or Third Party sublicensee or subcontractor) commercialize any Competing Product. As used herein, a “Competing Product” means any compound being
commercialized for any [...***...] Indication for which Licensed Product is being commercialized hereunder, and whose method of action is to reduce the reabsorption of bile acids in the intestinal tract. 

(b)     In the event of a Change in Control of Lumena, the exclusivity provisions in
Section 2.9(a) shall [...***...] to the extent that such [...***...] is developing or commercializing (alone or with a Third Party) a Competing Product; provided that (i) such [...***...] do not obtain rights or access
(other than access in connection with due diligence prior to the Change in Control transaction or customary internal company reporting) to any Confidential Information of Sanofi or the Sanofi Technology; (ii) the [...***...] development
and commercialization activities related to such Competing Product are kept separate from the Development, and Commercialization activities for Compounds and Licensed Products under this Agreement; and (iii) Lumena otherwise continues to meet
its obligations under this Agreement. 
  

	3.	COMPENSATION 

 3.1     Upfront
Payment.  Within five (5) business days after the Effective Date, Lumena shall pay Sanofi a one-time, non-refundable and non-creditable upfront cash payment of five hundred thousand Dollars ($500,000). 

3.2     Equity Consideration. 

(a)     Stock Issuance.  Upon the Effective Date, Lumena shall issue to
Sanofi’s designated Affiliate a number of shares of Lumena’s Series A-1 Preferred Stock that represents, on an as-converted basis, the number of shares determined by dividing five hundred thousand Dollars (US$500,000) by the purchase price
per share paid by the investors in Lumena’s Series A Preferred Stock Financing. Lumena shall use commercially reasonable efforts to ensure that its Series A Preferred Stock Financing generates aggregate gross proceeds to Lumena of at least
[...***...]. Concurrently with such issuance of Series A-1 Preferred Stock, Sanofi shall cause its designated Affiliate to execute and deliver, to Lumena and the investors in the Series A Preferred Stock Financing, customary documents (such
as, without limitation, an investor rights agreement and a voting agreement), containing the terms and conditions of the Series A Preferred Stock and the Series A-1 Preferred Stock (the “Series A Agreements”). 

(b)     Put Option.  At any time during the Term, Sanofi or its Affiliate, as the
holder of preferred or common stock of Lumena, will have the one time right to request in writing that Lumena purchase all of the Lumena preferred or common stock held by Sanofi or such Affiliate and, upon Lumena’s receipt of such written
notice, Lumena shall purchase such Lumena stock from Sanofi or such Affiliate, for a purchase price of one Dollar (US$1) in the aggregate. 

  
 12 

 3.3     Development Milestone Payments. 

(a)     General.  Lumena shall make the following non-refundable and non-creditable
development milestone payments to Sanofi within [...***...] after the first achievement of each applicable milestone by Lumena or its Affiliates or their sublicensees or subcontractors. Each such milestone payment shall be paid only once
during the Term of the Agreement, the first time a Licensed Product reaches such milestone event and regardless of the number of times such milestone is reached for a Licensed Product and of the number of subsequent Licensed Products reaching such
milestone. 
  

			
	  

Milestone Event
  
	  	  

Milestone Payment
  

	  

[...***...]
  
	  	 $[...***...]

 

	  

[...***...]
  
	  	 $[...***...]

 

	  

[...***...]
  
	  	 $[...***...]

 

	  

[...***...]
  
	  	 $[...***...]

 

	  

[...***...]
  
	  	 $[...***...]

 

	  

[...***...]
  
	  	 $[...***...]

 

	  

[...***...]
  
	  	 $[...***...]

 

 (b)     Determination that Milestone Events Have
Occurred.    Lumena shall notify Sanofi promptly of the achievement of each development milestone event under Section 3.3(a). In the event that, notwithstanding the fact that Lumena has not provided Sanofi such a notice,
Sanofi believes that any such milestone event has been achieved, it shall so notify Lumena in writing and the Parties shall promptly meet and discuss in good faith whether such milestone event has been achieved. Any dispute under this
Section 3.3(b) regarding whether or not a milestone event has been achieved shall be subject to resolution in accordance with Section 11.3. 

3.4     Sales Milestone Payments.  Lumena shall make the following one-time,
non-refundable and non-creditable sales milestone payments to Sanofi when the aggregate annual Net Sales of all Licensed Products in the Territory first reach the thresholds specified below. Lumena shall notify Sanofi promptly of the achievement of
each such sales threshold. Each sales milestone payment shall be made by Lumena within [...***...] after the end of the calendar quarter in which such sales threshold is achieved. To the extent more than one sales threshold is reached in any
given year, then the applicable milestone payment for each such achievement shall be due and owing with respect to such year. 
  

			
	  

Threshold for Aggregate Annual

Worldwide Net Sales
  
	  	  

Milestone Payment

	  

$[...***...]

 
	  	 $[...***...]

 

	  

$[...***...]

 
	  	 $[...***...]

 

  
 13 

 3.5     Royalty Payments. 

(a)     Royalty Rates.    Lumena shall pay to Sanofi non-refundable,
non-creditable royalties on Net Sales of all Licensed Products in the Territory during the Royalty Term, as calculated by multiplying the applicable amount of incremental Net Sales in the Territory of all Licensed Products in a calendar year by the
corresponding royalty rates, as set forth in the table below and by subsequently making the applicable adjustments in accordance with Sections 3.5(e) and (f) below: 
  

			
	  

Net Sales of Licensed Product
  
	  	
Royalty Rate
  

	  

For that portion of annual Net Sales less than $[...***...]

 
	  	 [...***...]%

 

	  

For that portion of annual Net Sales greater than or equal to $[...***...]

 
	  	 [...***...]%

 

 If Lumena exercises the Compound Manufacturing Option in accordance with Section 2.2, and unless
otherwise expressly provided in a Supply Agreement executed between the Parties pursuant to Section 5.2, then Lumena shall pay to Sanofi an additional [...***...] royalty on Net Sales of all Licensed Products in the Territory during the
Royalty Term (i.e. [...***...] for that portion of annual Net Sales less than $[...***...] and [...***...] for that portion of annual Net Sales greater than or equal to $[...***...]). 

(b)     Royalty Term.   Royalties under this Section 3.5 with respect to
a particular Licensed Product and country will commence on the First Commercial Sale of such Licensed Product in such country and shall continue until the later of (i) the expiration of the last-to-expire Valid Claim of the Sanofi Patents in
the country of sale claiming such Licensed Product, or the Compound, or its manufacture or use; and (ii) the tenth (10th) anniversary of the First Commercial Sale of such Licensed
Product in such country (the “Royalty Term”). Following expiration of the Royalty Term for any Licensed Product in a given country, no further royalties shall be payable in respect of sales of such Licensed Product in such country
and thereafter the licenses granted to Lumena under Sections 2.1 and 2.2 (as applicable), with respect to such Licensed Product in such country shall automatically become fully paid-up, perpetual and royalty-free. 

(c)     Blended Royalty.  Lumena acknowledges that (i) the Sanofi Know-How and
the Information included in the Regulatory Materials to be transferred by Sanofi to Lumena pursuant to Section 4.2 are proprietary and valuable, (ii) such Regulatory Approvals will be useful for Lumena to obtain and maintain regulatory
exclusivity with respect to Licensed Products in the Field in the Territory, (iii) access to the Sanofi Know-How and the rights with respect to the Regulatory Materials will provide Lumena with a competitive advantage in the marketplace in
addition to the exclusivity afforded by the Sanofi Patents, and (iv) the milestone payments and royalties set forth in Section 3.3, Section 3.4 and this Section 3.5, are, in part, intended to compensate Sanofi for such
exclusivity and such competitive advantage. The Parties agree that the royalty rates set forth in Section 3.5(a) reflect an efficient and reasonable blended allocation of the value provided by Sanofi to Lumena. 

(d)     Royalty Reports and Payments.   Within [...***...] following the
end of each calendar quarter following the First Commercial Sale of a Licensed Product anywhere in the Territory, Lumena shall provide Sanofi with a report containing the following information for the applicable calendar quarter, on a Licensed
Product-by-Licensed Product and country-by-country basis: (i) the amount of gross sales of such Licensed Product in such country, (ii) an itemized calculation of Net Sales in such country showing deductions provided for in the definition
of Net Sales in Section 1.31, (iii) 

  
 14 

 
a calculation of the royalty payment due on such sales, (iv) an accounting of the number of units and prices for Licensed Product sold, (v) the exchange rate for such country (as
published in The Wall Street Journal, Eastern Edition, on the last business day of the last month in the calendar quarter to which such payments relate), and (vi) the date of First Commercial Sale of such Licensed Product in such country.
Concurrent with the delivery of the applicable quarterly report, Lumena shall pay all amounts due to Sanofi pursuant to this Section 3.5 with respect to Net Sales by Lumena, its Affiliates and their respective sublicensees and subcontractors
for such calendar quarter. 
 (e)     Royalty Adjustment for Third Party Intellectual
Property.  If Lumena or its Affiliates or their sublicensees, as applicable, determines, in its reasonable judgment, that it is necessary to obtain a license from any Third Party (each a “Third Party License”) under
any Valid Claim that is a (i) composition-of-matter Patent claim owned or controlled by such Third Party directed to the Compound or (ii) provided that Lumena has not exercised the Compound Manufacturing Option, a process Patent claim
owned or controlled by such Third Party directed to the manufacturing process used by Sanofi to manufacture Compound supplied to Lumena pursuant Sections 4.2 or 4.3 or to a Supply Agreement, or (iii) in the event Lumena has exercised the
Compound Manufacturing Option, a process Patent claim owned or controlled by such Third Party directed to the manufacturing process for the Compound as it existed on the date Lumena exercised the Compound Manufacturing Option (each of (i),
(ii) and (iii) above a “Third Party Compound Claim”), in order to avoid potential infringement or misappropriation of such Third Party Compound Claim by the importation, sale, manufacture or use of a Licensed Product, then
the royalty payment that would otherwise be due in any calendar quarter pursuant to Section 3.5(a) shall be reduced, on a calendar quarter-by-calendar quarter basis, by either (i) [...***...] of any royalty amount payable by Lumena
or its Affiliates in such calendar quarter to such Third Party in consideration for such Third Party License, in the event such Third Party License is obtained by Lumena or its Affiliate, or (ii) [...***...] of the difference (if any)
between (x) the calendar quarter royalty payment due to Lumena pursuant to its sublicense agreement with such sublicensee and (y) the calendar quarter royalty payment that would otherwise be due to Lumena pursuant to such sublicense
agreement in the absence of such Third Party License, in the event such Third Party License is obtained by a sublicensee of Lumena hereunder and such sublicensee is entitled to [...***...]. In the event any such Third Party License includes a
license to Lumena under a Third Party Compound Claim as well as other intellectual property rights that are not Third Party Compound Claims, then the calendar quarter royalty payment that would otherwise be due pursuant to Section 3.5(a) shall
be reduced by up to [...***...] of that portion of the total royalty amount payable by Lumena or its Affiliates in such calendar quarter to such Third Party in consideration for such Third Party License that the Parties agree is a reasonable
royalty for a license under only the applicable Third Party Compound Claim(s). Notwithstanding the foregoing, the royalty payment that would otherwise be due to Sanofi pursuant to Section 3.5(a) with respect to a particular calendar quarter
shall not be reduced by more than [...***...] by operation of this Section 3.5(e). 

(f)     Royalty Adjustment in Certain Circumstances.    On a Licensed
Product-by-Licensed Product and country-by-country basis, if in any calendar quarter during the Royalty Term following introduction of a generic product in a country (“Generic Entry”) (i) there is no Valid Claim within the
Sanofi Patents in such country and (ii) the market share of Lumena and its Affiliates or their sublicensees, as applicable, for such Licensed Product in the Field in such country in such calendar quarter (as measured by reputable published data
for such country, e.g. by reference to market share data collected by IMS) (“Market Share”) is reduced by [...***...] or more compared to the Market Share in the immediately preceding calendar quarter, then the
applicable royalty payable to Sanofi under Section 3.5(a) shall be reduced by [...***...], provided however, that the applicable royalty under Section 3.5(a) shall be reduced to [...***...] upon a Market Share reduction
in any calendar quarter following Generic Entry of [...***...] or more compared to the Market Share in the 

  
 15 

 
immediately preceding calendar quarter. For the purposes of this Section 3.5(e), “generic product” means, with respect to a Licensed Product being sold by Lumena and its
Affiliates or their sublicensees or subcontractors, as applicable, a pharmaceutical product containing the same Compound as such Licensed Product (and the same other active ingredient(s), as applicable, in the case of a Combination Product) which is
marketed by an entity other than Lumena and its Affiliates or their sublicensees or subcontractors in the Field. Notwithstanding the foregoing, the royalty adjustment set forth in this Section 3.5(f) shall not apply in the event of any
reduction in the Market Share of any sublicensee of Lumena hereunder, unless such reduction in such sublicensee’s Market Share triggers an equivalent adjustment of royalties payable by such sublicensee to Lumena pursuant to the applicable
sublicense agreement. 
 3.6     Sublicensing Revenues.    If Lumena
sublicenses Commercialization rights to any Third Party, Lumena would pay to Sanofi, (i) the Royalties set forth in Section 3.5(a), and (ii) in lieu of the payments under Sections 3.3 and 3.4, a percentage of any and all licensing
revenues received by Lumena or its Affiliates from such Third Party in consideration for such sublicense, on a Licensed Product-by-Licensed Product basis, as follows: (a) [...***...], if such sublicense is entered into prior to
[...***...]; and (b) [...***...], if such sublicense is entered into after [...***...], provided however, that in the event that the total payments made by Lumena under subparagraph (ii) above are less than the payments
that would have been made by Lumena under Sections 3.3 and 3.4 for achievement of the milestone events in Sections 3.3 and 3.4 that are actually achieved, then Lumena will pay Sanofi [...***...]. For the purposes of this Section 3.6,
“licensing revenues” includes, without limitation, [...***...], but excludes [...***...]. 

3.7     Payment Method.   All payments due under this Agreement to Sanofi shall
be made by bank wire transfer in immediately available funds to an account designated by Sanofi. All payments hereunder shall be made in Dollars. 

3.8     Late Payment.    If Lumena fails to make any payment due to Sanofi
under this Agreement, then interest shall accrue on a monthly basis at the rate equal to [...***...] above the then-applicable prime commercial lending rate of BNP Paribas SA, Paris, France, or at the maximum rate permitted by applicable Law,
whichever is the lower. 
 3.9     Records; Inspection.    Lumena shall,
and shall ensure that its Affiliates and their respective sublicensees and subcontractors will, keep complete, true and accurate books of account and records for the purpose of determining the payments to be made under this Agreement. Such books and
records shall be kept for at least [...***...] following the end of the calendar year to which they pertain. Such records shall be open for inspection during such period by independent accountants, solely for the purpose of verifying payment
statements hereunder. Such inspections shall be made no more than once each calendar year, on reasonable notice during normal business hours. Any unpaid amounts (plus interest as set forth in Section 3.8) that are discovered shall be paid
promptly by Lumena. Inspections conducted under this Section 3.9 shall be at the expense of Sanofi, unless the inspection discloses an underpayment by Lumena of [...***...] or more of the amount due for any period covered by the
inspection, whereupon all costs relating to the inspection for such period shall be paid promptly by Lumena. 

  
 16 

 3.10     Taxes. 

  (a)     Taxes.  Each Party shall be solely responsible for the payment
of all taxes imposed on its share of income arising directly or indirectly from the efforts of the Parties under this Agreement. For clarity, all payments to me made under this Agreement shall be made plus value added tax, if applicable. 

  (b)     Tax Cooperation.   The Parties agree to cooperate with one
another and use reasonable efforts to reduce or eliminate tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made by Lumena to Sanofi under this Agreement. To the extent Lumena is required to
deduct and withhold taxes on any payment to Sanofi, Lumena shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Sanofi an official tax certificate or other evidence of such withholding
sufficient to enable Sanofi to claim such payment of taxes. Each Party shall provide the other with reasonable assistance to enable the recovery, as permitted by applicable Laws, of withholding taxes, value added taxes, or similar obligations
resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax. Lumena shall require its sublicensees to cooperate with Sanofi in a manner consistent with this
Section 3.10(b). 
   (c)     Taxes Resulting From Lumena
Action.    If Lumena is required to make a payment to Sanofi that is subject to a deduction or withholding of tax, then (i) if such withholding or deduction obligation arises as a result of any action by Lumena,
including any assignment or sublicense, or any failure on the part of Lumena or its Affiliate to comply with applicable Laws or filing or record retention requirements, that has the effect of modifying the tax treatment of the Parties hereto (a
“Lumena Withholding Tax Action”), then the sum payable by Lumena (in respect of which such deduction or withholding is required to be made) shall be increased to the extent necessary to ensure that Sanofi receives a sum equal to the
sum that it would have received had no such Lumena Withholding Tax Action occurred, and (ii) otherwise, the sum payable by Lumena (in respect of which such deduction or withholding is required to be made) shall be made to Sanofi after deduction
of the amount required to be so deducted or withheld, which deducted or withheld amount shall be remitted to the proper Governmental Authority in accordance with applicable Laws. 

 

	4.	DEVELOPMENT AND COMMERCIALIZATION 

4.1      Alliance Managers.  Within [...***...] after the Effective Date,
each Party shall appoint and notify the other Party of the identity of a representative having the appropriate qualifications, including a general understanding of pharmaceutical development and commercialization issues, to act as its alliance
manager under this Agreement (the “Alliance Manager”). The Alliance Managers shall serve as the primary contact points between the Parties for the purpose of providing Sanofi with information on the progress of Lumena’s
Development and Commercialization activities under this Agreement. The Alliance Managers shall also be primarily responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration between the
Parties. Each Party may replace its Alliance Manager at any time upon written notice to the other Party. 

4.2      Initial Know-How and Material Transfer.  Within [...***...]
after the Effective Date, Sanofi shall deliver to Lumena (i) the Sanofi Know-How in the file format specified in Exhibit 1.39, (ii) the Sanofi Manufacturing Know-How that is listed in Exhibit 1.39, as Lumena reasonably requires for filing
with Regulatory Authorities (“Initial Manufacturing Know-How”) and (iii) [...***...] of SAR-548304 from Sanofi manufacturing batch [...***...] (“Initial Materials”) meeting the specifications
detailed in Exhibit 4.2 (“Initial Material Specifications”). Notwithstanding anything in this Agreement to the contrary, Lumena will have the right effective upon the Effective Date, to include

  
 17 

 
the Initial Manufacturing Know-How in Lumena’s Regulatory Materials for filing or submission to, or correspondence or discussions with, Regulatory Authorities. EXCEPT AS EXPRESSLY PROVIDED
IN THIS AGREEMENT, ANY INITIAL MATERIALS SUPPLIED BY SANOFI UNDER THIS SECTION 4.2 ARE SUPPLIED “AS IS” AND SANOFI MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIALS DOES NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS OF A THIRD PARTY. Lumena assumes all liability for damages which may
arise from its use, storage or disposal of such Initial Materials. Sanofi will not be liable to Lumena for any loss, claim or demand made by Lumena, or made against Lumena by any Third Party, due to or arising from the use of such Initial Materials
except, to the extent permitted by applicable Laws, when caused by the negligence or willful misconduct of Sanofi. 

4.3     Additional Compound Supply. 

(a)     At any time prior to execution of the Pre-Commercial Supply Agreement pursuant to
Section 5.2, Lumena may request in writing that Sanofi (i) deliver to Lumena the additional quantities of SAR-548304 described in Exhibit 4.3 (the “Additional Existing Materials”); and (ii) perform the CMC
Activities with respect to the Additional Existing Materials as described in Exhibit 4.3. 

(b)     Upon a written request from Lumena for Additional Existing Materials, Sanofi shall
promptly deliver to Lumena such Additional Existing Materials, and shall perform, at Lumena’s expense, the CMC Activities with respect to such Additional Existing Materials as described in Exhibit 4.3, in accordance with a mutually agreed work
schedule and budget. Lumena will pay Sanofi [...***...] Euro per kilogram for the Additional Existing Materials, payable following delivery, within [...***...] after receipt of invoice from Sanofi. Sanofi will invoice Lumena for CMC
Activities conducted by Sanofi pursuant to this Section 4.3 and Lumena shall pay each such invoice within [...***...] after its receipt. The conduct by Sanofi of any CMC Activities pertaining to Additional Existing Materials that are not
described in Exhibit 4.3 shall be subject to the execution and terms and conditions of the Pre-Commercial Supply Agreement. 

4.4     Development Responsibilities.    As between the Parties, Lumena
shall have sole authority and responsibility for conducting or having conducted Development activities with respect to Compounds and Licensed Products in the Territory, at its sole cost and expense, in accordance with the terms and conditions of
this Agreement. Lumena shall conduct all such activities in compliance in all material respects with all applicable Laws. Lumena shall have sole responsibility and control with respect to seeking Regulatory Approvals to Commercialize the Licensed
Products. As between the Parties, Lumena shall hold legal title to all Regulatory Materials within the Territory. Promptly following the Effective Date, Sanofi shall take and cause to be taken such actions and execute such documents that are
requested in writing by Lumena to the extent necessary to transfer to Lumena all Regulatory Materials within the Sanofi Know-How. 

4.5     Development Plan.  Lumena shall prepare a written development plan, which
shall specify the Compound and Licensed Product Development activities to be conducted by Lumena, its Affiliates, sublicensees and subcontractors, and the timeline regarding such activities (collectively, the “Development Plan”). An
initial Development Plan is attached to this Agreement as Exhibit 4.5. Beginning with the first full calendar year following the Effective Date, on an annual basis (no later than October 31st), Lumena shall review and, as required,
prepare an update and amendment to the then-current Development Plan and send such updated and amended Development Plan to Sanofi for review and comment by Sanofi. Such updated and amended Development Plan shall reflect any changes with respect to,
the Development of Licensed Products. Lumena shall give good faith consideration to any 

  
 18 

 
written comments provided by Sanofi with respect to any update or amendment of the Development Plan. The Development of Compound and Licensed Product by Lumena or its Affiliates or their
sublicensees, as applicable, shall be conducted in accordance with the Development Plan. 

4.6      Development Records and Reports.  Lumena shall maintain complete and
accurate customary records (in the form of technical notebooks and/or electronic files where appropriate) of all Development activities conducted by it or its Affiliates or sublicensees, as applicable, under this Agreement and all Information
resulting from such work. Such records, including any electronic files where such Information may also be contained, shall fully and properly reflect all work done and results achieved in the performance of the Development activities in sufficient
detail and in good scientific manner appropriate for applicable patent and regulatory purposes. Upon the expiry of each consecutive [...***...] period during the Term, Lumena shall provide Sanofi with a written report summarizing its
Development activities conducted by Lumena or its Affiliates or sublicensees, as applicable, under this Agreement and the results of such activities. Any information or report provided by Lumena to Sanofi pursuant to this Section 4.6 shall be
deemed to be Lumena’s Confidential Information and subject to the provisions of Article 7. 

4.7      Commercialization Responsibilities.  As between the Parties, Lumena
shall have sole authority and responsibility for conducting or having conducted Commercialization activities with respect to Licensed Products in the Territory, at its sole cost and expense, in accordance with the terms and conditions of this
Agreement. Lumena shall conduct all such activities in compliance in all material respects with all applicable Laws. It is understood that as between the Parties, Lumena shall be solely responsible for handling all returns, order processing,
invoicing and collection, distribution, and receivables for Licensed Products in the Territory. 

4.8      Commercialization Plan.     Lumena or its Affiliate, or
their sublicensees or subcontractors (as applicable) shall establish written plans for the Commercialization of Licensed Products in the Major Markets (together, the “Commercialization Plan”). Lumena shall deliver an initial
Commercialization plan to Sanofi for review and comment by Sanofi no later than [...***...] prior to the anticipated date of [...***...]. After the establishment of the initial Commercialization Plan, Lumena or its Affiliate or their
sublicensees or subcontractors (as applicable) shall prepare updates and amendments to such Commercialization Plan at least annually (no later than October 31st of each calendar year) and submit each such updated Commercialization Plan to
Sanofi for review and comment by Sanofi. Lumena shall give good faith consideration to any written comments provided by Sanofi with respect to any update or amendment of the Commercialization Plan. The Commercialization of Compound and Licensed
Product by Lumena or its Affiliates or their sublicensees, as applicable, shall be conducted in accordance with the Commercialization Plan. 

4.9      Trademarks.  Lumena shall have the right to brand Licensed Products
using Lumena related trademarks and any other trademarks and trade names it determines appropriate for the Licensed Products which may vary by country or within a country (“Product Marks”), provided that Lumena shall not, and shall
not permit its Affiliates and sublicensees and subcontractors to, make any use of the trademarks or house marks of Sanofi or its Affiliates (including their corporate names) or any trademark confusingly similar thereto. As between the Parties,
Lumena or its Affiliate or their sublicensees or subcontractors (as applicable) shall own all rights in the Product Marks and shall register and maintain the Product Marks in the countries and regions it determines reasonably necessary at its own
cost and expense. 
 4.10    Standards of Conduct.    Lumena shall, and shall
ensure that its Affiliates and sublicensees and subcontractors have the written obligation to, comply in all material respects with all 

  
 19 

 
applicable Laws concerning the advertising, sales and marketing of prescription drug products in Commercializing Licensed Products in the Territory under this Agreement, including the Foreign
Corrupt Practices Act of 1977, as amended (“FCPA”) and any applicable local anti-bribery laws. Lumena shall during the Term, promptly notify Sanofi in writing with respect to any material non-compliance (other than non-compliance of
the FCPA which shall be without regard to materiality) regarding the Commercialization of Licensed Products of which it becomes aware. 

4.11    Commercialization Reports.    Lumena shall, on an annual basis, no
later than [...***...] of each calendar year, provide Sanofi with a reasonably detailed report of its and its Affiliate’s and sublicensee’s and subcontractor’s (as applicable) Commercialization activities with respect to
Licensed Products in the Major Markets in the immediately preceding calendar year. Any information or report provided by Lumena to Sanofi pursuant to this Section 4.11 shall be deemed to be Lumena’s Confidential Information and subject to
the provisions of Article 7. 
 4.12    Diligence.  During the Term, Lumena (by itself
or through its Affiliates or sublicensees, as applicable), shall use Diligent Efforts to (i) [...***...] (ii) [...***...], and (iii) [...***...]. For clarity, it is understood and acknowledged that to the extent that
Lumena uses Diligent Efforts (by itself or through its Affiliates or sublicensees, as applicable) to [...***...], Lumena shall be in compliance with Section 4.12(ii) with respect to [...***...]. Lumena will have no other obligations
to devote or cause to be devoted any level of diligence with respect to the Development, Regulatory Approval or Commercialization of Licensed Products except as set forth in this Section 4.12, provided any obligations expressly set forth
elsewhere in this Agreement shall not be affected by this sentence. 
  

	5.	MANUFACTURING 

5.1      General.  In general, from the Effective Date and until Lumena
exercises the Compound Manufacturing Option pursuant to Section 2.2: (a) subject to the Parties’ execution of an applicable Supply Agreement pursuant to Section 5.2, Sanofi shall (i) supply Lumena with quantities of
Compound, in addition to the Initial Materials and the Additional Existing Materials, that are requested by Lumena to Develop and Commercialize Licensed Product hereunder (“Additional New Materials”), and (ii) perform any
related CMC Activities with respect to such Additional New Materials, in each case in accordance with the terms of the applicable Supply Agreement; and (b) Lumena shall be responsible, at its sole cost and expense, for performing CMC Activities
with respect to Licensed Product and for Manufacturing Licensed Products. Upon Lumena’s exercise of the Compound Manufacturing Option, as between the Parties, Lumena shall assume sole responsibility for performing CMC Activities with respect to
Compound and for the manufacture of Compounds, subject to any Supply Agreement still in effect at such time. 

5.2      Supply Agreements.   After the Effective Date, and prior to the
Initiation of the first Phase 3 Clinical Trial, if requested by Lumena, the Parties shall use good faith efforts to negotiate and enter into a separate written agreement under which, prior to Lumena’s exercise of the Compound Manufacturing
Option, Lumena shall purchase Additional New Materials exclusively from Sanofi, and Sanofi shall manufacture Additional New Materials, perform CMC Activities with respect to Additional New Materials, and supply Additional New Materials exclusively
to Lumena, for use by Lumena in Developing Licensed Products in accordance with this Agreement (the “Pre-Commercial Supply Agreement”). In addition and provided that the Parties entered into a Pre-Commercial Supply

  
 20 

 
Agreement, then prior to [...***...], if requested by Lumena, the Parties shall use good faith efforts to negotiate and enter into a separate written agreement under which Lumena shall
purchase Additional New Materials from Sanofi and Sanofi shall supply Compounds exclusively to Lumena for use by Lumena in Commercializing Licensed Products in accordance with this Agreement (the “Commercial Supply Agreement”). The
Pre-Commercial Supply Agreement and Commercial Supply Agreement may together be referred to as the “Supply Agreements”). The Supply Agreements shall contain terms consistent with the terms of this Agreement and shall include the
terms set forth in Exhibit 5.2 as well as other terms customary for supply agreements of similar object and scope. In the event of any inconsistency between the terms of the Supply Agreements and the terms of this Agreement, the terms of this
Agreement shall prevail unless otherwise expressly provided in the Supply Agreements with respect to matters related to manufacture and supply of Compounds or performance of CMC Activities. 

5.3     Transfer of Manufacturing Technology.  Beginning promptly after
Lumena’s exercise of the Compound Manufacturing Option, and continuing for a period of up to [...***...] after Lumena’s exercise of the Compound Manufacturing Option, the Parties shall cooperate to transfer to Lumena or (with prior
written notice to Sanofi) its designee, the Sanofi Manufacturing Know-How existing at the time the Compound Manufacturing Option is exercised, at Lumena’s request and expense. Upon Lumena’s exercise of the Compound Manufacturing Option,
Lumena itself, or through a Third Party contract manufacturer, shall assume responsibility for CMC Activities with respect to Compound and for the manufacture of Compound. Within [...***...] after Lumena’s exercise of the Compound
Manufacturing Option, Sanofi shall transfer to Lumena or its designee, in electronic format, a data package containing such Sanofi Manufacturing Know-How existing at the time the Compound Manufacturing Option is exercised. In addition, during the
[...***...] period after Lumena’s exercise of the Compound Manufacturing Option, Sanofi shall make available to Lumena, on a reasonable consultation basis, such advice of its technical personnel as may be reasonably requested by Lumena in
connection with such transfer of Sanofi Manufacturing Know-How, up to [...***...] full-time equivalent personnel over such [...***...] period. Lumena agrees to reimburse Sanofi for the reasonable and documented fully-burdened charges for
the time and expenses of such personnel when consulting for Lumena (including reasonable documented travel expenses, lodging and meals) incurred by personnel of Sanofi at the request of Lumena while rendering services under this Section 5.3.
Lumena acknowledges and agrees that Sanofi may condition its agreement to transfer any Sanofi Manufacturing Know-How to a Third Party manufacturer on the execution of a confidentiality agreement between such Third Party manufacturer and Lumena that
contains terms substantially equivalent to those of Article 7 of this Agreement. Lumena and/or its Third Party manufacturer shall use the Sanofi Manufacturing Know-How solely for the purpose of manufacturing Compounds and Licensed Products and
performing the CMC Activities, in accordance with the terms and conditions of this Agreement, and for no other purpose. 
  

	6.	INTELLECTUAL PROPERTY 

 6.1     Lumena
Intellectual Property.  Lumena shall solely own all Information, discoveries and inventions (patentable or not) generated, conceived or reduced to practice in the performance of the Development, Manufacture, Commercialization or other
activities conducted by Lumena or its Affiliates or sublicensees, as applicable, under this Agreement using Sanofi Technology, including Patents filed thereon and other intellectual property rights therein (“Lumena Intellectual
Property”). 
 6.2     Patent Prosecution. 

(a)     Sanofi Patents.  All decisions and actions with respect to the preparation,
filing, prosecution and maintenance of the Sanofi Patents shall be the responsibility of Lumena, using patent counsel reasonably acceptable to Sanofi, at Lumena’s sole cost and expense, provided that Lumena shall

  
 21 

 
not abandon or discontinue the prosecution or maintenance of any Sanofi Patent in a country without notifying Sanofi in writing at least [...***...] in advance of the due date of any
payment or other action that is required to prosecute and maintain such Sanofi Patent, and, upon such notice, all licenses under such Patent granted in Section 2.1 or Section 2.2 shall terminate upon delivery of such notice and Sanofi
shall have the option, but not the obligation, to prepare, file, prosecute and maintain (including with respect to related interference, re-issuance, re-examination and opposition proceedings) such Patent in the Territory at its sole cost and
expense. 
 (b)     Lumena Patents.   Lumena shall be solely responsible, at
its discretion and expense, for all decisions and actions with respect to the preparation, filing, prosecution and maintenance of Patents within Lumena Intellectual Property (“Lumena Patents”). 

(c)     Patent Term Extensions.   As between the Parties, Lumena shall have
the authority and responsibility to file for and seek to obtain patent term extensions (including any pediatric exclusivity extensions as may be available) or supplemental protection certificates or their equivalents in any country with respect to
patent rights covering Licensed Products. 
 (d)     Data Exclusivity.  With
respect to data exclusivity periods, Lumena shall have the sole right, but not the obligation, (consistent with its obligations under applicable Laws (including any applicable consent order)), to seek, maintain and enforce all such data exclusivity
periods available for Licensed Products. 
 (e)     Cooperation.  Promptly
following the Effective Date, (but no less than [...***...] before any statutory bar date), Sanofi will transfer to Lumena all Information concerning the Sanofi Patents. Sanofi shall cooperate with Lumena and shall execute any power of
attorney or similar document, in each case to the extent reasonably required to allow Lumena to assume the preparation, filing, prosecution and maintenance of the Sanofi Patents in Sanofi’s name. Lumena shall cooperate with Sanofi, in each case
to the extent reasonably required to allow Sanofi to assume the preparation, filing, prosecution and maintenance, of any Patent abandoned by Lumena pursuant to Section 6.2(a). 

6.3     Patent Enforcement. 

(a)     Notification.   If either Party becomes aware of any existing or
threatened infringement of the Sanofi Patents in the Territory, which infringing activity involves the manufacture, use, import, offer for sale or sale of any Licensed Product in the Territory (a “Product Infringement”), it shall
promptly notify the other Party in writing to that effect, and the Parties will consult with each other regarding any actions to be taken with respect to such Product Infringement. 

(b)     Right to Enforce.  Lumena shall have the first right, but shall not be
obligated, to bring an infringement action against any person or entity engaged in a Product Infringement of the Sanofi Patents, at Lumena’s sole cost and expense. If Lumena fails to bring such an action with respect to a Sanofi Patent (or to
settle or otherwise secure the abatement of such Product Infringement) prior to the earlier of: (i) [...***...] following Lumena’s receipt or delivery of the notice under Section 6.3(a), or (ii) [...***...] before the
deadline, if any, set forth in the applicable Laws for the filing of such actions, Sanofi shall have the right to bring and control any such action, at its own expense and by counsel of its own choice. 

(c)     Cooperation.    Each Party shall provide to the enforcing Party
reasonable assistance in such enforcement, at such enforcing Party’s request and expense, including joining such action as a party plaintiff if required by applicable Laws to pursue such action. The enforcing Party shall keep the other Party
regularly informed of the status and progress of such enforcement efforts, shall 

  
 22 

 
reasonably consider the other Party’s comments on any such efforts, and shall seek consent of the other Party in any important aspects of such enforcement, including determination of
litigation strategy and filing of material papers to the competent court, which consent shall not be unreasonably withheld or delayed. The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice
and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party. Neither Party shall have the right to settle any patent infringement litigation under this Section 6.3 in a manner that diminishes the rights or
interests of the other Party without the prior written consent of such other Party, such consent not to be unreasonably withheld or delayed. 

(d)     Expenses and Recoveries.  The enforcing Party bringing a claim, suit or
action under Section 6.3(b) or 6.2(c) shall be solely responsible for any expenses incurred by such Party as a result of such claim, suit or action. If such Party recovers monetary damages in such claim, suit or action, such recovery shall be
allocated first to the reimbursement of any expenses incurred by the Parties in such litigation (including, for this purpose, a reasonable allocation of expenses of internal counsel), and any remaining amounts shall be shared as follows: (i) if
Sanofi is the enforcing Party: the remaining amount will be shared [...***...] to Sanofi and [...***...] to Lumena, or (ii) if Lumena is the enforcing Party: the remaining amount will be [...***...]. 

6.4     Patent Oppositions and Other Proceedings. 

(a)     If a Sanofi Patent becomes the subject of any proceeding commenced by a Third Party
in connection with an opposition, action for declaratory judgment, nullity action, interference or other attack upon the validity, title or enforceability thereof, then Lumena shall have the first right, but not the obligation, to control such
defense at its own expense using counsel of its own choice. If Lumena decides that it does not wish to defend against such action, it shall notify Sanofi reasonably in advance of all applicable deadlines, and Sanofi shall thereafter have the right,
but not the obligation, to assume defense of such action at its own expense. 
 (b)     The
Party controlling any defense under this Section 6.4 shall permit the non-controlling Party to participate in the proceedings to the extent permissible under applicable Laws and to be represented by its own counsel at the non-controlling
Party’s expense. Notwithstanding any of the foregoing, the Party controlling any enforcement action pursuant to Section 6.3 shall also have the sole right to control the response to any attack on the validity, title, or enforceability of a
Patent that is asserted by the alleged infringer(s) as a counterclaim or affirmative defense in such action. Neither Party shall have the right to settle any proceeding under this Section 6.4 in a manner that diminishes the rights or interests
of the other Party without the prior written consent of such other Party, such consent not to be unreasonably withheld or delayed. 

6.5     Patent Marking.   Lumena shall mark Licensed Product (or when the
character of the product precludes marking, the package containing any such Licensed Product) marketed and sold by Lumena or its Affiliates or their sublicensees or subcontractors hereunder in accordance with all applicable Laws relating to patent
marking. 
 6.6     Infringement of Third Party Rights.  If any Licensed Product
used or sold by Lumena or its Affiliates or their sublicensees or subcontractors becomes the subject of a Third Party’s claim or assertion of infringement of a Patent granted by a jurisdiction within the Territory, Lumena shall promptly notify
Sanofi, and the Parties shall agree on and enter into a “common interest agreement” wherein the Parties agree to their shared, mutual interest in the outcome of such potential dispute, and thereafter, the Parties shall promptly meet to
consider the claim or assertion and the appropriate course of action. Unless agreed otherwise by the Parties, Lumena shall be solely responsible for defending against any such claim 

  
 23 

 
or assertion, at its sole expense. Lumena shall keep Sanofi fully informed of such claim and its defense, and shall reasonably consider and seek to accommodate any timely comments of Sanofi with
respect thereto. 
  

	7.	CONFIDENTIALITY 

 7.1     Confidentiality
Obligations.  The Parties agree that during the Term and for a period of [...***...] thereafter, a Party receiving Confidential Information of the other Party shall: (a) use reasonable efforts to maintain in confidence such
Confidential Information (but not less than those efforts as such Party uses to maintain in confidence its own proprietary industrial information of similar kind and value); (b) not disclose such Confidential Information to any Third Party
without prior written consent of the other Party, except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties; and (c) not use such other Party’s Confidential Information for any purpose except
those permitted by this Agreement or in connection with exercising such Party’s or its Affiliates’ rights and/or fulfilling their obligations under this Agreement. Notwithstanding anything to the contrary in this Agreement, Sanofi and its
Affiliates may not disclose any Sanofi Know-How to any Third Party without the prior written consent of Lumena, except to the extent required to comply with applicable Laws, including regulations promulgated by applicable security exchanges, court
orders or administrative subpoenas or orders, provided that in such event, Sanofi shall promptly notify Lumena of such required disclosure and shall use reasonable efforts to assist Lumena, at Lumena’s expense, in obtaining a protective order
preventing or limiting the required disclosure. 
 7.2     Exceptions.  The
obligations in Section 7.1 shall not apply with respect to any portion of the other Party’s Confidential Information that the receiving Party can show by competent written proof: 

(a)     was known to the receiving Party, other than under an obligation of confidentiality,
at the time of disclosure by the other Party; 
 (b)     was generally available to the
public or otherwise part of the public domain, at the time of disclosure by the other Party; 

(c)     becomes generally available to the public or otherwise part of the public domain
after the disclosure by the other Party, other than through any act or omission of the receiving Party in breach of this Agreement; 

(d)     is subsequently disclosed to the receiving Party by a Third Party who has a legal
right to make such disclosure and who did not obtain such information directly or indirectly from the other Party; or 

(e)     is subsequently independently developed by employees, subcontractors or sublicensees
of the receiving Party or its Affiliates without use of the other Party’s Confidential Information. 

7.3     Authorized Disclosure.   A Party may disclose the Confidential Information
belonging to the other Party to the extent such disclosure is reasonably necessary in the following instances; provided that notice of any such disclosure shall be provided as soon as practicable to the other Party: 

(a)     filing or prosecuting Patents in accordance with Section 6.2; 

(b)    complying with the requirement of Regulatory Authorities with respect to obtaining and
maintaining Regulatory Approval of Licensed Products; 

  
 24 

 (c)     prosecuting or defending litigation as
contemplated by this Agreement; 
 (d)     disclosure to its or its Affiliates’
employees, directors, officers, agents, consultants, professional advisors, subcontractors, licensees or sublicensees or bona fide potential subcontractors, licensees or sublicensees, on a need-to-know basis for the sole purpose of performing
its or its Affiliates’ obligations or exercising its or its Affiliates’ rights under this Agreement; provided that in each case, the disclosees are bound by written or professional obligations of confidentiality and non-use consistent with
those contained in this Agreement; 
 (e)     disclosure to any bona fide potential
or actual investor, acquiror or merger partner or other potential or actual financial or commercial partner for the sole purpose of evaluating an actual or potential investment, acquisition or other business relationship; provided that in connection
with such disclosure, the disclosing Party shall use all reasonable efforts to inform each disclosee of the confidential nature of such Confidential Information and cause each disclosee to treat such Confidential Information as confidential; or 

(f)     complying with applicable Laws, including regulations promulgated by applicable
security exchanges, court orders or administrative subpoenas or orders. 
 Notwithstanding the foregoing, in the event a Party is required
to make a disclosure of the other Party’s Confidential Information pursuant to Sections 7.3 (c) or (f), such Party shall promptly notify the other Party of such required disclosure and shall use reasonable efforts to assist the other
Party, at such other Party’s expense, in obtaining a protective order preventing or limiting the required disclosure. 

7.4     Publicity; Terms of Agreement. 

(a)     If either Party desires to make a public announcement concerning the material terms
of this Agreement, such Party shall give reasonable prior advance notice of the proposed text of such announcement to the other Party for its prior review and approval (except as otherwise provided herein), such approval not to be unreasonably
withheld, except that in the case of a press release or governmental filing required by law, the disclosing Party shall provide the other Party with such advance notice as it reasonably can and shall not be required to obtain approval therefor. A
Party commenting on such a proposed press release shall provide its comments, if any, within [...***...] after receiving the press release for review. Neither Party shall be required to seek the permission of the other Party to repeat any
information regarding the terms of this Agreement or any amendment thereto that has already been publicly disclosed by such Party, or by the other Party, in accordance with this Section 7.4, provided such information remains accurate as of such
time. 
 (b)     The Parties acknowledge that either or both Parties may be obligated to
file under applicable Laws a copy of this Agreement with the U.S. Securities and Exchange Commission (“SEC”) or other Governmental Authorities. Each Party shall be entitled to make such a required filing, provided that it requests
confidential treatment of the commercial terms and sensitive technical terms hereof and thereof to the extent such confidential treatment is reasonably available to such Party and permitted by such Governmental Authority. In the event of any such
filing, each Party will provide the other Party with a copy of the Agreement marked to show provisions for which such Party intends to seek confidential treatment and shall reasonably consider and incorporate the other Party’s comments thereon
to the extent consistent with the legal requirements, with respect to the filing Party, governing disclosure of material agreements and material information that must be publicly filed. 

7.5     Equitable Relief.  Each Party acknowledges that its breach of this Article 7
may cause irreparable harm to the other Party, which cannot be reasonably or adequately compensated in damages in 

  
 25 

 
an action at law. By reasons thereof, each Party agrees that the other Party shall be entitled, in addition to any other remedies it may have under this Agreement or otherwise, to preliminary and
permanent injunctive and other equitable relief to prevent or curtail any actual or threatened breach of the obligations relating to Confidential Information set forth in this Article 7 by the other Party. 

7.6     Technical Publications.  During the Term, Sanofi may not publish any
Information related to a Compound or a Licensed Product (other than Information contained in a Patent within the Sanofi Technology that is published pursuant to applicable patent laws), without the prior written approval of Lumena, which approval
will not be unreasonably withheld or delayed. Lumena may freely publish any Information related to a Compound or a Licensed Product provided that any such publication does not contain any Confidential Information of Sanofi, without the prior written
consent of Sanofi, which consent will not be unreasonably withheld or delayed. 
  

	8.	TERM AND TERMINATION 

8.1     Term.  This Agreement shall become effective on the Effective Date and,
unless earlier terminated pursuant to this Article 8, shall remain in effect on a country-by-country and Licensed Product-by-Licensed Product basis, until the expiration of the Royalty Term of such Licensed Product in such country (the
“Term”). 
 8.2     Termination for Material Breach.  Each Party
shall have the right to terminate this Agreement in its entirety immediately upon written notice to the other Party if the other Party materially breaches its obligations under this Agreement and, after receiving written notice identifying such
material breach in reasonable detail, fails to cure such material breach within ninety (90) days from the date of such notice (or within ten (10) business days from the date of such notice in the event such material breach is solely based
on the breaching Party’s failure to pay any amounts due hereunder) provided, however, in the case of a breach or violation that cannot be cured within such ninety (90) day period, the non-breaching Party may terminate this Agreement
following such ninety (90) day period only if the breaching Party shall have failed to commence substantial remedial actions within such ninety (90) day period and to use best efforts to pursue the same. Any right to terminate under this
Section 8.2 shall be stayed and the cure period tolled in the event that, during any cure period, the breaching Party shall have initiated dispute resolution in accordance with Article 11 with respect to the alleged breach, which stay and
tolling shall last so long as the breaching Party diligently and in good faith cooperates in the prompt resolution of such dispute resolution proceedings. Each Party shall be entitled to offset, against amounts payable to the other Party under this
Agreement, any amounts of damages determined, in a final decision by the applicable court action or other legal proceeding, to be owed to such Party by the other Party based on the other Party’s material breach of this Agreement. 

8.3     Termination Upon Insolvency.  Either Party may terminate this Agreement upon
written notice to the other Party, if, at any time, the other Party (a) files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization or
for an arrangement or for the appointment of a receiver or trustee of such other Party or of its assets, (b) is served with an involuntary petition against it, filed in any insolvency proceeding that is not dismissed within [...***...]
after the filing thereof, or (c) makes an assignment of the assets associated with this Agreement for the benefit of its creditors. 

8.4     Termination for Patent Challenge.  Sanofi shall have the right to terminate
this Agreement in its entirety or in part, on a country-by-country and Licensed Product-by-Licensed Product basis, at its election, immediately upon written notice to Lumena if Lumena or its Affiliates or their

  
 26 

 
sublicensees or subcontractors of rights under this Agreement brings an action or proceeding that disputes the validity, of any Sanofi Patent anywhere in the Territory or files an opposition (or
any equivalent action) against any of the Sanofi Patents anywhere in the Territory. Any such termination shall only become effective if Lumena, or such Affiliates or such sublicensees or subcontractors, as applicable, have not withdrawn such action
before the end of the above notice period. 
 8.5     Termination by Lumena. 

(a)     Termination for Safety or Efficacy Failure.  Lumena may terminate this
Agreement in its entirety or on a country-by-country or Licensed Product-by-Licensed Product basis by providing written notice to Sanofi in the following circumstances: (a) if, after using its Diligent Efforts in accordance with
Section 4.12, Lumena reasonably determines that it, or its Affiliates or sublicensees, as applicable, is precluded from proceeding with the first Phase 2B Clinical Trial for a Licensed Product within any of the Major Markets because of
[...***...] (a “Safety Failure”); or (b) if, after using its Diligent Efforts in accordance with Section 4.12, Lumena reasonably determines that it, or its Affiliates or sublicensees, as applicable, is precluded from
proceeding with a Phase 3 Clinical Trial within any of the Major Markets because of (i) a Safety Failure or (ii) [...***...]. Any dispute between the Parties as to whether or not any determination of Lumena pursuant to this
Section 8.5 is “reasonable” shall be determined in accordance with Article 11. 

(b)     Termination for Reasons other than Safety.  Lumena may terminate this
Agreement in its entirety for any reason upon sixty (60) days prior written notice given at any time after the second anniversary of the Effective Date. 

8.6     Effects of Termination of the Agreement.  Upon any termination of this
Agreement, in its entirety or on a country-by-country or Licensed Product-by-Licensed Product basis (other than termination by Lumena under Section 8.2): 

(a)     Termination of License to Lumena.  All rights and licenses granted to
Lumena hereunder shall terminate, but in the case of termination in part, only to the extent such licenses relate to the country(ies) and Licensed Product(s) that are the subject of such termination, and Sanofi shall have the rights pursuant to
Section 2.3(d) with respect to the terminated country(ies) and Licensed Product(s). Section 2.9 will terminate. 

(b)     License to Sanofi.  Lumena and its Affiliates shall and hereby does grant
to Sanofi (effective only and automatically upon any termination pursuant to any of Sections 8.2 to 8.5, other than termination by Lumena under Section 8.2), an exclusive, royalty-bearing, license (with the right to grant sublicenses through
multiple tiers) under (i) all inventions and Information (including all data, know-how, inventions, Regulatory Materials and Regulatory Approvals) generated by Lumena or its sublicensee or subcontractor under an agreement entered into pursuant
to Section 2.3, that are related to the Licensed Product and are necessary or reasonably useful to Develop or Commercialize Licensed Products, and (ii) all Patents filed by Lumena or its Affiliates or sublicensees or subcontractors, as
applicable, claiming Information described in (i) above (and in each of (i) and (ii), subject to any retained non-exclusive rights of such sublicensee or subcontractor to use such inventions and Information for internal or academic
research purposes only), solely to Develop, make, have made, use, sell, offer for sale, import and otherwise Commercialize the terminated Licensed Product(s) in the Field, worldwide or in the terminated country(ies), as applicable, subject to
Sanofi’s payment to Lumena of a royalty of [...***...] of Net Sales (applied to Sanofi in the same manner as applied to Lumena under Section 3.5); provided however in the event of termination of this Agreement by Lumena under
Section 8.5(b), the license granted in this Section 8.6(b) shall be [...***...]. 

  
 27 

 (c)     Trademarks.  Lumena and its
Affiliates shall assign to Sanofi all right, title and interest in and to any and all trademarks for the terminated Licensed Product(s), including any pending trademark applications for such trademarks, worldwide, or in the terminated country(ies),
as applicable (excluding any trademarks that include any corporate name or logo of Lumena or its Affiliates). 

(d)     Regulatory Materials; Data.  As permitted by applicable Laws, Lumena shall
transfer and hereby assigns to Sanofi all Regulatory Materials and Regulatory Approvals, worldwide, or in the terminated country(ies), as applicable. 

(e)     Ongoing Clinical Trials.  If this Agreement is terminated while any
clinical trial is ongoing, Lumena shall notify Sanofi of its decision either to continue or wind down all such trials. The Parties shall negotiate in good faith and adopt a plan to wind-down the development activities in an orderly fashion (not to
exceed [...***...]) or, at Sanofi’s election, promptly transition such development activities to Sanofi, with due regard for patient safety and the rights of any subjects that are participants in any clinical trials of any terminated
Licensed Products, and take any actions it deems reasonably necessary or appropriate to avoid any human health or safety problems and in compliance with all applicable laws. 

(f)     Transition Assistance.  Promptly upon request by Sanofi, but in no event
commencing later than [...***...] after the effective date of termination or expiration, Lumena shall provide such assistance, at Sanofi’s expense (except in the event of termination by Sanofi pursuant to Section 8.2, or Lumena
pursuant to Section 8.5(b), in which case such assistance shall be provided at Lumena’s expense), as may be reasonably necessary or useful for Sanofi to commence or continue Developing, Manufacturing or Commercializing the terminated
Licensed Product(s) in the terminated country(ies) to the extent Lumena is then performing or having performed such activities, including transferring to Sanofi as permitted, upon request of Sanofi, any agreements or arrangements with Third Party
vendors to Develop, Manufacture, distribute, sell or otherwise Commercialize such Licensed Product(s). 

(g)     Know-How Transfer.  Promptly upon request by Sanofi, but in no event
commencing later than [...***...] after the effective date of termination or expiration, Lumena shall work with Sanofi to facilitate the timely transfer to Sanofi of all Information licensed to Sanofi under Section 8.6(b). 

(h)     Remaining Inventories.  If this Agreement is terminated in its entirety,
Lumena or its Affiliates or their subcontractors or sublicensees, to the extent that such parties continue to have stocks of usable Licensed Products, may continue to fulfill orders received for Licensed Products in the Field until [...***...]
following the date of termination. For Licensed Products sold by Lumena or its Affiliates or their subcontractors or sublicensees after the effective date of a termination, Lumena shall continue to pay Royalties pursuant to Section 3.5(a).
Prior to the end of such [...***...] period, Lumena shall provide Sanofi with a written notice of an estimate of the quantity of Licensed Products (or components thereof) and shelf life remaining in the inventory of Lumena at the end of such
[...***...] period and Sanofi shall have the right to purchase any or all of the inventory of Licensed Products (or components thereof) held by Lumena as of the date of such termination (that are not committed to be supplied to any Third Party
or sublicensee or subcontractor, in the ordinary course of business, as of the date of termination) at a price of [...***...] of COGS. 

8.7     Effects of Termination of the Agreement by Lumena under
Section 8.2.  Upon any termination of this Agreement by Lumena under Section 8.2: 

(a)     Any licenses granted to Sanofi under this Agreement, Sanofi’s rights under

  
 28 

 
Sections 2.3(iii), 2.7 and 2.8, and Section 2.9, will terminate automatically. 

(b)     At Lumena’s election, the licenses granted to Lumena in Section 2.1 and 2.2
will continue in full force and effect subject to the royalty obligations and adjustments in Section 3.5, and Lumena’s obligations under Section 4.12 will terminate. 

8.8     Damages; Relief.  Termination of this Agreement shall not preclude either
Party from claiming any other damages, compensation or relief that it may be entitled to upon such termination. 

8.9     Survival.  Termination or expiration of this Agreement shall not affect any
rights or obligations of the Parties under this Agreement that have accrued prior to the date of termination or expiration. Notwithstanding anything to the contrary, the following provisions shall survive any expiration or termination of this
Agreement: Articles 1, 8, 11 and 12 and Sections 2.6, 3.5(b) (final sentence only), 7.1 (for the term stated therein), 7.2, 7.3, 7.4, 7.5, 9.3(c), 9.6, 10.1, 10.2 and 10.3 (for 6 years). 

 

	9.	REPRESENTATIONS AND WARRANTIES AND COVENANTS 

9.1     Mutual Representations and Warranties.  Each Party hereby represents and
warrants to the other Party as follows: 
 (a)     Corporate Existence.  As of
the Effective Date, it is a company or corporation duly organized, validly existing, and in good standing under the Laws of the jurisdiction in which it is incorporated. 

(b)     Corporate Power, Authority and Binding Agreement.  As of the Effective
Date, (i) it has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (ii) it has taken all necessary corporate action on its part required to authorize the execution and
delivery of this Agreement and the performance of its obligations hereunder; and (iii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, and binding obligation of such Party that is
enforceable against it in accordance with its terms. 
 (c)     No
Conflicts.  The execution and delivery of this Agreement, and the performance by such Party of its obligations under this Agreement, including the grant of rights and licenses to the other Party pursuant to this Agreement, does not and
will not: (i) conflict with, nor result in any violation of or default under, any instrument, judgment, order, writ, decree, contract or provision to which such Party is bound; (ii) give rise to the suspension, revocation, impairment,
forfeiture or non-renewal of any material permit, license, authorization or approval that applies to such Party, its business or operations or any of its assets or properties; or (iii) conflict with any rights granted by such Party to any Third
Party or breach any obligation that such Party has to any Third Party. 

9.2     Representations and Warranties of Lumena.  Lumena represents and warrants to
Sanofi that: 
 (a)     Capitalization. 

(i)     The authorized capital stock of Lumena, as of immediately prior to the Effective
Date, consists of (i) thirty-one million five hundred thousand (31,500,000) shares of Common Stock, par value $0.001 per share, of which five hundred seven thousand (507,000) are issued and

  
 29 

 
outstanding, and (ii) twenty-seven million (27,000,000) shares of Preferred Stock, par value $0.001 per share, (x) twenty-four million (24,000,000) of which are designated
Series A Preferred Stock, of which eight million three hundred forty-one thousand two hundred six (8,341,206) are issued and outstanding and (y) three million (3,000,000) of which are designated Series A-1 Preferred Stock, of which no
shares are issued and outstanding. Under Lumena’s 2012 Equity Incentive Plan, as of immediately prior to the Effective Date, three million seven hundred thirty-seven thousand (3,737,000) shares of Common Stock are reserved for issuance to
officers, directors, employees or consultants of Lumena. 
 (ii)     All issued and
outstanding shares of Lumena’s voting stock (i) have been duly authorized and validly issued and are fully paid and nonassessable, and (ii) were issued in compliance with all applicable state and federal laws concerning the issuance
of securities. 
 (iii)     The rights, preferences, privileges and restrictions of the
Series A-1 Preferred Shares will be no less favorable to Sanofi than those contained in Exhibit 1.43. The shares of Series A-1 Preferred Stock are convertible into shares of Common Stock (such shares of Common Stock, the “Conversion
Shares”) on a one-for-one basis as of the date hereof. The consummation of the transactions contemplated hereunder will not result in any anti-dilution adjustment or other similar adjustment to any outstanding shares of capital stock of
Lumena. The Conversion Shares have been duly and validly reserved for issuance. When issued in compliance with the provisions of this Agreement and Lumena’s Amended and Restated Certificate of Incorporation (the “Charter”), the
shares of Series A-1 Preferred Stock and the Conversion Shares will be validly issued, fully paid and nonassessable, and will be free of any liens, restrictions or other encumbrances other than (i) liens and encumbrances created by or imposed
upon Sanofi, (ii) any right of first refusal set forth in Lumena’s Bylaws and (iii) restrictions set forth in this Agreement, the Series A Agreements or the Charter; provided, however, that the shares of Series A-1 Preferred
Stock and the Conversion Shares may be subject to restrictions on transfer under state and/or federal securities laws as set forth herein or as otherwise required by such laws at the time a transfer is proposed. The sale of the shares of Series A-1
Preferred Stock to Sanofi hereunder and the subsequent conversion of the shares of Series A-I Preferred Stock into Conversion Shares are not and will not be subject to any preemptive rights or rights of first refusal that have not been properly
waived or complied with. The Series A Agreements and the Charter are attached hereto as Exhibit 9.2(a). 

(b)     Financial Statements.  Attached hereto as Exhibit 9.2(b) is
Lumena’s unaudited balance sheet as of the Effective Date. 
 (c)     Offering
Valid.  Assuming the accuracy of the representations and warranties of Sanofi contained in Section 9.3 hereof, the offer, sale and issuance of the Shares and the Conversion Shares will be exempt from the registration requirements
of the Securities Act of 1933, as amended (the “Securities Act”), and will have been registered or qualified (or are exempt from registration and qualification) under the registration, permit or qualification requirements of all applicable
state securities laws. Neither Lumena nor any agent on its behalf has solicited or will solicit any offers to sell or has offered to sell or will offer to sell all or any part of the Shares to any person or persons so as to bring the sale of such
Shares by Lumena within the registration provisions of the Securities Act or any state securities laws. 

(d)     Full Disclosure.  None of this Agreement, the exhibits hereto, or any other
document delivered by Lumena to Sanofi or its attorneys or agents in connection herewith or therewith or with the transactions contemplated hereby or thereby contains any untrue statement of a material fact or omits to state a material fact
necessary in order to make the statements contained herein or therein not misleading. 

9.3     Sanofi Representations and Warranties.  Sanofi represents and warrants to
Lumena 

  
 30 

 
that: 
 (a)     Purchase Entirely for
Own Account.  The Series A-1 Preferred Stock to be acquired by Sanofi will be acquired for investment for Sanofi’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and
Sanofi has no present intention of selling, granting any participation in, or otherwise distributing the same. Sanofi does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant
participations to such Person or to any third Person, with respect to any of the Series A-1 Preferred Stock. 

(b)     Disclosure of Information.  Sanofi has had an opportunity to discuss
Lumena’s business, management, financial affairs and the terms and conditions of the offering of the Series A-1 Preferred Stock with Lumena’s management. 

(c)     Restricted Securities.  Sanofi understands that the Series A-1 Preferred
Stock have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among
other things, the bona fide nature of the investment intent and the accuracy of Sanofi’s representations as expressed herein. Sanofi understands that the Series A-1 Preferred Stock are “restricted securities” under applicable U.S.
federal and state securities laws and that, pursuant to these laws, Sanofi must hold such shares indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such
registration and qualification requirements is available. Sanofi acknowledges that Lumena has no obligation to register or qualify the Series A-1 Preferred Stock, or any shares into which such shares may be converted, for resale except as set forth
in the Series A Agreements. Sanofi further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding
period for the Series A-1 Preferred Stock, and on requirements relating to Lumena which are outside of the Sanofi’s control, and which Lumena is under no obligation and may not be able to satisfy. 

(d)     No Public Market.  Sanofi understands that no public market now exists for
the Series A-1 Preferred Stock, and that Lumena has made no assurances that a public market will ever exist for such shares. 

(e)     Accredited Investor.  Sanofi is an accredited investor as defined in Rule
501(a) of Regulation D promulgated under the Securities Act. 

(f)      Legends.  Sanofi understands that the stock certificates for the
Series A-1 Preferred Stock and any securities issued in respect of or exchange for such shares, may bear one or all of the following or similar legends: 
  

	 	(1)	 “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR
INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933”. 

  
 31 

	 	(2)	 Any legend set forth in, or required by, the Series A Agreements. 

 

	 	(3)	 Any legend required by the securities laws of any state to the extent such laws are applicable to such shares represented by the certificate
so legended. 

 9.4     Additional Representations, Warranties and Covenants
of Sanofi.  Sanofi represents, warrants and covenants to Lumena that, as of the Effective Date: 

(a)     Sanofi is the sole and exclusive owner of the Sanofi Patents free and clear of all
liens and Sanofi has the right to grant the licenses to the Sanofi Patents that it purports to grant hereunder. 

(b)     The [...***...] conform to the applicable specifications as described in
Exhibit 4.3. 
 9.5     Covenants.  Each Party covenants to the other Party
as follows: 
 (a)     No Debarment.  In the course of the Development or
Manufacture of Licensed Products or manufacture of Compounds, neither Party, nor its Affiliates or their sublicensees or subcontractors have used or shall use any employee or consultant who has been debarred by any Regulatory Authority or, to such
Party’s or its Affiliates’ Knowledge, is the subject of debarment proceedings by a Regulatory Authority. Lumena shall notify Sanofi promptly upon becoming aware that any of its or its Affiliates’ employees or consultants has been
debarred or is the subject of debarment proceedings by any Regulatory Authority. 

(b)     Compliance.  Lumena and its Affiliates shall comply in all material
respects with all applicable Laws in the Development, Manufacture and Commercialization of the Licensed Product, and Sanofi and its Affiliates shall comply in all material respects with all applicable Laws in the manufacture of Compound and
performance of the CMC Activities with respect to Compound, prior to the execution by the Parties of a Supply Agreement, in each case including the statutes, regulations and written directives of the FDA, the EMA and any other Regulatory
Authorities, the Federal Food, Drug & Cosmetic Act, as amended, the Prescription Drug Marketing Act, the Federal Health Care Programs Anti-Kickback Law, 42 U.S.C. 1320a-7b(b), the statutes, regulations and written directives of Medicare,
Medicaid and all other health care programs, as defined in 42 U.S.C. § 1320a-7b(f), and the Foreign Corrupt Practices Act of 1977, each as may be amended from time to time. 

9.6     Disclaimer.    EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO
REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN
BY OR ON BEHALF OF A PARTY, AND ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. 
  

	10.	INDEMNIFICATION AND LIMITATION OF LIABILITY 

10.1    Indemnification. 

(a)     Indemnification by Lumena.  Lumena shall defend, indemnify, and hold Sanofi
and its Affiliates and their respective officers, directors, employees, and agents (the “Sanofi Indemnitees”) harmless from and against any and all damages or other amounts payable to a Third Party

  
 32 

 
claimant, as well as any reasonable attorneys’ fees and costs of litigation incurred by such Sanofi Indemnitees, all to the extent resulting from claims, suits, proceedings, or causes of
action brought by such Third Party (“Claims”) against such Sanofi Indemnitees that arise from or are based on: (i) the Development, Manufacture or Commercialization of Licensed Products, or performance of the CMC Activities or
the manufacture of Compounds, by or on behalf of Lumena or its Affiliates or its or their sublicensees or subcontractors (excluding in all cases Sanofi or its Affiliates); (ii) the breach of any of Lumena’s obligations under this Agreement
including Lumena’s representations, warranties or covenants set forth herein; or (iii) the willful misconduct or negligent acts of Lumena or any of its Affiliates or any of its or their respective officers, directors, employees or agents.

 (b)     Indemnification by Sanofi.  Sanofi shall defend, indemnify, and hold
Lumena and its Affiliates and their respective officers, directors, employees, and agents (the “Lumena Indemnitees”) harmless from and against any and all damages or other amounts payable to a Third Party claimant, as well as any
reasonable attorneys’ fees and costs of litigation incurred by such Lumena Indemnitees, all to the extent resulting from Claims against such Lumena Indemnitees that arise from or are based on: (i) the performance by or on behalf of Sanofi
of the CMC Activities with respect to the Additional Existing Materials, (ii) the Development, manufacture or Commercialization of Licensed Products by or on behalf of Sanofi or its Affiliates or its or their sublicensees or subcontractors
under any license granted pursuant to Section 8.6(b), (iii) the breach of any of Sanofi’s obligations under this Agreement including of Sanofi’s representations, warranties or covenants set forth herein; or (iv) the willful
misconduct or negligent acts of Sanofi or any of its Affiliates or any of its or their respective officers, directors, employees or agents. The foregoing indemnity obligation shall not apply to the extent to the extent that any of the Claims arises
from, is based on, or results from any activity set forth in Section 10.1(a)(i), (ii) or (iii) for which Lumena is obligated to indemnify the Sanofi Indemnitees under Section 10.1(a). 

(c)     Indemnification Procedures.  The Party seeking indemnification
(individually, the “Indemnified Party”), shall promptly notify the other Party (the “Indemnifying Party”) in writing of the Claim. Such Claim for indemnity shall indicate the nature of the Claim and the basis
therefor. Promptly after a Claim is made for which the Indemnified Party seeks indemnity, the Indemnified Party shall permit the Indemnifying Party, at its option and expense, to assume the complete defense of such Claim, provided that (i) the
Indemnified Party will have the right to participate in the defense of any such Claim at its own cost and expense, (ii) the Indemnifying Party will conduct the defense of any such Claim with due regard for the business interests and potential
related liabilities of the Indemnified Party, and (iii) the Indemnifying Party will not agree to any settlement that would admit liability on the part of the Indemnified Party or involve relief other than payment of money, without the approval
of the Indemnified Party, not to be unreasonably withheld; and provided, further, that if it is reasonably likely that the Parties may have conflicting interests or if it is otherwise not advisable under applicable legal and ethical
requirements for the Indemnifying Party’s defense counsel to represent both Parties, separate independent counsel shall be retained for each Party at its own expense. The Indemnifying Party will not, in defense of any such Claim, except with
the consent of the Indemnified Party, consent to the entry of any judgment or enter into any settlement which does not include, as an unconditional term thereof, the giving by the claimant or plaintiff to the Indemnified Party of a release from all
liability in respect thereof. After notice to the Indemnified Party of the Indemnifying Party’s election to assume the defense of such Claim, the Indemnifying Party shall be liable to the Indemnified Party for such legal or other expenses
subsequently incurred by the Indemnified Party in connection with the defense thereof at the request of the Indemnifying Party. As to those Claims with respect to which the Indemnifying Party does not elect to assume control of the defense, the
Indemnified Party will afford the Indemnifying Party an opportunity to participate in such defense at the Indemnifying Party’s own cost and expense, and will not settle or otherwise dispose of any of the same without the consent of the
Indemnifying Party. 

  
 33 

 10.2     Limitation of
Liability.  NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF
SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 10.2 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 10.1 OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF
CONFIDENTIALITY OBLIGATIONS IN ARTICLE 7. 
 10.3     Insurance.  Each Party shall
procure and maintain insurance, including product liability insurance, with respect to its activities hereunder and which is consistent with normal business practices of prudent companies similarly situated at all times during which any Product is
being clinically tested in human subjects or commercially distributed or sold. Each Party shall provide the other Party with evidence of such insurance upon request and shall provide the other Party with written notice at least thirty (30) days
prior to the cancellation, non-renewal or material changes in such insurance. It is understood that such insurance shall not be construed to create a limit of either Party’s liability with respect to its indemnification obligations under this
Article 10. 
  

	11.	DISPUTE RESOLUTION 

11.1     Disputes.  The Parties recognize that disputes as to certain matters may
from time to time arise that relate to either Party’s rights and/or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising under this Agreement in an expedient manner
by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Article 11 to resolve any controversy or claim arising out of, relating to or in connection with any
provision of this Agreement, if and when a dispute arises under this Agreement. 

11.2     Internal Resolution; Mediation.  With respect to all disputes arising
between the Parties under this Agreement, including any alleged breach under this Agreement or any issue relating to the interpretation or application of this Agreement, if the Parties are unable to resolve such dispute within [...***...]
after such dispute is first notified by either Party in writing to the other, the Parties shall refer such dispute to the Executive Officers (or their designees) for attempted resolution by good faith negotiations within [...***...] after such
notice is received, including at least [...***...] in person [...***...] of the Executive Officers within [...***...] after such notice is received. If the Executive Officers of the Parties are not able to resolve such disputed
matter within [...***...] and either Party wishes to pursue the matter, the Parties agree to submit the disputed matter for non-binding mediation (with the understanding that the role of the mediator shall not be to render a decision but to
assist the Parties in reaching a mutually acceptable resolution), for a period of not more than [...***...]. 

11.3     Binding Arbitration.  If the disputed matter is not resolved by non-binding
mediation under Section 11.2 within [...***...] and either Party wishes to pursue the matter, each such dispute, controversy or claim, subject to Section 11.4, shall be finally resolved by binding arbitration administered by the
International Chamber of Commerce (“ICC”) pursuant to its Dispute Resolution Rules then in effect, and judgment on the arbitration award may be entered in any court having jurisdiction thereof. The Parties agree that: 

(a)     The arbitration shall be conducted by a panel of three persons experienced in the
pharmaceutical business. Within [...***...] after initiation of arbitration, each Party shall select one person to act as arbitrator and the two Party-selected arbitrators shall select a third arbitrator within [...***...] of their
appointment. If the arbitrators selected by the Parties are unable or fail to agree upon 

  
 34 

 
the third arbitrator, the third arbitrator shall be appointed by the ICC. The place of arbitration shall be New York, New York, and all proceedings and communications shall be in English. 

(b)     Either Party may apply to the arbitrators for interim injunctive relief until the
arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary to protect the
rights or property of that Party pending the arbitration award. The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damage. Each Party shall bear its own costs and
expenses and attorneys’ fees and an equal share of the arbitrators’ fees and any administrative fees of arbitration, unless the arbitrators determine that a Party has incurred unreasonable expense due to vexatious or bad faith position
taken by the other Party, in which event, the arbitrators may make an award of all or any portion of such expenses so incurred. 

(c)     Reasons for the arbitrators’ decisions should be complete and explicit,
including reasonable determinations of law and fact. The written reasons should also include the basis for any damages awarded and a statement of how the damages were calculated. Such a written decision shall be rendered by the arbitrators following
a full comprehensive hearing, no later than [...***...] following the selection of the arbitrators under Section 11.3(a). 

(d)     Except to the extent necessary to confirm an award or as may be required by
applicable Laws, neither Party nor any arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties. In no event shall an arbitration be initiated after the date when commencement of
a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable statute of limitations. 

11.4     Patent Disputes.  Notwithstanding Section 11.3, any dispute,
controversy or claim relating to the scope, validity, enforceability or infringement of any Patent covering the manufacturing, use, importation, offer for sale or sale of a Licensed Product shall be submitted to a court of competent jurisdiction in
the country in which such Patent was granted. 
  

	12.	MISCELLANEOUS 

 12.1     Entire Agreement;
Amendments.  This Agreement, including the Exhibits hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the
Parties hereto with respect to the subject matter hereof, and supersedes all prior agreements and understandings between the Parties with respect to the subject matter hereof. There are no covenants, promises, agreements, warranties,
representations, conditions or understandings, either oral or written, between the Parties other than as are set forth in this Agreement. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties
unless reduced to writing and signed by an authorized officer of each Party. 
 12.2     Force
Majeure.  Each Party shall be excused from the performance of its obligations under this Agreement to the extent that such performance is prevented by force majeure (as defined below) and the nonperforming Party promptly provides
notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming Party takes reasonable efforts to remove the condition. For purposes of this Agreement,
“force majeure” shall include conditions beyond the control of the Parties, including an act of God, war, civil commotion, terrorism, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers,
destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. Notwithstanding the foregoing, the payment of amounts due and owing hereunder shall in no 

  
 35 

 
event be delayed by the payor because of a force majeure affecting the payor. 

12.3      Notices.  Any notices given under this Agreement shall be in writing,
addressed to the Parties at the following addresses, and delivered by person, by facsimile (with receipt confirmation), or by FedEx or other reputable courier service. Any such notice shall be deemed to have been given: (a) as of the day of
personal delivery; (b) one (1) day after the date sent by facsimile service; or (c) on the day of successful delivery to the other Party confirmed by the courier service. Unless otherwise specified in writing, the mailing addresses of
the Parties shall be as described below. 
 If to Lumena: 

Lumena Pharmaceuticals, Inc. 

C/O Pappas Ventures 

2520 Meridian Parkway, Suite 400 

Durham 

NC 27713 

Attention: Mike Grey 

With copies (which shall not constitute notice) to: 

Cooley LLP 

4401 Eastgate Mall 

San Diego 

CA 92121-1909 

Attention: Jason Kent 

FAX: +1 858 550 6420 

If to Sanofi: 

Sanofi 

54 rue la Boétie 

75008 Paris 

France 

Attention: General Counsel 

FAX: +33 1 53 77 43 03 

With a copy (which shall not constitute notice) to: 

Sanofi 

9 Rue du Président Allende 94256 Gentilly Cedex 

France 

Attention: License Management 

FAX: +33 1 53 77 48 51 

12.4     Assignment.  Neither Party may assign or transfer this Agreement or any
rights or obligations hereunder without the prior written consent of the other, except that a Party may make such an assignment without the other Party’s consent to its Affiliates, including in connection with any re-domiciling of such Party or
its Affiliates, or, subject to Sanofi’s rights in Section 2.8, to a Third Party successor to substantially all of the business of such Party to which this Agreement relates (such Third Party, an “Acquiror”), whether in a
merger, sale of stock, sale of assets or other transaction. Any permitted assignment shall be binding on the successors of the assigning Party and any Acquiror or 

  
 36 

 
successor or assignee of a Party’s rights and/or obligations hereunder shall, in writing to the other Party, expressly assume performance of such Party’s rights and/or obligations under
this Agreement. Any assignment or attempted assignment by either Party in violation of the terms of this Section 12.4 shall be null, void and of no legal effect. 

12.5     Performance by Affiliates.  Each Party may discharge any obligations and
exercise any right hereunder through any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this
Agreement in connection with such performance. Any breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party
without any obligation to first proceed against such Party’s Affiliate. 
 12.6     Further
Actions.  Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

12.7     Severability.  If any of the provisions of this Agreement are held to be
invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties
shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized. 

12.8     No Waiver.  Any delay in enforcing a Party’s rights under this
Agreement or any waiver as to a particular default or other matter shall not constitute a waiver of such Party’s rights to the future enforcement of its rights under this Agreement, excepting only as to an express written and signed waiver as
to a particular matter for a particular period of time. 
 12.9      Independent
Contractors.  Each Party shall act solely as an independent contractor, and nothing in this Agreement shall be construed to give either Party the power or authority to act for, bind, or commit the other Party in any way. Nothing herein
shall be construed to create the relationship of partners, principal and agent, or joint-venture partners between the Parties. 

12.10    Governing Law.  Resolution of all disputes, controversies or claims arising out
of, relating to or in connection with this Agreement or the performance, enforcement, breach or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the State of New York,
U.S., without regard to conflicts of law rules. 
 12.11     Construction of this
Agreement.  When used in this Agreement, “including” means “including without limitation”. References to either Party include the successors and permitted assigns of that Party. The headings of this
Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The Parties have each consulted counsel of their choice
regarding this Agreement and have jointly prepared this Agreement, and, accordingly, no provisions of this Agreement shall be construed against either Party on the basis that the Party drafted this Agreement or any provision thereof. If the terms of
this Agreement conflict with the terms of any Exhibit, then the terms of this Agreement shall govern. This Agreement has been prepared in the English language and English shall control its interpretation. 

12.12     Counterparts.  This Agreement may be executed in two (2) or more
counterparts, each 

  
 37 

 
of which shall be an original and all of which shall constitute together the same document. Counterparts may be signed and delivered by facsimile, or electronically in PDF format, each of which
shall be binding when sent. 
 IN WITNESS WHEREOF, the Parties have
executed this Agreement in duplicate originals by their proper officers as of the Effective Date. 
  

									
	LUMENA PHARMACEUTICALS, INC.	 		 	SANOFI-AVENTIS DEUTSCHLAND GMBH
			
	 /s/ M G Grey
	 		 	
					
	 By:
	 	   M G Grey
	 		 	 By:
	 	 /s/ Illegible

									
					
	 Title:
	 	  President & CEO
	 		 	  Title:
	 	  General Manager R & D

					
	 Date:
	 	  September 27, 2012
	 		 	  Date:
	 	  27.09.2012

									
					
		 		 		 	     By:
	 	  /s/ Klaus Menken

									
					
		 		 		 	       Title:
	 	  Dr. Klaus Menken

					
		 		 		 	       Date:
	 	  27.09.2012

  
 38 

 Exhibit 1.39 

Sanofi Know-How 

[Attached] 

 [...***...] 

 Exhibit 1.40 

Sanofi Patents 
  

													
	Sanofi Reference	  	Country	  	 Filing

date
	  	Filing number	  	Publication
date	  	Grant
date	  	Grant no.
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]	  	[...***...]

 Exhibit 1.43 

Series A-1 Preferred Stock 

The Series A-1 Preferred Stock will have terms substantially equivalent to the Series A Preferred Stock except for the
following: (i) the holders of the Series A-1 Preferred Stock shall have the information rights substantially equivalent to those set forth below under “Information Rights”, (ii) the liquidation preference of the Series A
Preferred Stock shall be senior to the liquidation preference of the Series A-1 Preferred Stock, and (iii) the Series A-1 Preferred Stock shall be non-voting except as to matters required by law and provisions commonly known as protective
provisions substantially equivalent to those set forth below under “Protective Provisions”. 
 Information Rights. 

(i)        Delivery of Financial Statements.  As long as Sanofi owns
not less than fifty percent (50%) of the Series A-1 Preferred Stock it is receiving under this Agreement (or an equivalent amount of Common Stock issued upon conversion thereof), Lumena shall deliver to Sanofi: audited annual and audited or
unaudited quarterly financial statements, and other financial information as determined by Lumena’s Board of Directors (the “Board”) and as received by any other stockholders, such as budgets and capitalization information;
provided, however, that Lumena shall not be obligated under this Section to provide information (a) that Lumena reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable
confidentiality agreement, in form acceptable to Lumena) or (b) the disclosure of which would adversely affect the attorney-client privilege between Lumena and its counsel. Notwithstanding the foregoing, Lumena may cease providing the
information set forth in this Section during the period starting with the date sixty (60) days before Lumena’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with
the United States Securities and Exchange Commission rules applicable to such registration statement and related offering; provided that Lumena’s obligations under this Section shall be reinstated at such time as Lumena is no longer actively
employing its commercially reasonable efforts to cause such registration statement to become effective. 

(ii)       Termination of Information Rights.  The covenants set forth in
Section (i) shall terminate and be of no further force or effect (a) when Lumena first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Securities Exchange Act of 1934, as amended, or successor
provisions or (b) upon a Deemed Liquidation Event, as such term (or comparable term) is defined in Lumena’s Charter, or (c) if the License Agreement between Sanofi and Lumena is terminated by Lumena for material breach by Sanofi,
whichever event occurs first. 
 (iii)      Confidentiality.  Sanofi agrees
that it will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in Lumena) any confidential information obtained from Lumena pursuant to the terms of this Agreement (including information
obtained pursuant to Section (i) above, and notice of Lumena’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a
breach of this Section by Sanofi), (b) is or has been independently developed or conceived by Sanofi without use of Lumena’s confidential information, or (c) is or has been made known or disclosed to Sanofi by a third party without a
breach of any obligation of confidentiality such third party may have to Lumena; provided, however, that Sanofi may disclose confidential information received under Section (i) above (w) to its attorneys, accountants, consultants, and
other professionals to the extent necessary to obtain their services in connection with monitoring its investment in Lumena; (x) to any prospective purchaser from Sanofi of capital stock of Lumena, if such prospective purchaser agrees in

 
form acceptable to Lumena to be bound by the provisions of this Section (unless Lumena determines that such disclosure may result in disclosure of trade secrets or a conflict of interest, or if
the receiving party is a competitor of Lumena); or (y) as may otherwise be required by law, provided that Sanofi promptly notifies Lumena of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

Protective Provisions 

At any time when shares of Series A-1 Preferred Stock are outstanding, Lumena shall not, without the consent of the holders of
at least 80% of the outstanding Series A-1 Preferred Stock, voting as a separate class, amend Lumena’s Charter or Bylaws if the proposed amendment would alter or change the powers, preferences, or special rights of the Series A-1 Preferred
Stock so as to affect them adversely; provided, however, that if any proposed amendment would alter or change the powers, preferences or special rights of one or more series of Lumena’s preferred stock, including the Series A-1 Preferred Stock,
so as to affect them adversely, then the shares of the series of preferred stock so affected by the amendment, including the Series A-1 Preferred Stock, shall vote together as a single class on the proposed amendment and the Series A-1 Preferred
Stock shall not be entitled to vote as a separate class on such proposed amendment, unless otherwise required by the Delaware General Corporation Law. 

 Exhibit 4.2 

Initial Materials Specifications 

Specifications for SAR 548304B drug substance (Batch [...***...]) 

Table 1 lists the tests to be performed for release. The tests have to be carried out with each batch unless period testing is indicated. 

An additional column indicates the tests to be performed for retest. 

The acceptance criteria are valid for release and retest, unless otherwise indicated. 

References to pharmacopoeial analytical procedures and acceptance criteria are made to the current versions of the pharmacopoeias including
their supplements. In cases where more than one pharmacopoeia is referred to, all requirements have to be fulfilled 
 Table 1—
Specifications for SAR 548304B drug substance; batch [...***...] 
  

							
	Test	  	     Analytical

    procedure

    reference
	  	Acceptance Criteria	  	    Retest
	  	  	 	  	 	  	  
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]

 [...***...] 

Results of Analysis for SAR 548304B drug substance for Batch [...***...] 

[...***...] 

 Exhibit 4.3 

Additional Existing Materials 

Quantities & Specifications: 
  

	 	•	 	 [...***...] 

 CMC
Activities: 
  

	 	•	 	 [...***...] 

 Exhibit 4.5 

Development Plan 

SAR548304 is a [...***...] 

In this document, the development of SAR548304 is described in general terms from licensing through the FDA NDA submission. The anticipated
steps in the clinical and regulatory development of SAR548304 are as follows: 

      [...***...] 

 Exhibit 5.2 

Supply Terms 
  

			
	 Parties
	  	
LUMENA
 SANOFI AVENTIS DEUTSCHLAND
GMBH
  

	 Compound
	  	 SAR-548304
and [... ***... ].
  

	PRE-COMMERCIAL
SUPPLY
	 Pre-commercial Supply

 
	  	 [... ***... ]

	 Pricing Quotation
	  	
[... ***... ]
 The quotation
is subject to further negotiation by the parties provided however that the costs associated with the activities and other items outlined in the quotation represent the maximum cost for such activities and items.

 
 LUMENA and SANOFI will cooperate to reduce the cost for
supply of SAR548304.

			
	 Order
	  	
Any Purchase Orders for [...***...] placed by LUMENA, shall be placed on the
understanding that [...***...]

 

	 Liability
	  	
[...***...]
  

In no event shall either party be liable to the other party for [...***...]

 
 Liability for missing quantities of Compound

(a)  In the event that the amount of Compound delivered by SANOFI to LUMENA for a Purchase Order is below [...***...] of the ordered
quantity, [...***...]
  
 (b)  Should LUMENA elect
(i) under paragraph (a) above, [...***...]
  

(c)  [...***...]
  

Liability for non-conforming Compound and latent defect

If LUMENA discovers a nonconformance of any Compound with the specifications attributable to Sanofi or its Affiliates, sublicensees or
subcontractors, LUMENA shall contact SANOFI and [...***...]
  

As soon as LUMENA discovers a latent defect (i.e. defects that are not discoverable upon reasonable physical inspection or reasonable testing)
in any Compound, it shall notify SANOFI of the batches containing such latent defect within [...***...]
  

The parties shall cooperate in good faith to resolve any disputes arising in connection with the preceding sections, and, in the event that the
parties are unable to resolve such dispute within [...***...] from the date of LUMENA’s notice, then the parties shall jointly appoint an independent expert. The appointed expert will resolve such dispute. The determination of the expert
shall be final and binding. [...***...]
  
 In the
event of non-conformance of a Compound or a latent defect duly evidenced to be attributable to SANOFI or its Affiliates, sublicensees or subcontractors, SANOFI’s sole liability with respect thereto shall be limited, [...***...]

 
 In the event the replacement delivery is still not in
compliance with the technical and quality specifications, due to SANOFI’s or any of its Affiliates, sublicensees or subcontractors negligence or mistake, [...***...]

 
 Limitation of Liability.

In no event shall SANOFI’s total aggregate liability for any loss or damage suffered by LUMENA as a result of a
breach exceed, [...***...]
  

			
	 Indemnification
	  	
SANOFI shall be liable for and agrees to indemnify and save LUMENA, its affiliates and their directors, officers, employees, and agents,
harmless against any and all liability, damages, demands, claims, actions, proceedings, suits, judgments, costs, losses, and expenses that may be brought by a third-party (hereinafter referred to as “Claims”) against LUMENA, as a direct
result of any breach by SANOFI of its obligations or warranties hereunder, except to the extent that such Claims are due to the negligence, gross negligence, or intentional misconduct of LUMENA.

 
 LUMENA shall be liable for and agrees to indemnify and save
SANOFI (including its affiliated companies), its directors, officers, employees and agents harmless against any and all liability, damages, demands, claims, actions, proceedings, suits, judgments, costs, losses, and expenses that may be brought by a
third-party (hereinafter referred to as “Claims”) against SANOFI as a direct result of any breach by LUMENA of its obligations or warranties hereunder, except to the extent that such Claims are due to the negligence, gross negligence, or
intentional misconduct of SANOFI.
  
 If either party
expects to seek indemnification under this Agreement with respect to a Claim, made, or filed, the party seeking indemnification shall :

i)  promptly give notice to the other party of any such Claim against it, such Claim forming
the basis of indemnification under this Agreement, and
 ii) fully cooperate with the other
party in the investigation and defence of all such Claim.
  

The indemnifying party shall have the option to assume the other party’s defence in any such Claim with counsel reasonably satisfactory to
the other party. No settlement or compromise shall be binding on a party hereto without such party’s prior written consent, which will not be unreasonably withheld. The party seeking indemnification shall have the right of appearance of counsel
of its own selection, at its own cost and expense.
  

	 Termination
	  	
Either party may terminate the Pre-Commercial Supply Agreement, without prejudice to any claim for damages, if [...***...]

 
 LUMENA may terminate the Pre-Commercial Supply Agreement for
convenience at any time upon [...***...] and LUMENA shall pay SANOFI [...***...]
  

If LUMENA discontinues the development of Licensed Product, then [...***...]

 
 If LUMENA terminates the Pre-Commercial Supply Agreement for
material breach by SANOFI after the remedy period, then [...***...]
  

Either party may immediately terminate the Pre-Commercial Supply Agreement, by written notice to the other party in the following events:

 

a)    [...***...]

 

			
	 	  	
b)    [...***...]

 

	Effects of expiry or early termination	  	
Upon early termination of the Pre-Commercial Supply Agreement by LUMENA for breach by SANOFI, [...***...]

 
 Upon early termination of the Pre-Commercial Supply
Agreement by LUMENA if LUMENA decides to stop the development of the Licensed Product, for insolvency or bankruptcy of SANOFI, or a force majeure event or for convenience, [...***...]

 
 Upon any early termination SANOFI shall:

(i)   [...***...]

(ii)  [...***...]

 
 Upon early termination of the Pre-Commercial Supply
Agreement by SANOFI due to a breach by LUMENA, [...***...]
  

			
	 COMMERCIAL
SUPPLY

	Commercial Supply	  	 At
LUMENA’S discretion, LUMENA may elect to provide SANOFI with a request for proposal for the commercial supply of Compound. If LUMENA provides such request, SANOFI will evaluate the request for proposal and issue a quotation within
[...***...] of receipt of LUMENA’s request for proposal, for industrial supply of Compound with the manufacturing process used for the manufacture and supply of the commercial Compound.

 

	 Term
	  	
•     [...***...]

 

	Minimum Annual Volume Commitment	  	
LUMENA shall commit to purchase and SANOFI shall supply LUMENA with an annual minimum quantity of Compound to be agreed upon by the Parties,
such minimum quantity to represent at least [...***...] of LUMENA’s annual total requirements of Compound.
  

	 Order
	  	
Purchase Order for the first delivery of commercial supply to be placed at least [...***...] before the first delivery of the commercial
Compound to LUMENA.
  

	 Pricing
	  	
•     The initial price is currently estimated at [...***...] per kilogram of
Compound for a minimum supply of [...***...]. If a smaller quantity is requested by LUMENA, the price may be adjusted accordingly to reflect any loss of economy of scale.

 

			
	 	  	
•     Such price will be adjusted after [...***...]

•     In no event shall SANOFI be obligated to sell at a price below
[...***...]
 •     Revision of such price during the term will be limited to
[...***...]
 •     Quotation for specific quantities upon request.

 

	 Qualification of a second source supplier

 
	  	 [...***...] The Transfer of
Technology shall be performed as defined below.

	 Failure to supply
	  	
•     A failure to supply shall be deemed to exist if [...***...]

•     In the event the failure to supply continues after the remedy period agreed upon
by the parties, [...***...]
  
  
  

 

	 Forecast
	  	
•     [...***...]

 

	Manufacturing Changes	  	
•     [...***...]

 
  
  

 

	 	  	 TERMS
APPLICABLE TO BOTH PRE-COMMERCIAL AND COMMERCIAL SUPPLY AGREEMENTS
  

	 Delivery
	  	
[...***...]
  

			
	Transfer of Technology	  	
SANOFI shall transfer the process data package within [...***...] of request by LUMENA as applicable and will ensure all necessary
assistance to support the transfer of the process to LUMENA at LUMENA’s cost for any assistance and support which shall not exceed of [...***...] FTEs for [...***...].

 

	Payment	  	 SANOFI shall
invoice LUMENA promptly following the delivery of Compound to LUMENA. LUMENA shall pay such invoice no later than net [...***...] from the invoice date.

 

	Representations and Warranties	  	 Standard
representations and warranties from each party appropriate to each party’s respective obligations, including a warranty from SANOFI that the Compound will meet the defined specifications and be manufactured in accordance with all laws and
regulations including cGMP applicable to the manufacturing site.
  

	Indemnity and insurance	  	
•     Mutual rights to indemnification (defend, indemnify and hold harmless) from
damages and liabilities arising from a claim or a demand of a third party based on areas of responsibility as will be defined in the definitive agreement.

•     Each party will indemnify the other party for (i) breaches of representations and
warranties, (ii) applicable law, including cGMP, and (iii) negligence or willful misconduct.

•     Standard insurance provisions.

 

	General Provisions	  	 The definitive agreement
contemplated by SANOFI and LUMENA will contain the terms and conditions that are usual and customary in supply agreements, including but not limited to confidentiality, intellectual property, regulatory compliance, QA audit rights, warranties
etc.
  

	Quality Agreement	  	 Contemporaneously with the
execution of the supply agreements, the parties will enter into customary quality agreements.
  

 Exhibit 9.2(a) 

Series A Agreements; Charter 

[Attached] 

 LUMENA PHARMACEUTICALS, INC. 

INVESTOR RIGHTS AGREEMENT 

THIS INVESTOR RIGHTS AGREEMENT (the
“Agreement”) is entered into as of the 19th day of June, 2012, by and among LUMENA PHARMACEUTICALS, INC.,
a Delaware corporation (the “Company”), and the entities listed on EXHIBIT A hereto (each, an “Investor” and together the “Investors”). 

RECITALS 

WHEREAS, the Investors are purchasing shares of the Company’s Series A Preferred
Stock (the “Series A Preferred”) pursuant to that certain Series A Preferred Stock Purchase Agreement (the “Purchase Agreement”) of even date herewith (the “Financing”);

 WHEREAS, pursuant to agreements for the acquisition or licensing of technology or
intellectual property by the Company (each such agreement, a “Strategic Agreement”), the Company will issue to certain third parties shares of the Company’s Series A-1 Preferred Stock (the “Series A-1
Preferred”) concurrent with the Financing and may issue to an additional third party shares of Series A-1 Preferred in the future; 

WHEREAS, the obligations in the Purchase Agreement are conditioned upon the execution and
delivery of this Agreement; and 
 WHEREAS, in connection with the consummation of the
Financing, the parties desire to enter into this Agreement in order to grant registration rights, information rights and other rights to the Investors as set forth below. 

NOW, THEREFORE, in consideration of these premises
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

SECTION 1. GENERAL. 

1.1      Definitions. As used in this Agreement the following terms shall have the
following respective meanings: 
 (a)      “Exchange Act”
means the Securities Exchange Act of 1934, as amended. 
 (b)      “Form
S-3” means such form under the Securities Act as in effect on the date hereof or any successor or similar registration form under the Securities Act subsequently adopted by the SEC which permits inclusion or incorporation of substantial
information by reference to other documents filed by the Company with the SEC. 

(c)      “Holder” means any person owning of record Registrable
Securities that have not been sold to the public or any assignee of record of such Registrable Securities in accordance with Section 2.9 hereof. 

  
 1. 

 (d)      “Initial
Offering” means the Company’s first firm commitment underwritten public offering of its Common Stock registered under the Securities Act. 

(e)      “Register,” “registered,” and
“registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration
statement or document. 
 (f)      “Registrable Securities”
means (a) Common Stock of the Company issuable or issued upon conversion of the Shares, (b) any Common Stock of the Company issued as (or issuable upon the conversion or exercise of any warrant, right or other security which is issued as)
a dividend or other distribution with respect to, or in exchange for or in replacement of, such above-described securities and (c) any other Common Stock of the Company that may be held from time to time by the Investors. Notwithstanding the
foregoing, Registrable Securities shall not include any securities (i) sold by a person to the public either pursuant to a registration statement or Rule 144 or (ii) sold in a private transaction in which the transferor’s rights under
Section 2 of this Agreement are not assigned. 
 (g)      “Registrable
Securities then outstanding” shall be the number of shares of the Company’s Common Stock that are Registrable Securities and either (a) are then issued and outstanding or (b) are issuable pursuant to then exercisable or
convertible securities. 
 (h)      “Registration Expenses”
shall mean all expenses incurred by the Company in complying with Sections 2.2, 2.3 and 2.4 hereof, including, without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel for the Company, reasonable
fees and disbursements not to exceed $25,000 of a single special counsel for the Holders, blue sky fees and expenses and the expense of any special audits incident to or required by any such registration (but excluding the compensation of regular
employees of the Company which shall be paid in any event by the Company). 

(i)      “SEC” or “Commission” means the
Securities and Exchange Commission. 
 (j)      “Securities
Act” shall mean the Securities Act of 1933, as amended. 

(k)      “Selling Expenses” shall mean all underwriting
discounts and selling commissions applicable to the sale. 

(1)      “Shares” shall mean the Series A Preferred issued
pursuant to the Purchase Agreement and the Series A-1 Preferred issued pursuant to Strategic Agreements. 

(m)      “Special Registration Statement” shall mean (i) a
registration statement relating to any employee benefit plan or (ii) with respect to any corporate reorganization or transaction under Rule 145 of the Securities Act, any registration statements related to the issuance or resale of securities
issued in such a transaction or (iii) a registration related to stock issued upon conversion of debt securities. 

  
 2. 

 SECTION 2. REGISTRATION; RESTRICTIONS ON TRANSFER. 

2.1      Restrictions on Transfer. 

(a)      Each Holder agrees not to make any disposition of all or any portion of the
Shares or Registrable Securities unless and until: 
 (i)      there is then in effect
a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 

(ii)      (A) The transferee has agreed in writing to be bound by the terms of this
Agreement, (B) such Holder shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and (C) if reasonably
requested by the Company, such Holder shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require registration of such shares under the Securities Act. It is agreed that
the Company will not require opinions of counsel for transactions made pursuant to Rule 144, except in unusual circumstances. After its Initial Offering, the Company will not require any transferee pursuant to Rule 144 to be bound by the terms of
this Agreement if the shares so transferred do not remain Registrable Securities hereunder following such transfer. 

(b)      Notwithstanding the provisions of subsection (a) above, no such
restriction shall apply to a transfer by a Holder that is (A) a partnership transferring to its partners or former partners in accordance with partnership interests, (B) a partnership transferring to one or more affiliated partnerships or
funds managed by it or any of its respective directors, officers or partners, (C) a corporation transferring to a wholly-owned subsidiary or a parent corporation that owns all of the capital stock of the Holder, (D) a limited liability
company transferring to its members or former members in accordance with their interest in the limited liability company, or (E) an individual transferring to the Holder’s family member or trust for the benefit of an individual Holder;
provided that in each case the transferee will agree in writing to be subject to the terms of this Agreement to the same extent as if he were an original Holder hereunder. 

(c)      Each certificate representing Shares or Registrable Securities shall be stamped
or otherwise imprinted with legends substantially similar to the following (in addition to any legend required under applicable state securities laws): 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE
“ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY
AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 

  
 3. 

 THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES
REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN INVESTOR RIGHTS AGREEMENT BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE
COMPANY. 
 (d)      The Company shall be obligated to reissue promptly unlegended
certificates at the request of any Holder thereof if the Company has completed its Initial Offering and the Holder shall have obtained an opinion of counsel (which counsel may be counsel to the Company) reasonably acceptable to the Company to the
effect that the securities proposed to be disposed of may lawfully be so disposed of without registration, qualification and legend, provided that the second legend listed above shall be removed only at such time as the Holder of such
certificate is no longer subject to any restrictions hereunder. 
 (e)      Any legend
endorsed on an instrument pursuant to applicable state securities laws and the stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company of an order of the appropriate blue sky authority authorizing such
removal. 
 2.2      Demand Registration. 

(a)      Subject to the conditions of this Section 2.2, if the Company shall
receive a written request from the Holders of at least 62% of the Registrable Securities (the “Initiating Holders”) that the Company file a registration statement under the Securities Act covering the registration of at least
25% of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of underwriting discounts and commissions, would exceed $10,000,000, then the Company shall, within 15 days of the receipt
thereof, give written notice of such request to all Holders, and, subject to the limitations of this Section 2.2, as soon as practicable, and in any event within sixty days after the date such request is given by the Initiating Holders, file a
Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other
Holders, and effect, as expeditiously as reasonably possible, the registration under the Securities Act of all Registrable Securities that all Holders request to be registered. 

(b)      If the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.2 or any request pursuant to Section 2.4 and the Company shall include such information in
the written notice referred to in Section 2.2(a) or Section 2.4(a), as applicable. In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation
in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting
agreement in customary form with the underwriter 

  
 4. 

 
or underwriters selected for such underwriting by the Holders of at least 62% of the Registrable Securities held by all Initiating Holders (which underwriter or underwriters shall be reasonably
acceptable to the Company). Notwithstanding any other provision of this Section 2.2 or Section 2.4, if the underwriter advises the Company in writing that marketing factors require a limitation of the number of securities to be
underwritten (including Registrable Securities) then the Company shall so advise all Holders of Registrable Securities that would otherwise be underwritten pursuant hereto, and the number of shares that may be included in the underwriting shall be
allocated to the Holders of such Registrable Securities on a pro rata basis based on the number of Registrable Securities held by all such Holders (including the Initiating Holders); provided, however, that the number of shares of
Registrable Securities to be included in such underwriting and registration shall not be reduced unless all other securities of the Company are first entirely excluded from the underwriting and registration. Any Registrable Securities excluded or
withdrawn from such underwriting shall he withdrawn from the registration. 
 (c)     The
Company shall not be required to effect a registration pursuant to this Section 2.2: 

(i)      prior to the earlier of (A) the fifth anniversary of the date of this
Agreement or (B) of the expiration of the restrictions on transfer set forth in Section 2.11 following the Initial Offering; 

(ii)      after the Company has effected two registrations pursuant to this
Section 2.2, and such registrations have been declared or ordered effective; 

(iii)     during the period starting with the date of filing of, and ending on the date 180
days following the effective date of the registration statement pertaining to a public offering, other than pursuant to a Special Registration Statement; provided that the Company makes reasonable good faith efforts to cause such registration
statement to become effective; 
 (iv)     if within 30 days of receipt of a written
request from Initiating Holders pursuant to Section 2.2(a), the Company gives notice to the Holders of the Company’s intention to file a registration statement for a public offering, other than pursuant to a Special Registration Statement
within 90 days; 
 (v)      if the Company shall furnish to Holders requesting a
registration statement pursuant to this Section 2.2 a certificate signed by the Chairman of the Board stating that in the good faith judgment of the Board of Directors of the Company (the “Board”), it would be seriously
detrimental to the Company and its stockholders for such registration statement to be effected at such time, in which event the Company shall have the right to defer such filing for a period of not more than 120 days after receipt of the request of
the Initiating Holders; provided that such right to delay a request shall be exercised by the Company not more than once in any 12 month period; 

(vi)     if the Initiating Holders propose to dispose of shares of Registrable Securities
that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.4 below; or 

  
 5. 

 (vii)    in any particular jurisdiction in which the
Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance. 

2.3      Piggyback Registrations. The Company shall notify all Holders of Registrable
Securities in writing at least 15 days prior to the filing of any registration statement under the Securities Act for purposes of a public offering of securities of the Company (including, but not limited to, registration statements relating to
secondary offerings of securities of the Company, but excluding Special Registration Statements) and will afford each such Holder an opportunity to include in such registration statement all or part of such Registrable Securities held by such
Holder. Each Holder desiring to include in any such registration statement all or any part of the Registrable Securities held by it shall, within 15 days after the above-described notice from the Company, so notify the Company in writing. Such
notice shall state the intended method of disposition of the Registrable Securities by such Holder. If a Holder decides not to include all of its Registrable Securities in any registration statement thereafter filed by the Company, such Holder shall
nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the Company with respect to offerings of its securities, all upon the terms and
conditions set forth herein. 
 (a)      Underwriting. If the registration statement
of which the Company gives notice under this Section 2.3 is for an underwritten offering, the Company shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder to include Registrable Securities in a
registration pursuant to this Section 2.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All
Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company. Notwithstanding
any other provision of this Agreement, if the underwriter determines in good faith that marketing factors require a limitation of the number of shares to be underwritten, the number of shares that may be included in the underwriting shall be
allocated, first, to the Company; second, to the Holders on a pro rata basis based on the total number of Registrable Securities held by the Holders; and third, to any stockholder of the Company (other than a Holder) on a pro rata
basis; provided, however, that no such reduction shall reduce the amount of securities of the selling Holders included in the registration below 30% of the total amount of securities included in such registration, unless such offering is the
Initial Offering and such registration does not include shares of any other selling stockholders, in which event any or all of the Registrable Securities of the Holders may be excluded in accordance with the immediately preceding clause. In no event
will shares of any other selling stockholder be included in such registration that would reduce the number of shares which may be included by Holders without the written consent of Holders of not less than at least 62% of the Registrable Securities
proposed to be sold in the offering. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter, delivered at least 10 business days prior to the
effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the registration. For any Holder which is a partnership, limited liability company or
corporation, the partners, retired partners, members, retired members and stockholders of such Holder, or the estates and family members of any such 

  
 6. 

 
partners, retired partners, members and retired members and any trusts for the benefit of any of the foregoing person shall be deemed to be a single “Holder,” and any pro rata
reduction with respect to such “Holder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such “Holder,” as defined in this sentence. 

(b)      Right to Terminate Registration.  The Company shall have the right to
terminate or withdraw any registration initiated by it under this Section 2.3 whether or not any Holder has elected to include securities in such registration, and shall promptly notify any Holder that has elected to include shares in such
registration of such termination or withdrawal. The Registration Expenses of such withdrawn registration shall be borne by the Company in accordance with Section 2.5 hereof. 

2.4      Form S-3 Registration. In case the Company shall receive from any Holder or
Holders of Registrable Securities a written request or requests that the Company effect a registration on Form S-3 (or any successor to Form S-3) or any similar short-form registration statement and any related qualification or compliance with
respect to all or a part of the Registrable Securities owned by such Holder or Holders, the Company will: 

(a)      promptly give written notice of the proposed registration, and any related
qualification or compliance, to all other Holders of Registrable Securities; and 

(b)      as soon as practicable, effect such registration and all such qualifications
and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such
portion of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within 15 days after receipt of such written notice from the Company; provided, however, that the Company
shall not be obligated to effect any such registration, qualification or compliance pursuant to this Section 2.4: 

(i)    if Form S-3 is not available for such offering by the Holders; or 

(ii)   if the Holders, together with the holders of any other securities of the Company entitled to
inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than $1,000,000; or 

(iii)  if within 30 days of receipt of a written request from any Holder or Holders pursuant to this
Section 2.4, the Company gives notice to such Holder or Holders of the Company’s intention to make a public offering within 90 days, other than pursuant to a Special Registration Statement; or 

(iv)  if the Company shall furnish to the Holders a certificate signed by the Chairman of the Board stating
that in the good faith judgment of the Board, it would be seriously detrimental to the Company and its stockholders for such Form S-3 registration to be effected at such time, in which event the Company shall have the right to defer the filing of
the Form S-3 registration statement for a period of not more than 120 days after receipt of the 

  
 7. 

 
request of the Holder or Holders under this Section 2.4; provided that such right to delay a request shall be exercised by the Company not more than once in any 12 month period; or

 (v)      if the Company has, within the 12 month period preceding the date of such
request, already effected two registrations on Form S-3 for the Holders pursuant to this Section 2.4; or 

(vi)     in any particular jurisdiction in which the Company would be required to qualify to
do business or to execute a general consent to service of process in effecting such registration, qualification or compliance. 

(c)      Subject to the foregoing, the Company shall file a Form S-3 registration
statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the requests of the Holders. Registrations effected pursuant to this Section 2.4 shall not be counted as
demands for registration or registrations effected pursuant to Section 2.2. All Registration Expenses incurred in connection with registrations requested pursuant to this Section 2.4 after the first two registrations shall be paid by the
selling Holders pro rata in proportion to the number of shares to be sold by each such Holder in any such registration. 

2.5      Expenses of Registration. Except as specifically provided herein, all
Registration Expenses incurred in connection with any registration, qualification or compliance pursuant to Section 2.2, 2.3 or 2.4 herein shall be borne by the Company. All Selling Expenses incurred in connection with any registrations
hereunder, shall be borne by the holders of the securities so registered pro rata on the basis of the number of shares so registered. The Company shall not, however, be required to pay for expenses of any registration proceeding begun
pursuant to Section 2.2 or 2.4, the request of which has been subsequently withdrawn by the Initiating Holders unless (a) the withdrawal is based upon material adverse information concerning the Company of which the Initiating Holders were
not aware at the time of such request or (b) the Holders of at least 62% of Registrable Securities agree to deem such registration to have been effected as of the date of such withdrawal for purposes of determining whether the Company shall be
obligated pursuant to Section 2.2(c)(ii) or 2.4(b)(v), as applicable, to undertake any subsequent registration, in which event such right shall be forfeited by all Holders). If the Holders are required to pay the Registration Expenses, such
expenses shall be borne by the holders of securities (including Registrable Securities) requesting such registration in proportion to the number of shares for which registration was requested. If the Company is required to pay the Registration
Expenses of a withdrawn offering pursuant to clause (a) above, then such registration shall not be deemed to have been effected for purposes of determining whether the Company shall be obligated pursuant to Section 2.2(c)(ii) or 2.4(b)(v),
as applicable, to undertake any subsequent registration. 
 2.6      Obligations of the
Company. Whenever required to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 

(a)      Prepare and file with the SEC a registration statement with respect to such
Registrable Securities and use all reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of at least 62% of the Registrable 

  
 8. 

 
Securities registered thereunder, keep such registration statement effective for up to 30 days or, if earlier, until the Holder or Holders have completed the distribution related thereto;
provided, however, that at any time, upon written notice to the participating Holders and for a period not to exceed 60 days thereafter (the “Suspension Period”), the Company may delay the filing or effectiveness of
any registration statement or suspend the use or effectiveness of any registration statement (and the Initiating Holders hereby agree not to offer or sell any Registrable Securities pursuant to such registration statement during the Suspension
Period) if the Company reasonably believes that there is or may be in existence material nonpublic information or events involving the Company, the failure of which to be disclosed in the prospectus included in the registration statement could
result in a Violation (as defined below). In the event that the Company shall exercise its right to delay or suspend the filing or effectiveness of a registration hereunder, the applicable time period during which the registration statement is to
remain effective shall be extended by a period of time equal to the duration of the Suspension Period. The Company may extend the Suspension Period for an additional consecutive 30 days with the consent of the holders of at least 62% of the
Registrable Securities registered under the applicable registration statement, which consent shall not be unreasonably withheld. No more than two such Suspension Periods shall occur in any 12 month period. In no event shall any Suspension Period,
when taken together with all prior Suspension Periods, exceed 90 days in the aggregate. If so directed by the Company, all Holders registering shares under such registration statement shall (i) not offer to sell any Registrable Securities
pursuant to the registration statement during the period in which the delay or suspension is in effect after receiving notice of such delay or suspension; and (ii) use their reasonable efforts to deliver to the Company (at the Company’s
expense) all copies, other than permanent file copies then in such Holders’ possession, of the prospectus relating to such Registrable Securities current at the time of receipt of such notice. Notwithstanding the foregoing, the Company shall
not be required to file, cause to become effective or maintain the effectiveness of any registration statement other than a registration statement on Form S-3 that contemplates a distribution of securities on a delayed or continuous basis pursuant
to Rule 415 under the Securities Act. 
 (b)      Prepare and file with the SEC such
amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all
securities covered by such registration statement for the period set forth in subsection (a) above. 

(c)      Furnish to the Holders such number of copies of a prospectus, including a
preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 

(d)      Use its reasonable efforts to register and qualify the securities covered by
such registration statement under such other securities or Blue Sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a condition thereto
to qualify to do business or to file a general consent to service of process in any such states or jurisdictions. 

  
 9. 

 (e)      In the event of any underwritten
public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter(s) of such offering. Each Holder participating in such underwriting shall also enter into and perform
its obligations under such an agreement. 
 (f)      Notify each Holder of Registrable
Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration
statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing.
The Company will use reasonable efforts to amend or supplement such prospectus in order to cause such prospectus not to include any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to
make the statements therein not misleading in the light of the circumstances then existing. 

(g)      Use its reasonable efforts to furnish, on the date that such Registrable
Securities are delivered to the underwriters for sale, if such securities are being sold through underwriters, (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in form and
substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and (ii) a letter, dated as of such date, from the independent certified public accountants of the Company, in form and
substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering addressed to the underwriters. 

2.7       Delay of Registration; Furnishing Information. 

(a)      No Holder shall have any right to obtain or seek an injunction restraining or
otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

(b)      It shall be a condition precedent to the obligations of the Company to take any
action pursuant to Section 2.2, 2.3 or 2.4 that the selling Holders shall furnish to the Company such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities as shall
be required to effect the registration of their Registrable Securities. 

(c)      The Company shall have no obligation with respect to any registration requested
pursuant to Section 2.2 or Section 2.4 if the number of shares or the anticipated aggregate offering price of the Registrable Securities to be included in the registration does not equal or exceed the number of shares or the anticipated
aggregate offering price required to originally trigger the Company’s obligation to initiate such registration as specified in Section 2.2 or Section 2.4, whichever is applicable. 

2.8      Indemnification. In the event any Registrable Securities are included in a
registration statement under Sections 2.2, 2.3 or 2.4: 

  
 10. 

 (a)      To the extent permitted by law,
the Company will indemnify and hold harmless each Holder, the partners, members, officers and directors of each Holder, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or
underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act or other federal or state
law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a “Violation”) by the Company:
(i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated reference therein, including any preliminary prospectus or final prospectus contained therein or any amendments or
supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged violation by the
Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law in connection with the offering covered by such registration
statement; and the Company will reimburse each such Holder, partner, member, officer, director, underwriter or controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending any such
loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such
settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of
or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for use in connection with such registration by such Holder, partner, member, officer, director, underwriter or controlling
person of such Holder. 
 (b)      To the extent permitted by law, each Holder will,
if Registrable Securities held by such Holder are included in the securities as to which such registration qualifications or compliance is being effected, indemnify and hold harmless the Company, each of its directors, its officers and each person,
if any, who controls the Company within the meaning of the Securities Act, any underwriter and any other Holder selling securities under such registration statement or any of such other Holder’s partners, directors or officers or any person who
controls such Holder, against any losses, claims, damages or liabilities (joint or several) to which the Company or any such director, officer, controlling person, underwriter or other such Holder, or partner, director, officer or controlling person
of such other Holder may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any of the
following statements: (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement or incorporated reference therein, including any preliminary prospectus or final prospectus contained therein
or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading, or (iii) any violation or alleged
violation by the Company of the Securities Act (collectively, a “Holder Violation”), in each case to the extent (and only to the extent) that such Holder Violation occurs in reliance upon and in conformity with written
information furnished by such Holder under an instrument 

  
 11. 

 
duly executed by such Holder and stated to be specifically for use in connection with such registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by the
Company or any such director, officer, controlling person, underwriter or other Holder, or partner, officer, director or controlling person of such other Holder in connection with investigating or defending any such loss, claim, damage, liability or
action if it is judicially determined that there was such a Holder Violation; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such loss, claim, damage,
liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; provided further, that in no event shall any indemnity under this Section 2.8 exceed the net proceeds
from the offering received by such Holder. 
 (c)      Promptly after receipt by an
indemnified party under this Section 2.8 of notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2.8, deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other
indemnifying party similarly noticed, to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses
thereof to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any
other party represented by such counsel in such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the
indemnified party under this Section 2.8 to the extent, and only to the extent, prejudicial to its ability to defend such action, but the omission so to deliver written notice to the indemnifying party will not relieve it of any liability that
it may have to any indemnified party otherwise than under this Section 2.8. 

(d)      If the indemnification provided for in this Section 2.8 is held by a court
of competent jurisdiction to be unavailable to an indemnified party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall to the extent
permitted by applicable law contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the
one hand and of the indemnified party on the other in connection with the Violation(s) or Holder Violation(s) that resulted in such loss, claim, damage or liability, as well as any other relevant equitable considerations. The relative fault of the
indemnifying party and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided that in no event
shall any contribution by a Holder hereunder exceed the proceeds from the offering received by such Holder. 

  
 12. 

 (e)      The obligations of the Company and
Holders under this Section 2.8 shall survive completion of any offering of Registrable Securities in a registration statement and, with respect to liability arising from an offering to which this Section 2.8 would apply that is covered by
a registration filed before termination of this Agreement, such termination. No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter
into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. 

2.9        Assignment of Registration Rights. The rights to cause the Company
to register Registrable Securities pursuant to this Section 2 may be assigned by a Holder to a transferee or assignee of Registrable Securities (for so long as such shares remain Registrable Securities) that (a) is a subsidiary, parent,
general partner, limited partner, retired partner, member or retired member, or stockholder of a Holder that is a corporation, partnership or limited liability company, (b) is a Holder’s family member or trust for the benefit of an
individual Holder, or (c) acquires at least 50,000 shares of Registrable Securities (as adjusted for stock splits and combinations), or (d) is an entity affiliated by common control (or other related entity) with such Holder; provided,
however, (i) the transferor shall, within 10 days after such transfer, furnish to the Company written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being
assigned and (ii) such transferee shall agree to be subject to all restrictions set forth in this Agreement. 

2.10      Limitation on Subsequent Registration Rights.  Other than as provided
in Section 5.10, after the date of this Agreement, the Company shall not enter into any agreement with any holder or prospective holder of any securities of the Company that would grant such holder rights to demand the registration of shares of
the Company’s capital stock, or to include such shares in a registration statement that would reduce the number of shares includable by the Holders. 

2.11      “Market Stand-Off” Agreement.  Each Holder hereby agrees
that such Holder shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, any Common Stock (or other securities) of
the Company held by such Holder (other than those included in the registration) during the 180-day period following the effective date of the Initial Offering (or such longer period, not to exceed 34 days after the expiration of the 180-day period,
as the underwriters or the Company shall request in order to facilitate compliance with NASD Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation); provided that, with respect to (i) and (ii) above, all
officers and directors of the Company and holders of at least one percent of the Company’s voting securities are bound by and have entered into similar agreements. 

2.12      Agreement to Furnish Information.  Each Holder agrees to execute and
deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the Holder’s obligations under Section 2.11 or that are necessary to give further effect thereto. In addition, if
reasonably requested by the Company or the representative of the underwriters of Common Stock (or other securities) of the Company, each Holder shall provide, within 10 days of such request, such information as may be required by the Company or

  
 13. 

 
such representative in connection with the completion of any public offering of the Company’s securities pursuant to a registration statement filed under the Securities Act. The obligations
described in Section 2.11 and this Section 2.12 shall not apply to a Special Registration Statement. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to such shares of Common Stock
(or other securities) subject to the foregoing restriction until the end of such period. Each Holder agrees that any transferee of any shares of Registrable Securities shall be bound by Sections 2.11 and 2.12. The underwriters of the Company’s
stock are intended third party beneficiaries of Sections 2.11 and 2.12 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

2.13      Rule 144 Reporting. With a view to making available to the Holders the benefits
of certain rules and regulations of the SEC which may permit the sale of the Registrable Securities to the public without registration, the Company agrees to use its best efforts to: 

(a)      Make and keep public information available, as those terms are understood and
defined in SEC Rule 144 or any similar or analogous rule promulgated under the Securities Act, at all times after the effective date of the first registration filed by the Company for an offering of its securities to the general public; 

(b)      File with the SEC, in a timely manner, all reports and other documents required
of the Company under the Exchange Act; and 
 (c)      So long as a Holder owns any
Registrable Securities, furnish to such Holder forthwith upon request: a written statement by the Company as to its compliance with the reporting requirements of said Rule 144 of the Securities Act, and of the Exchange Act (at any time after it has
become subject to such reporting requirements); a copy of the most recent annual or quarterly report of the Company filed with the Commission; and such other reports and documents as a Holder may reasonably request in connection with availing itself
of any rule or regulation of the SEC allowing it to sell any such securities without registration. 

2.14      Termination of Registration Rights.  The right of any Holder to
request registration or inclusion of Registrable Securities in any registration pursuant to Section 2.2, Section 2.3, or Section 2.4 hereof shall terminate upon the earlier of: (i) the date three years following an initial public
offering that results in the conversion of all outstanding shares of Preferred stock; or (ii) such time as such Holder, as reflected on the Company’s list of stockholders, holds less than one percent of the Company’s outstanding
Common Stock (treating all shares of Preferred Stock on an as converted basis), the Company has completed its Initial Offering and all Registrable Securities of the Company issuable or issued upon conversion of the Shares held by and issuable to
such Holder (and its affiliates) may be sold pursuant to Rule 144 during any 90 day period. Upon such termination, such shares shall cease to be “Registrable Securities” hereunder for all purposes. 

SECTION 3.  COVENANTS OF THE COMPANY. 

3.1        Matters Requiring Investor Director Approval. For so long as any
shares of Series A Preferred remain outstanding, in addition to any other vote or consent required herein or 

  
 14. 

 
by law, the vote or written consent of a majority of the Board, including the Required Series A Director Consent (as defined in the Company’s Amended and Restated Certificate of
Incorporation (as may be amended from time to time, the “Charter”)) shall be necessary for effecting or validating the following actions: 

(a)      any Acquisition, Asset Transfer, or Liquidation Event (each as defined in the
Charter); and 
 (b)      any action to initiate or commence a clinical trial. 

3.2        Basic Financial Information and Reporting. 

(a)      The Company will maintain true books and records of account in which full and
correct entries will be made of all its business transactions pursuant to a system of accounting established and administered in accordance with generally accepted accounting principles consistently applied (except as noted therein or as disclosed
to the recipients thereof), and will set aside on its books all such proper accruals and reserves as shall be required under generally accepted accounting principles consistently applied. 

(b)      So long as any Shares remain outstanding, as soon as practicable after the end
of each fiscal year of the Company, and in any event within 180 days thereafter, the Company will furnish any Investor holding together with its affiliates at least 2,500,000 shares of Series A Preferred (as adjusted for any stock dividends,
combinations, splits, recapitalizations and the like after the date hereof) (each, a “Major Investor”) an audited balance sheet of the Company, as at the end of such fiscal year, and an audited statement of income and an
audited statement of cash flows of the Company, for such year, all prepared in accordance with generally accepted accounting principles consistently applied (except as noted therein or as disclosed to the recipients thereof), and setting forth in
each case in comparative form the figures for the previous fiscal year, all in reasonable detail. Such financial statements shall be accompanied by a report and opinion thereon by independent public accountants selected by the Board. 

(c)      The Company will furnish each Major Investor, as soon as practicable after the
end of the first, second and third quarterly accounting periods in each fiscal year of the Company, and in any event within 60 days thereafter, an unaudited balance sheet of the Company as of the end of each such quarterly period and an unaudited
statement of income and statement of cash flows of the Company for such period and for the current fiscal year to date, prepared in accordance with generally accepted accounting principles consistently applied (except as noted therein or as
disclosed to the recipients thereof), with the exception that no notes need be attached to such statements and year-end audit adjustments may not have been made, as well as an up-to-date capitalization table of the Company. 

(d)      The Company will furnish each Major Investor at least 30 days prior to the
beginning of each fiscal year an annual budget and operating plans for such fiscal year that each have been approved by the Board (and as soon as available, any subsequent written revisions thereto). 

3.3        Inspection Rights. Each Major Investor shall have the right to visit
and inspect any of the properties of the Company or any of its subsidiaries, and to discuss the affairs, 

  
 15. 

 
finances and accounts of the Company or any of its subsidiaries with its officers, and to review such information as is reasonably requested all at such reasonable times and as often as may be
reasonably requested; provided, however, that the Company shall not be obligated under this Section 3.3 with respect to a competitor of the Company or with respect to information which the Board reasonably determines in good faith is
confidential (unless covered by an enforceable confidentiality agreement, in form reasonably acceptable to the Company) or attorney-client privileged and should not, therefore, be disclosed. 

3.4      Confidentiality of Records. Each Investor agrees to use the same degree of care
as such Investor uses to protect its own confidential information to keep confidential any information furnished to such Investor pursuant to Sections 3.2 and 3.3 hereof that the Company identifies as being confidential or proprietary (so long as
such information is not in the public domain), except that such Investor may disclose such proprietary or confidential information (i) to any former partners who retained an economic interest in such Investor, current or prospective partner of
the partnership or any subsequent partnership under common investment management, limited partner, general partner, member or management company of such Investor, employee or representative of such Investor having a need to know the contents of such
information, such Investor’s legal counsel, accountants or other professional advisors, subsidiary or parent of such Investor, in each case as long as such party is advised of and agrees or has agreed to be bound by the confidentiality
provisions of this Section 3.4 or comparable restrictions, (ii) at such time as it enters the public domain through no fault of such Investor, (iii) that is communicated to it free of any obligation of confidentiality, (iv) that
is developed by such Investor or its agents independently of and without reference to any confidential information communicated by the Company, or (v) as required by applicable law. 

3.5      Reservation of Common Stock. The Company will at all times reserve and keep
available, solely for issuance and delivery upon the conversion of the Preferred Stock, all Common Stock issuable from time to time upon such conversion. 

3.6      Proprietary Information and Inventions Agreement. The Company shall require all
employees and consultants to execute and deliver a Proprietary Information and Inventions Agreement substantially in a form approved by the Company’s counsel or Board. 

3.7      Directors’ Liability and Indemnification.  The Company’s
Certificate of Incorporation and Bylaws shall provide (a) for elimination of the liability of director to the maximum extent permitted by law and (b) for indemnification of directors for acts on behalf of the Company to the maximum extent
permitted by law. 
 3.8      Qualified Small Business.  For so long as any
of the Shares are held by an Investor (or a transferee in whose hands such Shares are eligible to qualify as “Qualified Small Business Stock” as defined in Section 1202(c) of the Internal Revenue Code of 1986, as amended (the
“Code”)), the Company will use its reasonable efforts to comply with the reporting and recordkeeping requirements of Section 1202 of the Code, any regulations promulgated thereunder and any similar state laws and
regulations. 
 3.9      Termination of Covenants. All covenants of the Company
contained in Section 3 of this Agreement (other than the provisions of Sections 3.4 and 3.7) shall expire and terminate 

  
 16. 

 
as to Investors upon the earlier of (i) the effective date of the registration statement pertaining to an Initial Offering that results in the Preferred Stock being converted into Common
Stock, or (ii) upon an “Acquisition” as defined in the Company’s Certificate of Incorporation as in effect as of the date hereof, as may be amended from time to time. 

SECTION 4. RIGHTS OF FIRST REFUSAL. 

4.1      Subsequent Offerings. Subject to applicable securities laws, each Major Investor
shall have a right of first refusal to purchase its pro rata share of all Equity Securities (as defined below) that the Company may, from time to time, propose to sell and issue after the date of this Agreement, other than the Equity
Securities excluded by Section 4.6 hereof Each Major Investor’s pro rata share is equal to the ratio of (a) the number of shares of the Company’s Common Stock (including all shares of Common Stock issuable or issued upon
conversion of the Shares or upon the exercise of outstanding warrants or options) of which such Major Investor is deemed to be a holder immediately prior to the issuance of such Equity Securities to (b) the total number of shares of the
Company’s outstanding Common Stock (including all shares of Common Stock issued or issuable upon conversion of the Shares or upon the exercise of any outstanding warrants or options) immediately prior to the issuance of the Equity Securities.
The term “Equity Securities” shall mean (i) any Common Stock, Preferred Stock or other security of the Company, (ii) any security convertible into or exercisable or exchangeable for, with or without consideration,
any Common Stock, Preferred Stock or other security (including any option to purchase such a convertible security), (iii) any security carrying any warrant or right to subscribe to or purchase any Common Stock, Preferred Stock or other
security, or (iv) any such warrant or right. 
 4.2      Exercise of Rights. If
the Company proposes to issue any Equity Securities, it shall give each Major Investor written notice of its intention, describing the Equity Securities, the price and the terms and conditions upon which the Company proposes to issue the same. Each
Major Investor shall have 15 days from the giving of such notice to agree to purchase its pro rata share of the Equity Securities for the price and upon the terms and conditions specified in the notice by giving written notice to the Company
and stating therein the quantity of Equity Securities to be purchased. Notwithstanding the foregoing, the Company shall not be required to offer or sell such Equity Securities to any Major Investor if such offer or sale would cause the Company to be
in violation of applicable federal securities laws by virtue of such offer or sale. 

4.3      Issuance of Equity Securities to Other Persons.  If not all of the
Major Investors elect to purchase their pro rata share of the Equity Securities, then the Company shall promptly notify in writing the Major Investors who do so elect and shall offer such Major Investors the right to acquire such unsubscribed
shares on a pro rata basis. The Major Investors shall have five days after receipt of such notice to notify the Company of its election to purchase all or a portion thereof of the unsubscribed shares. The Company shall have 90 days thereafter
to sell the Equity Securities in respect of which the Major Investor’s rights were not exercised, at a price not lower and and upon general terms and conditions not materially more favorable to the purchasers thereof than specified in the
Company’s notice to the Major Investors pursuant to Section 4.2 hereof. If the Company has not sold such Equity Securities within 90 days of the notice provided pursuant to Section 4.2, the Company shall not thereafter issue or sell
any Equity 

  
 17. 

 
Securities, without first offering such securities to the Major Investors in the manner provided above. 

4.4        Termination of Rights of First Refusal. The rights of first refusal
established by this Section 4 shall not apply to, and shall terminate upon the earlier of (i) the effective date of the registration statement pertaining to the Company’s Initial Offering or (ii) an Acquisition. 

4.5        Assignment of Rights of First Refusal. The rights of first refusal
of Major Investors under this Section 4 may be assigned to the same parties and subject to the same restrictions as any transfer of registration rights pursuant to Section 2.9. 

4.6        Excluded Securities. The rights of first refusal established by this
Section 4 shall have no application to any of the following Equity Securities: 

(a)      shares of Common Stock issued upon conversion of any shares of Preferred Stock
of the Company or as a dividend or other distribution on any shares of Preferred Stock of the Company; 

(b)      shares of Common Stock and/or options, warrants or other Common Stock purchase
rights and the Common Stock issued pursuant to such options, warrants or other rights (as adjusted for any stock dividends, combinations, splits, recapitalizations and the like after the date hereof) issued or to be issued after the date hereof to
employees, officers or directors of, or consultants or advisors to the Company or any subsidiary, pursuant to stock purchase or equity incentive plans or other arrangements that are approved by the Board; 

(c)      any Equity Securities issued pursuant to any equipment loan or leasing
arrangement, real property leasing arrangement, or debt financing from a bank or similar financial or lending institution; provided that the issuance has been approved by the Board, including the Required Series A Director Consent; 

(d)      any Equity Securities issued for consideration other than cash pursuant to a
merger, consolidation, acquisition or similar business combination; provided that the issuance has been approved by the Board, including the Required Series A Director Consent; 

(e)      stock issued or issuable pursuant to any rights or agreements, options,
warrants or convertible securities outstanding as of the date of this Agreement; and stock issued pursuant to any such rights or agreements granted after the date of this Agreement, so long as the rights of first refusal established by this
Section 4 were complied with, waived, or were inapplicable pursuant to any provision of this Section 4.6 with respect to the initial sale or grant by the Company of such rights or agreements; 

(f)      any Equity Securities issued in connection with any stock split, stock dividend
or recapitalization by the Company; 
 (g)      any Equity Securities issued in
connection with any strategic partnering or investment arrangement involving the Company and/or the acquisition or licensing of technology or intellectual property by the Company, in each such case as approved by the Board, including the Required
Series A Director Consent; 

  
 18. 

 (h)      any Equity Securities that are
issued by the Company in connection with a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act; and 

(i)      any Equity Securities issued by the Company pursuant to the terms of
Section 2.3 of the Purchase Agreement or pursuant to the terms of a Strategic Agreement. 
 SECTION 5. MISCELLANEOUS. 

5.1        Governing Law. This Agreement shall be governed by and construed
under the laws of the State of California in all respects as such laws are applied to agreements among California residents entered into and to be performed entirely within California, without reference to conflicts of laws or principles thereof.
The parties agree that any action brought by either party under or in relation to this Agreement, including without limitation to interpret or enforce any provision of this Agreement, shall be brought in, and each party agrees to and does hereby
submit to the jurisdiction and venue of, any state or federal court located in the County of San Diego, State of California. 

5.2        Successors and Assigns. Except as otherwise expressly provided
herein, the provisions hereof shall inure to the benefit of, and be binding upon, the parties hereto and their respective successors, assigns, heirs, executors, and administrators and shall inure to the benefit of and be enforceable by each person
who shall be a holder of Registrable Securities from time to time; provided, however, that prior to the receipt by the Company of adequate written notice of the transfer of any Registrable Securities specifying the full name and address of
the transferee, the Company may deem and treat the person listed as the holder of such shares in its records as the absolute owner and holder of such shares for all purposes, including the payment of dividends or any redemption price. 

5.3        Entire Agreement.  This Agreement, the Exhibits and
Schedules hereto, the Purchase Agreement and the other documents delivered pursuant thereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable or bound to
any other in any manner by any oral or written representations, warranties, covenants and agreements except as specifically set forth herein and therein. Each party expressly represents and warrants that it is not relying on any oral or written
representations, warranties, covenants or agreements outside of this Agreement. 

5.4        Severability. In the event one or more of the provisions of this
Agreement should, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if
such invalid, illegal or unenforceable provision had never been contained herein. 

  
 19. 

 5.5        Amendment and Waiver.

 (a)      Except as otherwise expressly provided, this Agreement may be amended
or modified, and the obligations of the Company and the rights of the Holders under this Agreement may be waived, only upon the written consent of the Company and the holders of at least 62% of the then-outstanding Registrable Securities. 

(b)      For the purposes of determining the number of Holders or Investors entitled to
vote or exercise any rights hereunder, the Company shall be entitled to rely solely on the list of record holders of its stock as maintained by or on behalf of the Company. 

5.6        Delays or Omissions. It is agreed that no delay or omission to
exercise any right, power, or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement shall impair any such right, power, or remedy, nor shall it be construed to be a waiver of any such breach,
default or noncompliance, or any acquiescence therein, or of any similar breach, default or noncompliance thereafter occurring. It is further agreed that any waiver, permit, consent, or approval of any kind or character on any party’s part of
any breach, default or noncompliance under this Agreement or any waiver on such party’s part of any provisions or conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing.
All remedies, either under this Agreement, by law, or otherwise afforded to any party, shall be cumulative and not alternative. 

5.7        Notices. All notices required or permitted hereunder shall be in
writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient; if not, then on the next
business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with
written verification of receipt. All communications shall be sent to the party to be notified at the address as set forth on the signature pages hereof or EXHIBIT A hereto or at such other address or electronic mail address as
such party may designate by 10 days advance written notice to the other parties hereto. 

5.8        Attorneys’ Fees. In the event that any suit or action is
instituted under or in relation to this Agreement, including without limitation to enforce any provision in this Agreement, the prevailing party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of
enforcing any right of such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses
of appeals. 
 5.9        Titles and Subtitles. The titles of the sections
and subsections of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement. 

5.10      Additional Investors. Notwithstanding anything to the contrary contained
herein, if the Company shall issue additional shares of its Series A Preferred pursuant to the Purchase Agreement or shares of its Series A-1 Preferred pursuant to Strategic Agreements, any party acquiring such shares of Series A Preferred or Series
A-1 Preferred shall become a party to this Agreement by executing and delivering an additional counterpart signature page to this 

  
 20. 

 
Agreement and shall be deemed an “Investor,” a “Holder” and a party hereunder. Notwithstanding anything to the contrary contained herein, if the
Company shall issue Equity Securities in accordance with Section 4.6 (c) or (d) of this Agreement, any purchaser of such Equity Securities may become a party to this Agreement by executing and delivering an additional counterpart
signature page to this Agreement and shall be deemed an “Investor,” a “Holder” and a party hereunder. 

5.11    Counterparts; Electronic or Facsimile Signatures. This Agreement may be executed in any
number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. This Agreement may be executed and delivered electronically or by facsimile and upon such delivery such electronic or facsimile
signature will be deemed to have the same effect as if the original signature had been delivered to the other party. 

5.12    Aggregation of Stock. All shares of Registrable Securities held or acquired by affiliated
entities or persons or persons or entities under common management or control shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

5.13    Pronouns. All pronouns contained herein, and any variations thereof, shall be deemed to
refer to the masculine, feminine or neutral, singular or plural, as to the identity of the parties hereto may require. 

5.14    Termination. This Agreement shall terminate and be of no further force or effect upon the
earlier of (i) an Acquisition, or (ii) the date three years following the Closing of the Initial Offering that results in the conversion of all outstanding shares of Preferred Stock. 

[THIS SPACE INTENTIONALLY LEFT BLANK] 

  
 21. 

 IN WITNESS
WHEREOF, the parties hereto have executed this INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

COMPANY: 
 LUMENA
PHARMACEUTICALS, INC. 
  

			
	 By:
	 	 /s/ Michael Grey

 

			
	 Name:
	 	 Michael Grey

 

			
	 Title:
	 	 Chief Executive Officer

 

			
	 Address:
	 	 P.O. Box 110287

		 	 Research Triangle Park, NC 27709

  
 INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 IN WITNESS
WHEREOF, the parties hereto have executed this INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof 

INVESTOR: 

ALTA PARTNERS VIII, L.P 

BY: ALTA PARTNERS MANAGEMENT VIII, LLC 

ITS: GENERAL PARTNER 

 

			
	By:	 	 /s/ Hilary Strain

		 	  Chief Financial Officer

  
 INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 IN WITNESS
WHEREOF, the parties hereto have executed this INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof; 

 

			
	 INVESTORS:

	
	 A.M. PAPPAS LIFE SCIENCE

	       VENTURES IV, L.P.

	 By:
	 	 AMP&A Management IV, LLC

		
	 By:
	 	 /s/ Ford S. Worthy

			
	 Name:
	 	 Ford S. Worthy

			
	 Title:
	 	 Partner & CFO

  

			
	 Address:
	 	 c/o Mr. Ford S. Worthy

		 	 Pappas Ventures

		 	 2520 Meridian Parkway, Suite 400

		 	 Durham, NC 27713

  

			
	 PV IV CEO FUND, L.P.

	 By:
	 	 AMP&A Management IV, LLC

		
	 By:
	 	 /s/ Ford S. Worthy

			
	 Name:
	 	 Ford S. Worthy

			
	 Title:
	 	 Partner & CFO

  

			
	Address:	 	c/o Mr. Ford S. Worthy
		 	Pappas Ventures
		 	2520 Meridian Parkway, Suite 400
		 	Durham, NC 27713

  
 INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 IN WITNESS
WHEREOF, the parties hereto have executed this INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

INVESTORS: 

RIVERVEST VENTURE FUND II, L.P. 

BY: RIVERVEST VENTURE PARTNERS II, LP., ITS
GENERAL PARTNER 
 BY: RIVERVEST VENTURE
PARTNERS II, LLC, ITS SOLE GENERAL PARTNER 
  

			
	 By:
	 	 /s/ John McKearn

			
	 Name:
	 	 John McKearn, Ph.D.

			
	 Title:
	 	 Authorized Person

 RIVERVEST VENTURE FUND II
(OHIO), L.P. 
 BY: RIVERVEST VENTURE
PARTNERS II (OHIO), LLC, ITS GENERAL PARTNER 

BY: RIVERVEST VENTURE PARTNERS II, L.P., ITS
SOLE MEMBER 
 BY: RIVERVEST VENTURE
PARTNERS II, LLC, ITS GENERAL PARTNER 
  

			
	 By:
	 	 /s/ John McKearn

			
	 Name:
	 	 John McKearn, Ph.D.

			
	 Title:
	 	 Authorized Person

  
 INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 IN WITNESS
WHEREOF, the parties hereto have executed this INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

INVESTOR: 

GREENE FAMILY TRUST 

 

			
	 By:
	 	 /s/ Howard E. Greene Jr.

 

			
	 Name:
	 	 Howard E. Greene Jr.

 

			
	 Title:
	 	 Trustee

  
 INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 IN WITNESS
WHEREOF, the parties hereto have executed this INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

INVESTOR: 

LAWRENCE D. STERN 2010 QUALIFIED ANNUITY TRUST
AGREEMENT 
  

			
	 By:
	 	 /s/ Lawrence D. Stern

 

			
	 Name:
	 	 Lawrence D. Stern

 

			
	 Title:
	 	 Trustee

  
 INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 IN WITNESS
WHEREOF, the parties hereto have executed this INVESTOR RIGHTS AGREEMENT as of the date set forth in the first paragraph hereof. 

INVESTOR: 

GC&H INVESTMENTS, LLC 
  

			
	By:	 	 /s/ James C. Kitch

 

			
	Name:	 	 James C. Kitch

 

			
	Title:	 	 Managing Member

  
 INVESTOR RIGHTS AGREEMENT

 SIGNATURE PAGE 

 EXHIBIT A 

INVESTORS 

ALTA PARTNERS VIII, L.P. 

One Embarcadero Center, 37th Floor 

San Francisco, CA 94111 

RIVERVEST VENTURE FUND II, L.P. 

7733 Forsyth Boulevard, Suite 1650 

St. Louis, MO 63105 

RIVERVEST VENTURE FUND II (OHIO), L.P. 

7733 Forsyth Boulevard, Suite 1650 

St. Louis, MO 63105 
 A.M.
PAPPAS LIFE SCIENCE VENTURES IV, L.P. 
 c/o Mr. Ford S. Worthy

 Pappas Ventures 
 2520
Meridian Parkway, Suite 400 
 Durham, NC 27713 

PV IV CEO FUND, L.P. 

c/o Mr. Ford S. Worthy 

Pappas Ventures 
 2520 Meridian
Parkway, Suite 400 
 Durham, NC 27713 

GREENE FAMILY TRUST 

277 Crystal Drive 
 Frankfort,
MI 49635 
 LAWRENCE D. STERN 2010 QUALIFIED ANNUITY TRUST
AGREEMENT 
 1540 Fox Chase Lane 

Pittsburgh, PA 15241 

GC&H INVESTMENTS, LLC 

101 California Street 
 5th Floor 
 San Francisco, CA 94111-5800 

  
 INVESTOR RIGHTS AGREEMENT

 EXHIBIT A 

					
		  	  Delaware
	  	  

        PAGE    1

		  	  
 The First State
	  	

 I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO
HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF “LUMENA PHARMACEUTICALS, INC.”, FILED IN THIS OFFICE ON THE FIFTEENTH DAY OF JUNE, A.D. 2012, AT 12:30 O’CLOCK P.M. 

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS. 

 
  

							
		 	 

	 		 	

		 	 		 	  
 Jeffrey W. Bullock,
Secretary of State

	
                    4930859     
 8100 
  

                    120743350
	 	 		 	AUTHENTICATION:    9646727
	 	 		 	  

                       DATE:  
  06-15-12

	You may verify this certificate online
at corp.delaware.gov/authver.shtml	 		 	

 AMENDED AND RESTATED 

CERTIFICATE OF INCORPORATION 

OF 
 LUMENA
PHARMACEUTICALS, INC. 
 Michael Grey hereby certifies that: 

ONE:       The date of filing the original Certificate of Incorporation of this
corporation with the Secretary of State of the State of Delaware was January 24, 2011. 

TWO:       He is the duly elected and acting President and Chief Executive Officer
of Lumena Pharmaceuticals, Inc., a Delaware corporation. 
 THREE:  The Certificate of Incorporation of
this corporation is hereby amended and restated to read as follows: 
 I. 

The name of this corporation is LUMENA PHARMACEUTICALS, INC. (the
“Company”). 
 II. 

The address of the registered office of this Company in the State of Delaware is 2711 Centerville Road, Suite 400, Wilmington,
New Castle County, Delaware 19808, and the name of the registered agent of this Company in the State of Delaware at such address is Corporation Service Company. 

III. 
 The
purpose of the Company is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law (“DGCL”). 

IV. 

A.      The Company is authorized to issue two classes of stock to be designated,
respectively, “Common Stock” and “Preferred Stock.” The total number of shares that the Company is authorized to issue is 58,500,000 shares, 31,500,000 shares of which shall be Common Stock (the “Common
Stock”) and 27,000,000 shares of which shall be Preferred Stock (the “Preferred Stock”). The Common Stock shall have a par value of $0,001 per share and the Preferred Stock shall have a par value of $0.001 per
share. 
 B.      The number of authorized shares of Common Stock may be increased or
decreased (but not below the number of shares of Common Stock then outstanding) by the affirmative vote of the holders of a majority of the stock of the Company entitled to vote (voting 

  
 1. 

 
together as a single class on an as-if-converted basis), irrespective of the provisions of Section 242(b)(2) of the DGCL. 

C.      24,000,000 of the authorized shares of Preferred Stock are hereby designated
“Series A Preferred Stock” (the “Series A Preferred”) and 3,000,000 of the authorized shares of Preferred Stock are hereby designated “Series A-1 Preferred Stock” (the “Series A-1
Preferred”). The Series A Preferred and Series A-1 Preferred are collectively referred to herein as the “Series Preferred.” 

D.      The rights, preferences, privileges, restrictions and other matters relating to
the Series Preferred are as follows: 
 1.       DIVIDEND
RIGHTS. 
 (a)        Holders of Series A Preferred, in
preference to the holders of any other stock of the Company, shall be entitled to receive, when, as and if declared by the Board of Directors (the “Board”), but only out of funds that are legally available therefor,
non-cumulative cash dividends at the rate of eight percent of the applicable Original Issue Price (as defined in Section 3(a)) per annum on each outstanding share of Series A Preferred. 

(b)        So long as any shares of Series A Preferred are outstanding, the Company
shall not pay or declare any dividend (whether in cash or property), or make any other distribution on the Common Stock or Series A-1 Preferred, or purchase, redeem or otherwise acquire for value any shares of Common Stock or Series A-1 Preferred,
until all dividends as set forth in Section 1(a) above on the Series A Preferred shall have been paid or declared and set apart, except for; 

(i)      acquisitions of Common Stock by the Company pursuant to agreements that permit the
Company to repurchase such shares at no more than cost upon termination of services to the Company; 

(ii)     acquisitions of Common Stock in exercise of the Company’s right of first refusal to
repurchase such shares; 
 (iii)    acquisitions of Series A-1 Preferred by the Company pursuant to
that certain Series A-1 Preferred Stock Issuance Agreement, dated the date that the first share of Series A-1 Preferred is issued, by and between the Company and Pfizer Inc.; or 

(iv)    distributions to holders of Common Stock in accordance with Section 3. 

(c)        In the event dividends are paid on any share of Common Stock, the Company
shall pay an additional dividend on all outstanding shares of Series Preferred in a per share amount equal (on an as-if-converted to Common Stock basis) to the amount paid or set aside for each share of Common Stock. 

  
 2. 

 (d)        The provisions of Sections
1(b) and 1(c) shall not apply to a dividend payable solely in Common Stock to which the provisions of Section 4(f) hereof are applicable, or any repurchase of any outstanding securities of the Company that is approved by the Board and
(ii) the requisite holders of Series A Preferred pursuant to Section 2(b) hereof. 

(e)        A distribution to the Company’s stockholders may be made without
regard to the preferential dividends arrears amount or any preferential rights amount (each as determined under applicable law). 

2.       VOTING RIGHTS. 

(a)        General Rights.  Each holder of shares of the Series A
Preferred shall be entitled to the number of votes equal to the number of shares of Common Stock into which such shares of Series A Preferred could be converted (pursuant to Section 4 hereof) immediately after the close of business on the
record date fixed for such meeting or the effective date of such written consent and shall have voting rights and powers equal to the voting rights and powers of the Common Stock and shall be entitled to notice of any stockholders’ meeting in
accordance with the Bylaws of the Company. Except as otherwise provided herein or as required by law, the Series A Preferred shall vote together with the Common Stock at any annual or special meeting of the stockholders and not as a separate class,
and may act by written consent in the same manner as the Common Stock. Except as otherwise provided herein or as otherwise required by law, the Series A-1 Preferred shall have no voting rights. In the event the Series A-1 Preferred is entitled by
law to exercise voting rights, then except as otherwise required by law, the Series A-1 Preferred shall be entitled to the number of votes equal to the number of shares of Common Stock into which such shares of Series A-1 Preferred could be
converted (pursuant to Section 4 hereof) immediately after the close of business on the record date fixed for such meeting or the effective date of such written consent and shall vote together with the Series A Preferred and the Common Stock at
any annual or special meeting of the stockholders and not as a separate class, and may act by written consent in the same manner as the Common Stock. 

(b)        Separate Vote of Series A Preferred. For so long as any shares of
Series A Preferred remain outstanding, in addition to any other vote or consent required herein or by law, the vote or written consent of the holders of at least 66 2/3% of the outstanding Series A Preferred shall be necessary for effecting or
validating the following actions (whether by merger, recapitalization or otherwise): 

(i)      Any amendment or change of the rights, preferences, privileges or powers of, or the
restrictions that provide for the benefit of, the Series A Preferred; 
 (ii)     Any amendment,
alteration, or repeal of any provision of the Certificate of Incorporation or the Bylaws of the Company (including any filing of a Certificate of Designation) that alters or changes the voting or other powers, preferences, or other special rights,
privileges or restrictions of the Series A Preferred so as to affect them adversely; 
 (iii)    Any
increase or decrease in the authorized number of shares of Preferred Stock or Series A Preferred; 

  
 3. 

 (iv)     Any authorization or any designation, whether
by reclassification or otherwise, of any new class or series of stock or any other securities convertible into equity securities of the Company ranking on a parity with or senior to the Series A Preferred in right of redemption, liquidation
preference, voting or dividend rights or any increase in the authorized or designated number or issuance of any such class or series; 

(v)      Any redemption, repurchase, payment or declaration of dividends or other distributions
with respect to Common Stock or Series Preferred (except for acquisitions of Common Stock or Series A-1 Preferred by the Company permitted by Section 1(b)(i), (ii), (iii) and (iv) hereof); 

(vi)      Any agreement by the Company or its stockholders regarding an Asset Transfer or
Acquisition (each as defined in Section 3 hereof); 
 (vii)     Any voluntary dissolution or
liquidation of the Company; or 
 (viii)    Any increase or decrease in the authorized number of
members of the Company’s Board, 
 (c)        Separate Vote of Series A-1
Preferred. As long as any shares of Series A-1 Preferred are outstanding, the Company shall not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series A-1 Preferred, alter or amend the Certificate
of Incorporation or the Bylaws of the Company (including any filing of a Certificate of Designation) if such amendment would alter or change adversely the powers, preferences or special rights given to the Series A-1 Preferred; provided,
however, that if any amendment to the Certificate of Incorporation or the Bylaws of the Company (including any filing of a Certificate of Designation) would alter or change the powers, preferences or special rights of any series of Series
Preferred which includes the Series A-1 Preferred so as to affect them adversely, then, in addition to any other vote or consent required herein or by law, the shares of all series of Series Preferred so affected by such amendment shall vote
together as a single class on the proposed amendment and the Series A-1 Preferred shall not be entitled to vote as a separate class on such proposed amendment unless otherwise required by the DGCL. 

(d)        Election of Board of Directors. 

(i)       For so long as any shares of Series A Preferred remain outstanding, the holders
of Series A Preferred, voting as a separate class, shall be entitled to elect three members of the Board (the “Series A Preferred Directors”) at each meeting or pursuant to each consent of the Company’s stockholders for
the election of directors, and to remove from office such directors in accordance with applicable law and to fill any vacancy caused by the resignation, death or removal of such directors. 

(ii)      The holders of Common Stock, voting as a separate class, shall be entitled to elect
one member of the Board at each meeting or pursuant to each consent of the Company’s stockholders for the election of directors, and to remove from office such director 

  
 4. 

 
in accordance with applicable law and to fill any vacancy caused by the resignation, death or removal of such director. 

(iii)     The holders of Common Stock and Series A Preferred, voting together as a single class on
an as-if-converted basis, shall be entitled to elect all remaining members of the Board at each meeting or pursuant to each consent of the Company’s stockholders for the election of directors, and to remove from office such directors in
accordance with applicable law and to fill any vacancy caused by the resignation, death or removal of such directors. 

(iv)      Notwithstanding the provisions of Section 223(a)(1) and 223(a)(2) of the DGCL,
any vacancy, including newly created directorships resulting from any increase in the authorized number of directors or amendment of this Amended and Restated Certificate of Incorporation, and vacancies created by removal or resignation of a
director, may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director, and the directors so chosen shall hold office until the next annual election and until their successors are duly
elected and shall qualify, unless sooner displaced; provided, however, that where such vacancy occurs among the directors elected by the holders of a class or series of stock, the holders of shares of such class or series may override the
Board’s action to fill such vacancy by (A) voting for their own designee to fill such vacancy at a meeting of the Company’s stockholders or (B) written consent, if the consenting stockholders hold a sufficient number of shares to
elect their designee at a meeting of the stockholders in which all members of such class or series are present and voted. Any director may be removed during his or her term of office without cause, by, and only by, the affirmative vote of the
holders of the shares of the class or series of stock entitled to elect such director or directors, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders, and any vacancy
thereby created may be filled by the holders of that class or series of stock represented at the meeting or pursuant to written consent. At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of
a majority of the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing such director. 

(v)      No person entitled to vote at an election for directors may cumulate votes to which
such person is entitled unless required by applicable law at the time of such election. During such time or times that applicable law requires cumulative voting, every stockholder entitled to vote at an election for directors may cumulate such
stockholder’s votes and give one candidate a number of votes equal to the number of directors to be elected multiplied by the number of votes to which such stockholder’s shares are otherwise entitled, or distribute the stockholder’s
votes on the same principle among as many candidates as such stockholder desires. No stockholder, however, shall be entitled to so cumulate such stockholder’s votes unless (A) the names of such candidate or candidates have been placed in
nomination prior to the voting and (B) the stockholder has given notice at the meeting, prior to the voting, of such stockholder’s intention to cumulate such stockholder’s votes. If any stockholder has given proper notice to cumulate
votes, all stockholders may cumulate their votes for any candidates who have been properly placed in nomination. Under cumulative voting, the 

  
 5. 

 
candidates receiving the highest number of votes, up to the number of directors to be elected, are elected. 

3.       LIQUIDATION RIGHTS. 

(a)      The “Original Issue Price” of the Series Preferred shall be
$1,00 for the Series A Preferred and $1,00 for the Series A-1 Preferred (each as adjusted for any stock dividends, combinations, splits, recapitalizations and the like with respect to such shares after the filing date hereof). Upon any liquidation,
dissolution, or winding up of the Company, whether voluntary or involuntary (a “Liquidation Event”), before any distribution or payment shall be made to the holders of any Series A-1 Preferred or Common Stock, the holders of
Series A Preferred shall be entitled to be paid out of the assets of the Company legally available for distribution (or the consideration received by the Company or its stockholders in an Acquisition) for each share of Series A Preferred held by
them, an amount per share of Series A Preferred equal to the applicable Original Issue Price plus all declared and unpaid dividends on such share of Series A Preferred for each share of Series A Preferred held by them. If, upon any such Liquidation
Event, the assets of the Company (or the consideration received in such transaction) shall be insufficient to make payment in full to all holders of Series A Preferred of the liquidation preference set forth in this Section 3(a), then such
assets (or consideration) shall be distributed among the holders of Series A Preferred at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively entitled. 

(b)      After the payment of the full liquidation preference of the Series A Preferred as set
forth in Section 3(a) above, before any distribution or payment shall be made to the holders of any Common Stock, the holders of Series A-1 Preferred shall be entitled to be paid out of the assets of the Company legally available for
distribution (or the consideration received by the Company or its stockholders in an Acquisition) for each share of Series A-1 Preferred held by them, an amount per share of Series A-1 Preferred equal to the applicable Original Issue Price plus all
declared and unpaid dividends on such share of Series A-1 Preferred for each share of Series A-1 Preferred held by them, If, upon any such Liquidation Event, after the payment of the full liquidation preference of the Series A Preferred as set forth
in Section 3(a) above the assets of the Company (or the consideration received in such transaction) shall be insufficient to make payment in full to all holders of Series A-1 Preferred of the liquidation preference set forth in this
Section 3(b), then such assets (or consideration) shall be distributed among the holders of Series A-1 Preferred at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively entitled. 

(c)      After the payment of the full liquidation preference of the Series A Preferred and
Series A-1 Preferred as set forth in Sections 3(a) and 3(b) above, the remaining assets of the Company legally available for distribution in such Liquidation Event (or the consideration received by the Company or its stockholders in an Acquisition),
if any, shall be distributed ratably to the holders of the Common Stock and Series Preferred on an as-if-converted to Common Stock basis until such holders of Series Preferred have received pursuant to Sections 3(a) and 3(b) above and this
Section 3(c) an aggregate amount per share of Series Preferred equal to three times the applicable Original Issue Price, plus all declared and unpaid dividends thereon; thereafter, the remaining assets of the Company legally available for

  
 6. 

 
distribution in such Liquidation Event (or the consideration received by the Company or its stockholders in an Acquisition), if any, shall be distributed ratably to the holders of the Common
Stock. 
 (d)        Notwithstanding anything to the contrary contained in Sections
3(a), 3(b) or 3(c) above, for purposes of determining the amount each holder of shares of Series Preferred is entitled to receive with respect to any Liquidation Event, each such holder of shares of a series of Series Preferred shall be deemed to
have converted (regardless of whether such holder actually converted) such holder’s shares of such series into shares of Common Stock immediately prior to such Liquidation Event if, as a result of an actual conversion, such holder would
receive, in the aggregate, an amount greater than the amount that would be distributed to such holder in respect of such shares of such series of Series Preferred if such holder did not convert such shares of such series of Series Preferred into
shares of Common Stock. 
 (e)        The following events shall be deemed a
Liquidation Event for purposes of this Amended and Restated Certificate of Incorporation: (A) “Acquisition” shall mean (I) any consolidation or merger of the Company with or into any other corporation or other
entity or person, or any other corporate reorganization, other than any such consolidation, merger or reorganization in which the shares of capital stock of the Company immediately prior to such consolidation, merger or reorganization, continue to
represent a majority of the voting power of the surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such consolidation, merger or reorganization, (provided that, for the purpose of this
Section 3(e), all shares of Common Stock issuable upon exercise of options outstanding immediately prior to such consolidation or merger or upon conversion of Convertible Securities (as defined below) outstanding immediately prior to such
merger or consolidation shall be deemed to be outstanding immediately prior to such merger or consolidation and, if applicable, converted or exchanged in such merger or consolidation on the same terms as the actual outstanding shares of capital
stock are converted or exchanged); or (II) any transaction or series of related transactions to which the Company is a party in which in excess of fifty percent of the Company’s voting power is transferred; provided that an Acquisition shall
not include any transaction or series of transactions principally for bona fide equity financing purposes; and (B) “Asset Transfer” shall mean a sale, lease, exclusive license or other disposition of all or substantially
all of the assets or intellectual property of the Company. 
 (i)      In any Acquisition or
Asset Transfer, if the consideration to be received is securities of a corporation or other property other than cash, its value will be deemed its fair market value as determined in good faith by the Board on the date such determination is made
except that any publicly-traded securities to be distributed to stockholders in an Acquisition or Asset Transfer shall be valued as follows: 

(A)     if the securities are then traded on a national securities exchange, then the value of the
securities shall be deemed to be the average of the closing prices of the securities on such exchange over the ten trading day period ending five trading days prior to the closing date of such transaction; and 

  
 7. 

 (B)      if the securities are actively traded
over-the-counter, then the value of the securities shall be deemed to be the average of the closing bid prices of the securities over the ten trading day period ending five trading days prior to the closing date of such transaction. 

(ii)      The Company shall not have the power to effect an Acquisition or Asset Transfer
unless the definitive agreement for such transaction (the “Agreement”) provides that the consideration payable to the stockholders of the Company in connection therewith shall be allocated among the holders of capital stock
of the Company in accordance with this Section 3. 
 (iii)     In the event of a Liquidation
Event (including an Acquisition or Asset Transfer), if any portion of the consideration payable to the stockholders of the Company is placed into escrow or subject to contingencies, the Agreement shall provide that (A) the portion of such
consideration that is not placed in escrow and not subject to any contingencies (the “Initial Consideration”) shall be allocated among the holders of capital stock of the Company in accordance with Sections 3(a), 3(b) and
3(c) (and subject to Section 3(d)) as if the Initial Consideration were the only consideration payable in connection with such Acquisition or Asset Transfer and (B) any additional consideration that becomes payable to the stockholders of
the Company upon release from escrow or satisfaction of contingencies shall be allocated among the holders of capital stock of the Company in accordance with Sections 3(a), 3(b) and 3(c) (and subject to Section 3(d)) after taking into account
the previous payment of the Initial Consideration as part of the same transaction. For avoidance of doubt, in applying distributions upon a Liquidation Event pursuant to this Section 3(e)(iii) that involve escrow, installment or contingent
payments, the holders of the Series Preferred will be entitled to an amount, recalculated at the time of each escrow, installment or contingent payment and applied on a cumulative basis, that is the greater of (I) the amounts specified in
Sections 3(a), (b) or (c) and (II) the amount to which such holder of Series Preferred would have been entitled to on an as-if-converted to Common Stock basis as provided in Section 3(d), taking into account cumulative escrow,
installment or contingent payments. 
 4.      CONVERSION
RIGHTS. 
 The holders of the Series Preferred shall have the following rights with respect to the
conversion of the Series Preferred into shares of Common Stock (the “Conversion Rights”): 

(a)      Optional Conversion. Subject to and in compliance with the provisions of this
Section 4, any shares of Series Preferred may, at the option of the holder, be converted at any time into fully-paid and nonassessable shares of Common Stock. The number of shares of Common Stock to which a holder of Series Preferred shall be
entitled upon conversion shall be the product obtained by multiplying the applicable Series Preferred Conversion Rate then in effect (determined as provided in Section 4(b)) by the number of shares of Series Preferred being converted. 

  
 8. 

 (b)      Series Preferred Conversion Rate.
The conversion rate in effect at any time for conversion of the Series Preferred (the “Series Preferred Conversion Rate”) shall be the quotient obtained by dividing the applicable Original Issue Price of such series of Series
Preferred by the applicable Series Preferred Conversion Price, calculated as provided in Section 4(c), then in effect for such series of Series Preferred being converted. 

(c)      Series Preferred Conversion Price. The conversion price for each series of
Series Preferred shall initially be the applicable Original Issue Price of each series of Series Preferred (the “Series Preferred Conversion Price”). Such initial Series Preferred Conversion Price for each series of Series
Preferred shall be adjusted from time to time in accordance with this Section 4. All references to the Series Preferred Conversion Price herein shall mean the Series Preferred Conversion Price as so adjusted. The Series Preferred Conversion
Price for the Series A Preferred is sometimes hereinafter referred to as the “Series A Preferred Conversion Price.” The Series Preferred Conversion Price for the Series A-1 Preferred is sometimes hereinafter referred to as
the “SeriesA-1 Preferred Conversion Price.” 
 (d)      Mechanics
of Optional Conversion. Each holder of Series Preferred who desires to convert the same into shares of Common Stock pursuant to this Section 4 shall surrender the certificate or certificates therefor, duly endorsed, at the office of the
Company or any transfer agent for the Series Preferred, and shall give written notice to the Company at such office that such holder elects to convert the same. Such notice shall state the number of shares of Series Preferred being converted.
Thereupon, the Company shall promptly issue and deliver at such office to such holder a certificate or certificates for the number of shares of Common Stock to which such holder is entitled and shall promptly pay (i) in cash or, to the extent
sufficient funds are not then legally available therefor, in Common Stock (at the Common Stock’s fair market value determined by the Board as of the date of such conversion), any declared and unpaid dividends on the shares of Series Preferred
being converted and (ii) in cash (at the Common Stock’s fair market value determined by the Board as of the date of conversion) the value of any fractional share of Common Stock otherwise issuable to any holder of Series Preferred. Such
conversion shall be deemed to have been made at the close of business on the date of such surrender of the certificates representing the shares of Series Preferred to be converted, and the person entitled to receive the shares of Common Stock
issuable upon such conversion shall be treated for all purposes as the record holder of such shares of Common Stock on such date. 

(e)      Adjustment for Stock Splits and Combinations. If at any time or from time to
time on or after the date that the first share of Series A Preferred is issued (the “Original Issue Date”) the Company effects a subdivision of the outstanding Common Stock without a corresponding subdivision of the Series
Preferred, the Series Preferred Conversion Price in effect for each series of Series Preferred not so subdivided immediately before that subdivision shall be proportionately decreased. Conversely, if at any time or from time to time after the
Original Issue Date the Company combines the outstanding shares of Common Stock into a smaller number of shares without a corresponding combination of the Series Preferred, the Series Preferred Conversion Price in effect for each series of Series
Preferred not so combined immediately before the combination shall be proportionately increased. Any adjustment under 

  
 9. 

 
this Section 4(e) shall become effective at the close of business on the date the subdivision or combination becomes effective. 

(f)       Adjustment for Common Stock Dividends and Distributions. If at any time
or from time to time on or after the Original Issue Date the Company pays to holders of Common Stock a dividend or other distribution in additional shares of Common Stock, each Series Preferred Conversion Price then in effect shall be decreased as
of the time of such issuance, as provided below: 
 (i)       Each Series Preferred
Conversion Price shall be adjusted by multiplying the Series Preferred Conversion Price then in effect by a fraction equal to: 

(A)      the numerator of which is the total number of shares of Common Stock issued and
outstanding immediately prior to the time of such issuance, and 
 (B)      the denominator
of which is the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance plus the number of shares of Common Stock issuable in payment of such dividend or distribution; 

(ii)      If the Company fixes a record date to determine which holders of Common Stock are
entitled to receive such dividend or other distribution, each Series Preferred Conversion Price shall be fixed as of the close of business on such record date and the number of shares of Common Stock shall be calculated immediately prior to the
close of business on such record date; and 
 (iii)     If such record date is fixed and such
dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, each Series Preferred Conversion Price shall be recomputed accordingly as of the close of business on such record date and thereafter the applicable
Series Preferred Conversion Price shall be adjusted pursuant to this Section 4(f) to reflect the actual payment of such dividend or distribution. 

(g)       Adjustment for Reclassification, Exchange, Substitution,
Reorganization, Merger or Consolidation.  If at any time or from time to time on or after the Original Issue Date the Common Stock issuable upon the conversion of the Series Preferred is changed into the same or a different number
of shares of any class or classes of stock, whether by recapitalization, reclassification, merger, consolidation or otherwise (other than an Acquisition as defined in Section 3 or a subdivision or combination of shares or stock dividend
provided for elsewhere in this Section 4), in any such event each share of Series Preferred shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of securities,
cash or other property that a holder of the number of shares of Common Stock of the Company issuable upon conversion of such shares of Series Preferred immediately prior to such recapitalization, reclassification, merger, consolidation or other
transaction would have been entitled to receive pursuant to such transaction, all subject to further adjustment as provided herein or with respect to such other securities or property by the terms thereof. In any such case, appropriate adjustment
shall be made in the application of the 

  
 10. 

 
provisions of this Section 4 with respect to the rights of the holders of Series Preferred after the capital reorganization to the end that the provisions of this Section 4 (including
adjustment of the applicable Series Preferred Conversion Price then in effect and the number of shares issuable upon conversion of such shares of Series Preferred) shall be applicable after that event and be as nearly equivalent as practicable. 

(h)       Sale of Shares Below Series Preferred Conversion Price. 

(i)      If at any time or from time to time on or after the Original Issue Date the Company
issues or sells, or is deemed by the express provisions of this Section 4(h) to have issued or sold, Additional Shares of Common Stock (as defined below), other than as provided in Section 4(e), 4(f) or 4(g) above, for an Effective Price
(as defined below) less than the then effective Series A Preferred Conversion Price and/or Series A-1 Preferred Conversion Price (a “Qualifying Dilutive Issuance”), then and in each such case, the then existing Series A
Preferred Conversion Price and/or Series A-1 Preferred Conversion Price, as applicable, shall be reduced, as of the opening of business on the date of such issue or sale, to a price determined by multiplying such Series Preferred Conversion Price in
effect immediately prior to such issuance or sale by a fraction: 
 (A)     the numerator of which
shall be (I) the number of shares of Common Stock deemed outstanding (as determined below) immediately prior to such issue or sale, plus (II) the number of shares of Common Stock that the Aggregate Consideration (as defined below) received or
deemed received by the Company for the total number of Additional Shares of Common Stock so issued would purchase at such applicable then-existing Series Preferred Conversion Price, and 

(B)     the denominator of which shall be the number of shares of Common Stock deemed outstanding
(as determined below) immediately prior to such issue or sale plus the total number of Additional Shares of Common Stock so issued. 

For the purposes of the preceding sentence, the number of shares of Common Stock deemed to be outstanding as of a given date
shall be the sum of (I) the number of shares of Common Stock outstanding, (II) the number of shares of Common Stock into which the then outstanding shares of Series Preferred could be converted if fully converted on the day immediately
preceding the given date, and (III) the number of shares of Common Stock that are issuable upon the exercise or conversion of all other rights, options and convertible securities outstanding on the day immediately preceding the given date. 

(ii)      No adjustment shall be made to any Series Preferred Conversion Price in an amount
less than one percent of the applicable Series Preferred Conversion Price then in effect. Any adjustment otherwise required by this Section 4(h) that is not required to be made due to the first sentence of this subsection (ii) shall be
included in any subsequent adjustment to any Series Preferred Conversion Price. Any adjustment required by this Section 4(h) shall be rounded to the first decimal for which such rounding represents less than one percent of the applicable Series
Preferred Conversion Price in effect after such adjustment. 

  
 11. 

 (iii)     For the purpose of making any adjustment
required under this Section 4(h), the aggregate consideration received by the Company for any issue or sale of securities (the “Aggregate Consideration”) shall be defined as: (A) to the extent it consists of cash,
the gross amount of cash received by the Company before deduction of any underwriting or similar commissions, compensation or concessions paid or allowed by the Company in connection with such issue or sale and without deduction of any expenses
payable by the Company, (B) to the extent it consists of property other than cash, the fair market value of that property as determined in good faith by the Board, and (C) if Additional Shares of Common Stock, Convertible Securities (as
defined below) or rights or options to purchase either Additional Shares of Common Stock or Convertible Securities are issued or sold together with other stock or securities or other assets of the Company for a consideration that covers both, the
portion of the consideration so received that may be reasonably determined in good faith by the Board to be allocable to such Additional Shares of Common Stock, Convertible Securities or rights or options. 

(iv)     For the purpose of the adjustment required under this Section 4(h), if the Company
issues or sells (A) Preferred Stock or other stock, options, warrants, purchase rights or other securities exercisable for or convertible into, Additional Shares of Common Stock (such convertible stock or securities being herein referred to as
“Convertible Securities”) or (B) rights or options for the purchase of Additional Shares of Common Stock or Convertible Securities and if the Effective Price of such Additional Shares of Common Stock is less than the
Series A Preferred Conversion Price and/or Series A-1 Preferred Conversion Price, in each case the Company shall be deemed to have issued at the time of the issuance of such rights or options or Convertible Securities the maximum number of
Additional Shares of Common Stock issuable upon exercise or conversion thereof and to have received as consideration for the issuance of such shares an amount equal to the total amount of the consideration, if any, received by the Company for the
issuance of such rights or options or Convertible Securities plus (I) in the case of such rights or options, the minimum amounts of consideration, if any, payable to the Company upon the exercise of such rights or options, and (II) in the case
of Convertible Securities, the minimum amounts of consideration, if any, payable to the Company upon the conversion thereof (other than by cancellation of liabilities or obligations evidenced by such Convertible Securities); provided that if
the minimum amounts of such consideration cannot be ascertained, but are a function of antidilution or similar protective clauses, the Company shall be deemed to have received the minimum amounts of consideration without reference to such clauses.

 (A)      If the minimum amount of consideration payable to the Company upon the exercise
or conversion of rights, options or Convertible Securities is reduced over time or on the occurrence or non-occurrence of specified events other than by reason of antidilution adjustments, the Effective Price shall be recalculated using the figure
to which such minimum amount of consideration is reduced; provided further, that if the minimum amount of consideration payable to the Company upon the exercise or conversion of such rights, options or Convertible Securities is subsequently
increased, the Effective Price shall be again recalculated using the increased minimum amount of consideration payable to the Company upon the exercise or conversion of such rights, options or Convertible Securities. 

  
 12. 

 (B)      No further adjustment of the Series A
Preferred Conversion Price and/or Series A-1 Preferred Conversion Price, as applicable, as adjusted upon the issuance of such rights, options or Convertible Securities, shall be made as a result of the actual issuance of Additional Shares of Common
Stock or the exercise of any such rights or options or the conversion of any such Convertible Securities. If any such rights or options or the conversion privilege represented by any such Convertible Securities shall expire without having been
exercised, the Series A Preferred Conversion Price and/or Series A-1 Preferred Conversion Price, as applicable and as adjusted upon the issuance of such rights, options or Convertible Securities shall be readjusted to the Series A Preferred
Conversion Price and/or Series A-1 Preferred Conversion Price, as applicable, that would have been in effect had an adjustment been made on the basis that the only Additional Shares of Common Stock so issued were the Additional Shares of Common
Stock, if any, actually issued or sold on the exercise of such rights or options or rights of conversion of such Convertible Securities, and such Additional Shares of Common Stock, if any, were issued or sold for the consideration actually received
by the Company upon such exercise, plus the consideration, if any, actually received by the Company for the granting of all such rights or options, whether or not exercised, plus the consideration received for issuing or selling the Convertible
Securities actually converted, plus the consideration, if any, actually received by the Company (other than by cancellation of liabilities or obligations evidenced by such Convertible Securities) on the conversion of such Convertible Securities,
provided that such readjustment shall not apply to prior conversions of Series Preferred. 

(v)      For the purpose of making any adjustment to the Conversion Price of any series of
Series Preferred required under this Section 4(h), “Additional Shares of Common Stock” shall mean all shares of Common Stock issued by the Company or deemed to be issued pursuant to this Section 4(h) (including
shares of Common Stock subsequently reacquired or retired by the Company), other than: 

(A)      shares of Common Stock issued upon conversion of any Series Preferred or as dividend
or other distribution on any series of Series Preferred; 
 (B)      shares of Common Stock
or Convertible Securities issued upon a stock split, stock dividend, distribution, recapitalization and the like; 

(C)      shares of Common Stock or Convertible Securities issued after the Original Issue Date
to employees, officers or directors of, or consultants or advisors to the Company or any subsidiary pursuant to stock purchase or equity incentive plans or other arrangements that are approved by the Board; 

(D)      shares of Common Stock or Preferred Stock issued pursuant to the exercise or
conversion of Convertible Securities outstanding as of the Original Issue Date; 

(E)      shares of Common Stock or Convertible Securities issued for consideration other than
cash pursuant to a merger, consolidation, acquisition or similar business combination approved by the Board including at least two of the Series A 

  
 13. 

 
Preferred Directors (one of whom shall be the Series A Preferred Director designated by Alta Partners (“Alta”) so long as Alta or its affiliates continue to hold any
shares of Series A Preferred) (the “Required Series A Director Consent”); 

(F)      shares of Common Stock or Convertible Securities issued pursuant to any equipment loan
or leasing arrangement, real property leasing arrangement or debt financing from a bank or similar financial or lending institution approved by the Board, including the Required Series A Director Consent; 

(G)      shares of Common Stock issued in connection with a firmly underwritten public offering
pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Securities Act”); 

(H)      shares of Common Stock or Convertible Securities issued in connection with any
strategic partnering or investment arrangement involving the Company and/or the acquisition or licensing of technology or intellectual property by the Company, in each such case as approved by the Board, including the Required Series A Director
Consent; and 
 (I)       shares of Common Stock or Convertible Securities that the
holders of at least 66 2/3% of the outstanding shares of Series A Preferred elect in writing to exclude from the definition of “Additional Shares of Common Stock” for purposes of this Section 4. 

References to Common Stock in the subsections of this clause (v) above shall mean all shares of Common Stock issued by
the Company or deemed to be issued pursuant to this Section 4(h). The “Effective Price” of Additional Shares of Common Stock shall mean the quotient determined by dividing the total number of Additional Shares of Common
Stock issued or sold, or deemed to have been issued or sold by the Company under this Section 4(h), into the Aggregate Consideration received, or deemed to have been received by the Company for such issue under this Section 4(h), for such
Additional Shares of Common Stock. In the event that the number of shares of Additional Shares of Common Stock or the Effective Price cannot be ascertained at the time of issuance, such Additional Shares of Common Stock shall be deemed issued
immediately upon the occurrence of the first event that makes such number of shares or the Effective Price, as applicable, ascertainable. 

(vi)     In the event that the Company issues or sells, or is deemed to have issued or sold,
Additional Shares of Common Stock in a Qualifying Dilutive Issuance (the “First Dilutive Issuance”), then in the event that the Company issues or sells, or is deemed to have issued or sold, Additional Shares of Common Stock
in a Qualifying Dilutive Issuance other than the First Dilutive Issuance as a part of the same transaction or series of related transactions as the First Dilutive Issuance (a “Subsequent Dilutive Issuance”), then and in each
such case upon a Subsequent Dilutive Issuance the Series Preferred Conversion Price shall be reduced to the Series Preferred Conversion Price that would have been in effect had the First Dilutive Issuance and each Subsequent Dilutive Issuance all
occurred on the closing date of the First Dilutive Issuance. 

  
 14. 

 (i)      Certificate of
Adjustment.   In each case of an adjustment or readjustment of any Series Preferred Conversion Price for the number of shares of Common Stock or other securities issuable upon conversion of any series of Series Preferred, if such
Series Preferred is then convertible pursuant to this Section 4, the Company, at its expense, shall compute such adjustment or readjustment in accordance with the provisions hereof and shall, upon request, prepare a certificate showing such
adjustment or readjustment, and shall mail such certificate, by first class mail, postage prepaid, to each registered holder of the applicable Series Preferred so requesting at the holder’s address as shown in the Company’s books. The
certificate shall set forth such adjustment or readjustment, showing in detail the facts upon which such adjustment or readjustment is based, including a statement of (A) the consideration received or deemed to be received by the Company for
any Additional Shares of Common Stock issued or sold or deemed to have been issued or sold, (B) the applicable Series Preferred Conversion Price at the time in effect, (C) the number of Additional Shares of Common Stock and (D) the
type and amount, if any, of other property that at the time would be received upon conversion of the applicable Series Preferred. Failure to request or provide such notice shall have no effect on any such adjustment. 

(j)      Notices of Record Date.  Upon (A) any taking by the Company of a
record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled to receive any dividend or other distribution, or (B) any Acquisition or other capital reorganization of the Company, any
reclassification or recapitalization of the capital stock of the Company, any merger or consolidation of the Company with or into any other corporation, or any Asset Transfer, or any voluntary or involuntary dissolution, liquidation or winding up of
the Company, the Company shall mail to each holder of Series Preferred at least ten days prior to (I) the record date, if any, specified therein; or (II) if no record date is specified, the date upon which such action is to take effect (or, in
either case, such shorter period approved by the holders of a majority of the outstanding Series Preferred) a notice specifying (x) the date on which any such record is to be taken for the purpose of such dividend or distribution and a
description of such dividend or distribution, (y) the date on which any such Acquisition, reorganization, reclassification, transfer, consolidation, merger, Asset Transfer, dissolution, liquidation or winding up is expected to become effective,
and (z) the date, if any, that is to be fixed as to when the holders of record of Common Stock (or other securities) shall be entitled to exchange their shares of Common Stock (or other securities) for securities or other property deliverable
upon such Acquisition, reorganization, reclassification, transfer, consolidation, merger, Asset Transfer, dissolution, liquidation or winding up, 

(k)      Automatic Conversion.  

(i)      Each share of Series Preferred shall automatically be converted into shares of Common
Stock, based on the applicable then-effective Series Preferred Conversion Price, (A) at any time upon the affirmative election of the holders of at least 66 2/3% of the outstanding shares of the Series A Preferred, or (B) immediately upon
the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act covering the offer and sale of Common Stock for the account of the Company in which (I) the valuation of the Company
immediately prior to such firmly underwritten public offering is at least $200,000,000, (H) the gross cash proceeds to the Company (before 

  
 15. 

 
underwriting discounts, commissions and fees) are at least $30,000,000 and (III) the Company’s shares have been listed for trading on the New York Stock Exchange, NASDAQ Global Select Market
or NASDAQ Global Market. Upon such automatic conversion, any declared and unpaid dividends shall be paid in accordance with the provisions of Section 4(d). 

(ii)      Upon the occurrence of either of the events specified in Section 4(k)(i) above,
the outstanding shares of Series Preferred shall be converted automatically without any further action by the holders of such shares and whether or not the certificates representing such shares are surrendered to the Company or its transfer agent;
provided, however, that the Company shall not be obligated to issue certificates evidencing the shares of Common Stock issuable upon such conversion unless the certificates evidencing such shares of Series Preferred are either
delivered to the Company or its transfer agent as provided below, or the holder notifies the Company or its transfer agent that such certificates have been lost, stolen or destroyed and executes an agreement satisfactory to the Company to indemnify
the Company from any loss incurred by it in connection with such certificates. Upon the occurrence of such automatic conversion of the Series Preferred, the holders of Series Preferred shall surrender the certificates representing such shares at the
office of the Company or any transfer agent for the Series Preferred. Thereupon, there shall be issued and delivered to such holder promptly at such office and in its name as shown on such surrendered certificate or certificates, a certificate or
certificates for the number of shares of Common Stock into which such shares of Series Preferred surrendered were convertible on the date on which such automatic conversion occurred, and any declared and unpaid dividends shall be paid in accordance
with the provisions of Section 4(d). 
 (l)        Fractional Shares.
No fractional shares of Common Stock shall be issued upon conversion of any Series Preferred. All shares of Common Stock (including fractions thereof) issuable upon conversion of more than one share of Series Preferred by a holder thereof shall be
aggregated for purposes of determining whether the conversion would result in the issuance of any fractional share, If after the aforementioned aggregation the conversion would result in the issuance of any fractional share, the Company shall, in
lieu of issuing any fractional share, pay cash equal to the product of such fraction multiplied by the fair market value of one share of Common Stock (as determined by the Board) on the date of conversion. 

(m)      Reservation of Stock Issuable Upon Conversion. The Company shall at all times
reserve and keep available out of its authorized but unissued shares of Common Stock, solely for the purpose of effecting the conversion of the shares of the Series Preferred, such number of its shares of Common Stock as shall from time to time be
sufficient to effect the conversion of all outstanding shares of the Series Preferred. If at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the
Series Preferred, the Company will take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purpose. 

(n)       Notices. Any notice required by the provisions of this Section 4
shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by electronic transmission in compliance with the provisions of the

  
 16. 

 
DGCL if sent during normal business hours of the recipient; if not, then on the next business day, (iii) five days after having been sent by registered or certified mail, return receipt
requested, postage prepaid, or (iv) one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with verification of receipt. All notices shall be addressed to each holder of record at the address of such
holder appearing on the books of the Company. 
 (o)      Payment of Taxes. The
Company will pay all taxes (other than taxes based upon income) and other governmental charges that may be imposed with respect to the issue or delivery of shares of Common Stock upon conversion of shares of Series Preferred, excluding any tax or
other charge imposed in connection with any transfer involved in the issue and delivery of shares of Common Stock in a name other than that in which the shares of Series Preferred so converted were registered. 

5.       NO REDEMPTION
RIGHTS. The Series Preferred shall not be redeemable. 

6.       NO REISSUANCE OF
SERIES PREFERRED. Any shares or shares of Series Preferred redeemed, purchased, converted or exchanged by the Company shall be cancelled and retired and shall not be reissued or transferred. 

V. 

A.        The liability of the directors of the Company for monetary damages
shall be eliminated to the fullest extent under applicable law. 

B.        To the fullest extent permitted by applicable law, the Company is
authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Company (and any other persons to which applicable law permits the Company to provide indemnification) through Bylaw provisions,
agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise in excess of the indemnification and advancement otherwise permitted by such applicable law, If applicable law is amended after approval by
the stockholders of this Article V to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director to the Company shall be eliminated or limited to the fullest extent permitted by
applicable law as so amended. 
 C.        Any repeal or modification of this
Article V shall only be prospective and shall not affect the rights or protections or increase the liability of any director under this Article V in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability
or indemnification. 
 D.        The Company renounces any interest or
expectancy of the Company in, or in being offered an opportunity to participate in, any Excluded Opportunity. An “Excluded Opportunity” is any matter, transaction or interest that is presented to, or acquired, created or
developed by, or which otherwise comes into the possession of, (i) any director of the Company who is not an employee of the Company or any of its subsidiaries, or (ii) any holder of Series A Preferred or any partner, member, director,
stockholder employee or agent of any such holder, other than someone who is an employee of the Company or any of its subsidiaries (collectively, 

  
 17. 

 
“Covered Persons”), unless in either case such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the
possession of, a Covered Person expressly and solely in such Covered Person’s capacity as a director of the Company. 
 VI. 

For the management of the business and for the conduct of the affairs of the Company, and in further definition, limitation
and regulation of the powers of the Company, of its directors and of its stockholders or any class thereof as the case may be, it is further provided that: 

A.      The management of the business and the conduct of the affairs of the Company shall
be vested in its Board. The number of directors that shall constitute the whole Board shall be fixed by the Board in the manner provided in the Bylaws of the Company, subject to any restrictions which may be set forth in this Amended and Restated
Certificate of Incorporation. 
 B.      The Board is expressly empowered to adopt,
amend or repeal the Bylaws of the Company, subject to any restrictions that may be set forth in this Amended and Restated Certificate of Incorporation. The stockholders shall also have the power to adopt, amend or repeal the Bylaws of the Company,
subject to any restrictions that may be set forth in this Amended and Restated Certificate of Incorporation. 

C.      The directors of the Company need not be elected by written ballot unless the
Bylaws of the Company so provide. 
 * * * * 

FOUR:         This Amended and Restated Certificate of Incorporation has
been duly approved by the Board. 
 FIVE:           This
Amended and Restated Certificate of Incorporation was approved by the holders of the requisite number of shares of the Company in accordance with Section 228 of the DGCL. This Amended and Restated Certificate of Incorporation has been duly
adopted in accordance with the provisions of Sections 242 and 245 of the DGCL by the stockholders of the Company. 
 [THIS SPACE
INTENTIONALLY LEFT BLANK] 

  
 18. 

 IN WITNESS WHEREOF,
LUMENA PHARMACEUTICALS, INC. has caused this Amended and Restated Certificate of Incorporation to be signed by its President and Chief Executive Officer this 15th day of June 2012. 
  

	
	LUMENA PHARMACEUTICALS, INC.
	
	 /s/ Michael Grey

	      MICHAEL GREY
	      President and Chief Executive Officer

 CERTIFICATE OF AMENDMENT OF 

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF 

LUMENA PHARMACEUTICALS, INC. 

LUMENA PHARMACEUTICALS, INC. (the
“Company”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: 

FIRST:          The name
of the Company is Lumena Pharmaceuticals, Inc. 

SECOND:      The date on which the
Company’s Certificate of Incorporation was originally filed with the Secretary of State of the State of Delaware is January 24, 2011. 

THIRD:         The Board of
Directors of the Company, acting in accordance with the provisions of Sections 141 and 242 of the DGCL, adopted resolutions amending its Amended and Restated Certificate of Incorporation as follows: 

Section D.2(c) of Article IV shall be amended and restated to read in its entirety as follows: 

“Separate Vote of Series A-1 Preferred. As long as any shares of Series A-1 Preferred are
outstanding, the Company shall not, without the affirmative vote of the holders of at least 80% of the then outstanding shares of the Series A-1 Preferred, alter or amend the Certificate of Incorporation or the Bylaws of the Company (including any
filing of a Certificate of Designation) if such amendment would alter or change adversely the powers, preferences or special rights given to the Series A-1 Preferred; provided, however, that if any amendment to the Certificate of Incorporation or
the Bylaws of the Company (including any filing of a Certificate of Designation) would alter or change the powers, preferences or special rights of any series of Series Preferred which includes the Series A-1 Preferred so as to affect them
adversely, then, in addition to any other vote or consent required herein or by law, the shares of all series of Series Preferred so affected by such amendment shall vote together as a single class on the proposed amendment and the Series A-1
Preferred shall not be entitled to vote as a separate class on such proposed amendment unless otherwise required by the DGCL.” 

FOURTH:      The foregoing amendment was
submitted to the stockholders of the Company for their approval, and was duly adopted by the required vote of stockholders of the Company in accordance with the provisions of Sections 228 and 242 of the DGCL. 

[SIGNATURE PAGE FOLLOWS] 

 IN WITNESS
WHEREOF, Lumena Pharmaceuticals, Inc. has caused this Certificate of Amendment to be signed by its President and Chief Executive Officer this     day of September, 2012. 

 

			
	 By:
	 	  

		 	 Michael Grey

		 	 President and Chief Executive Officer

 Exhibit 9.2(b) 

Financial Statements 

[Attached] 

 

 
 Balance Sheets 

August 31, 2012 
 CONFIDENTIAL

  

					
	 	 	  

August 31, 2012
  
	    	  

December 31, 2011
  

			
	 Assets
	 		    	
			
	 Cash and Cash Equivalents
	 	    $          [...***...]        	    	    $          [...***...]        
	 Prepaids and Other Current Assets
	 	    $          [...***...]        	    	    $          [...***...]        
		 	  
	    	  

	 Total Current Assets
	 	    $          [...***...]        	    	    $          [...***...]        
		 	  
	    	  

			
	 Property, Plant & Equipment, net
	 	    $          [...***...]        	    	    $          [...***...]        
	 Other Assets
	 	    $          [...***...]        	    	    $          [...***...]        
		 	  
	    	  

	 Total Assets
	 	    $          [...***...]        	    	    $          [...***...]        
		 	  
	    	  

			
	 Liabilities and Stockholders’ Equity
	 		    	
			
	 Accounts Payable
	 	    $          [...***...]        	    	    $          [...***...]        
	 Other Liabilities
	 	    $          [...***...]        	    	    $          [...***...]        
		 	  
	    	  

	 Total Current Liabilities
	 	    $          [...***...]        	    	    $          [...***...]        
		 	  
	    	  

			
	 Note Payable
	 	    $          [...***...]        	    	    $          [...***...]        
	 Debt Issuance Costs
	 	    $          [...***...]        	    	    $          [...***...]        
		 	  
	    	  

	 Total Long Term Liabilities
	 	    $          [...***...]        	    	    $          [...***...]        
		 	  
	    	  

			
	 Common Stock
	 	    $          [...***...]        	    	    $          [...***...]        
	 Series A Preferred Stock
	 	    $          [...***...]        	    	    $          [...***...]        
	 Stock Issuance Costs
	 	    $          [...***...]        	    	    $          [...***...]        
	 Accumulated Deficit
	 	    $          [...***...]        	    	    $          [...***...]        
		 	  
	    	  

	 Total Stockholders’ Equity
	 	    $          [...***...]        	    	    $          [...***...]        
		 	  
	    	  

		 		    	
		 	  
	    	  

	 Total Liabilities and Stockholders’ Equity
	 	    $          [...***...]        	    	    $          [...***...]EX-10.14

 Exhibit 10.14 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 230.406 
  

 
 LICENSE AGREEMENT 

BETWEEN 
 LUMENA
PHARMACEUTICALS, INC. 
 AND 

SATIOGEN PHARMACEUTICALS, INC. 

EFFECTIVE AS OF FEBRUARY 8, 2011 

 LICENSE AGREEMENT 

THIS LICENSE AGREEMENT (this “Agreement”) is entered into
as of February 8, 2011 (the “Effective Date”), by and between Lumena Pharmaceuticals, Inc. (“Licensee”), a corporation organized and existing under the laws of the State of Delaware, and Satiogen
Pharmaceuticals, Inc. (“Satiogen”), a corporation organized and existing under the laws of the State of Delaware. Licensee and Satiogen are sometimes referred to herein individually as a “Party” and collectively as
“Parties.” The Parties agree as follows: 
 BACKGROUND 

Satiogen has certain intellectual property rights relating to its research programs related to ASBT inhibitors, including the
ASBTi Patents and ASBTi Know-How (each as defined herein). Licensee is interested in further developing and commercializing such intellectual property rights. Subject to the terms and conditions set forth in this Agreement, Satiogen is willing to
grant Licensee a license to further develop and commercialize, on a worldwide basis, Licensed Products (as defined herein) relating to the ASBTi Patents and ASBTi Know-How. 

Satiogen also has certain intellectual property rights relating to its research programs related to TGR5 agonists, including
the TGR5 Patents and TGR5 Know-How (each as defined herein). Licensee is interested in further developing and commercializing such intellectual property rights. Subject to the terms and conditions set forth in this Agreement, Satiogen is willing to
grant Licensee a license to further develop and commercialize, on a worldwide basis, Licensed Products (as defined herein) relating to the TGR5 Patents and TGR5 Know-How. 

Licensee and Satiogen are willing to defer the effectiveness of certain license grants under the ASBTi Patents, ASBTi
Know-How, TGR5 Patents and TGR5 Know-How until the occurrence of certain events as further set forth herein. 

NOW, THEREFORE, in consideration of the above premises and the mutual covenants and agreements
set forth below, the Parties hereto agree as follows. 
 Article 1 

DEFINITIONS 

As used in this Agreement, the following words and phrases shall have the following meanings: 

“Affiliate” means, with respect to a Party, any Person directly or indirectly controlling, controlled by, or
under common control with, such Party. For purposes of this definition only, the term “controlled” (including the terms “controlled by” and “under common control with”) as used in this context, means the direct or
indirect ability or power to direct or cause the direction of management policies of a Person or otherwise direct the affairs of such Person, whether through ownership of equity, voting securities, beneficial interest, by contract or otherwise. 

  
 1 

 “Applicable Laws” means all applicable laws, ordinances, rules
and regulations of any kind whatsoever of any governmental (including international, foreign, federal, state and local) or regulatory authority, including all laws, ordinances, rules and regulations promulgated by the FDA or its counterparts in
foreign jurisdictions. 
 “Application for Marketing Authorization” means, with respect to a Licensed
Product, (i) in the United States, a New Drug Application filed with the FDA pursuant to 21 U.S.C. Section 355 and 21 C.F.R. Section 314 or any successor regulatory scheme (“NDA”), and (ii) in any country other
than the United States, an application or set of applications for marketing approval comparable to an NDA and necessary to make and sell Licensed Products commercially in such country. 

“ASBTi Effective Event” means the date of the initial closing of the Financing. 

“ASBTi Exclusivity Period” means a period of [...***...] following the Effective Date, which may be extended
to a total period of [...***...] if, within the initial [...***...] period, Licensee provides notice to Satiogen indicating the continuation of good faith negotiations regarding the Financing. 

“ASBTi Know-How” means any and all Know-How owned or Controlled by Satiogen as of the Effective Date or
during the term of this Agreement reasonably necessary or useful with respect to (i) the ASBTi Program, (ii) ASBT inhibitors or their use or manufacture, or (iii) inhibition, activation, regulation or other modulation of the ASBT
pathway; provided, however, that ASBTi Know-How does not include the ASBTi Patents. 
 “ASBTi License”
means the license set forth in Section 2.1. 
 “ASBTi Patents” means all Patent Rights owned or
Controlled by Satiogen as of the Effective Date or during the term of this Agreement covering (i) the ASBTi Program or any results thereof, (ii) ASBT inhibitors or their use or manufacture, or (iii) inhibition, activation, regulation
or other modulation of the ASBT pathway, including without limitation those Patent Rights listed in Exhibit A. 

“ASBTi Program” means all activities conducted by or on behalf of Satiogen relating to ASBT inhibitors or
their use or manufacture, including all research, development, manufacture and other related activities. 

“Attributed” means, with respect to Sublicense Revenues and subject to Section 3.3(h),
(i) reasonably attributed by Licensee to any Patent Rights or Know-How licensed to Licensee by a Third Party and sublicensed by Licensee under the applicable sublicense together with Licensed Patents or Licensed Know-How, which Third Party
Patent Rights or Know-How are reasonably necessary for the applicable sublicensee’s exercise of the rights under Licensed Patents or Licensed Know-How, or the development, making, having made, using, selling, offering to sell or importing any
Licensed Products in the Field in the Territory, pursuant to the sublicense from Licensee, or (ii) if Satiogen reasonably disputes such attribution, as determined in accordance with the dispute resolution provisions set forth in
Section 10.14(b). 

  
 2 

 “Calendar Quarter” means a three (3) month period ending on
March 31, June 30, September 30 or December 31. 
 “Combination Product”
means any product comprised of a combination of a Licensed Product and another active product(s) or product component(s) that is not a Licensed Product. 

“Commercially Reasonable Efforts” means use of commercially reasonable efforts, consistent with normal
business practices within the pharmaceutical industry, taking into account efficacy, the competitiveness of alternative products in the marketplace, the availability of a partner for commercialization of any Licensed Product, the degree of
intellectual property protection available for any Licensed Product, the likelihood of Regulatory Approval, the potential profitability of any Licensed Product, the potential impact of the prevailing conditions (such as pricing) in one market on one
or more other markets, alternative products and other relevant factors. 
 “Common Shares” has the meaning
set forth in Section 3.1(c). 
 “Confidential Information” means information received (whether
disclosed in writing, electronically, orally or by observation) by one Party (the “Receiving Party”) from the other Party (the “Disclosing Party”) unless in each case such information, as shown by competent
evidence: 
 (a)      was known to the Receiving Party or to the
general public prior to the Disclosing Party’s disclosure, as demonstrated by contemporaneous written records; 

(b)      became known to the general public, after the Disclosing
Party’s disclosure hereunder, other than through a breach of the confidentiality provisions of this Agreement by the Receiving Party or any Person to whom such Receiving Party disclosed such information; 

(c)      was subsequently disclosed to the Receiving Party by a Person
having a legal right to disclose, without any restrictions, such information or data; or 

(d)      was developed by the Receiving Party independent of the
Disclosing Party’s Confidential Information; 
 provided, however, that the Licensed Patents, the Licensed
Know-How (in each case, as it relates to Licensed Products) and any other information that relates to Licensed Products that is disclosed to Licensee by Satiogen hereunder shall be deemed the Confidential Information of Licensee as well as Satiogen
and subject to the confidentiality provisions hereof during the term of this Agreement. 
 “Control” means
the possession of the ability to grant a license without violating the terms of any agreement or other arrangement with any Third Party. 

“Damages” means any and all costs, losses, claims, demands for payment, government enforcement actions,
liabilities, fines, penalties, expenses, court costs and reasonable fees and disbursements of counsel, consultants and expert witnesses incurred by a Party hereto or its 

  
 3 

 
Affiliates (including any court-imposed interest in connection therewith), each as a result of any claim, demand, action, investigation or other proceeding by any Third Party. 

“Effective Date” has the meaning set forth in the first paragraph hereof. 

“FDA” means the United States Food and Drug Administration, or any successor federal agency having
responsibility over Regulatory Approval. “FDA” shall also be deemed to include the applicable governmental or regulatory authority having jurisdiction over Licensed Products in any particular country or region in the Territory (for
example, the European Medicines Evaluation Agency for the European Union). 
 “Field” means the diagnosis,
treatment, prevention, mitigation and cure of any and all human diseases and disorders. 
 “Financing”
means the next sale after the Effective Date of shares of Licensee’s capital stock in one transaction or a series of related transactions which is a bona fide financing transaction and in which the proceeds to be received by Licensee are
principally from investors who are venture capital, private equity, institutional, corporate or similar investors, on terms and conditions negotiated among Licensee and such investors, but which is not structured on terms and conditions for the
purpose of reducing the number of shares of Series A-1 Shares to be received by Satiogen pursuant to Section 3.1. 

“First Commercial Sale” means the first arm’s length sale of a Licensed Product in a country by Licensee
or its Affiliate to a Third Party that is not an Affiliate or sublicensee of the selling party following Regulatory Approval in such country. 

“Full Allocation of Common Shares” means 690,000 shares of common stock of Licensee. 

“Full Allocation of Series A-1 Shares” means 1,380,000 shares of Series A-1 Shares. 

“GAAP” means United States Generally Accepted Accounting Principles, consistently applied. 

“Initiation” means, in any clinical trial, the first dosing of the first patient in such clinical trial. 

“Investors” has the meaning set forth in Section 3.1(a). 

“Joint Inventions” means inventions or discoveries in which one or more employees, officers, directors,
contractors or agents of Satiogen and one or more employees, officers, directors, contractors or agents of Licensee have contributed in a significant manner to the conception of such invention or discovery. 

“Know-How” means all data, knowledge and information, including all tangible and intangible techniques,
technology, practices, inventions (whether patentable or not), trade secrets, methods, knowledge, know-how, skill, experience, works of authorship and related copyrights, analytical and quality control data, results, descriptions and compositions of
matter, 

  
 4 

 
chemical manufacturing data, data from toxicological, pharmacological, preclinical and clinical testing and studies, assays, platforms, materials, samples, cell lines, DNA constructs,
formulations and specifications. 
 “Licensed Know-How” means, collectively, the ASBTi Know-How and the
TGR5 Know-How. 
 “Licensed Patents” means, collectively, the ASBTi Patents and the TGR5 Patents. 

“Licensed Product” means (a) [...***...] of which is covered by the ASBTi Patents, or (ii) which is
based on the ASBTi Know-How; and/or (b) [...***...] of which is covered by the TGR5 Patents, or (ii) which is based on the TGR5 Know-How; provided, that “Licensed Products” shall not include [...***...]; provided, further,
however that no product shall be excluded from the foregoing definition based solely on [...***...]. For clarity, [...***...] shall not be considered Licensed Products under this Agreement. 

“Licensee Improvements” means any Patent Rights that (i) are conceived and reduced to practice by
Licensee pursuant to and during the course of its activities under this Agreement, (ii) are solely owned by Licensee, (iii) constitute improvements of inventions claimed or disclosed in one or more of the Licensed Patents, and
(iv) the practice of which would infringe a Valid Claim in one or more of the issued Licensed Patents. 

“Licensee Inventions” has the meaning set forth in Section 5.4(b)(i). 

“Licensee Invention Improvements” has the meaning set forth in Section 5.4(b)(iv). 

“Licenses” means, collectively, the ASBTi License and the TGR5 License. 

“NDA” has the meaning set forth under the definition of “Application for Marketing Authorization.”

 “Net Sales” means the gross amounts invoiced by Licensee, its Affiliates or (as may be applicable under
Section 3.3(i)) sublicensees for sales of Licensed Products to independent Third Parties, less the following deductions: [...***...] 

  
 5 

 
in accordance with GAAP consistently applied. Use of Licensed Products for promotional, sampling or compassionate use purposes, in commercially reasonable quantities, [...***...]. Sales between
Licensee, its Affiliate and/or a sublicensee for end use by the purchasing entity (but not sales for further resale, or for production of finished Licensed Products for sale, by such purchasing entity) [...***...]. 

For Licensed Products which are sold as Combination Products, the Net Sales for such Combination Products shall be adjusted by
multiplying the actual Net Sales by the fraction A/(A+B) where A is [...***...], and B is [...***...], if such other active product or product component is sold separately. If the other product or product component is not sold
separately, then the actual Net Sales shall be adjusted by multiplying the actual Net Sales by the fraction A/C where A is [...***...], if sold separately, and C is [...***...]. If neither of the foregoing applies, then the Parties shall
determine the Net Sales of the Combination Product in good faith based on the respective values of the components of such Combination Product. In the event the Parties are not able to reach agreement, Net Sales for such Combination Product shall be
determined by an expert jointly appointed by the parties, with such determination to be based on the respective values of the components of such Combination Product. The decision of the expert shall be final and binding on the Parties and the fees
of the expert shall be equally shared between the Parties. 
 Net Sales amounts shall be determined from the books and
records of Licensee maintained in accordance with GAAP, consistently applied. 
 “Patent Rights” means all
rights and interests in and to all issued patents and pending patent applications, including all provisional applications, substitutions, continuations, continuations-in-part, divisions, and renewals, all letters patent granted thereon, and all
patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms (including regulatory extensions), and all supplementary protection certificates, together with any foreign
counterparts thereof. 
 “Person” means a natural person, a corporation, a partnership, a trust, a joint
venture, a limited liability company, any governmental authority, or any other entity or organization. 
 “Phase III
Clinical Trial” means a human clinical trial that would satisfy the requirements for a Phase III study as defined in 21 C.F.R. § 312.21(c) (or its successor regulation). 

“Program” or “Programs” means either the ASBTi Program or the TGR5 Program or both,
respectively. 

  
 6 

 “Regulatory Approval” means approval of an Application for
Marketing Authorization, including all pricing and reimbursement approvals, and satisfaction of any related applicable FDA registration and notification requirements (if any). 

“Royalty Term” means, with respect to each country in which a Licensed Product is sold, on a Licensed Product
by Licensed Product basis, that time period beginning on the First Commercial Sale of such Licensed Product in such country and ending on the expiration in such country of the last-to-expire Valid Claim of any Licensed Patent (other than Licensee
Invention Improvements) that, absent the licenses granted in this Agreement, would be infringed by the making, using, selling, offering for sale, or importing of such Licensed Product in such country. 

“Series A-1 Shares” means: if the Financing consists of common stock, then shares of common stock of
Licensee; and if the Financing consists of preferred stock, then shares of preferred stock of Licensee having terms substantially equivalent to the Series A-2 Shares except for the following: (i) the holders of the Series A-1 Shares shall have the information rights substantially equivalent to those set forth on Exhibit B, (ii) the holders of the Series A-1 Shares shall have the board observation rights
substantially equivalent to those set forth on Exhibit B, (iii) the liquidation preference of the Series A-2 Shares shall be senior to the liquidation preference of the Series A-1 Shares, (iv) the Series A-1 Shares shall be
non-voting except as to matters required by law and provisions commonly known as protective provisions substantially equivalent to those set forth on Exhibit B, and (v) the Series A-1 Shares shall not have redemption rights. 

“Series A-2 Shares” has the meaning set forth in Section 3.1(a). 

“Sublicense Revenues” means any upfront payments, milestone payments or other similar cash consideration (but
excluding the royalty payments from sublicensees to Licensee on sales of Licensed Products by sublicensees) or any capital stock or other similar equity ownership interest (subject to Section 3.3(g)), in each case (i) received by Licensee
from a Third Party in consideration of the grant of a sublicense to a Third Party of rights under the Licensed Patents or Licensed Know-How and (ii) subject to Section 3.3(h), not Attributed to Third Party Patent Rights or Know-How
licensed thereunder. Notwithstanding the foregoing, the term Sublicense Revenues shall exclude [...***...]. 

“Sublicense Royalties” means the royalties received by Licensee from a Third Party in consideration of the
grant of a sublicense to a Third Party of rights under the Licensed Patents or Licensed Know-How based on a percentage of revenue generated by such sublicensee for sales of Licensed Products during the Royalty Term. 

“Territory” means all countries of the world, or worldwide. 

  
 7 

 “TGR5 Effective Event” means the later to occur of the delivery
of written notice by Licensee to Satiogen that the license set forth in Section 2.2 has become effective, and the ASBTi Effective Event. 

“TGR5 Exclusivity Period” means a period of [...***...] following the Effective Date. 

“TGR5 Know-How” means any and all Know-How owned or Controlled by Satiogen as of the Effective Date or during
the term of this Agreement reasonably necessary or useful with respect to (i) the TGR5 Program, (ii) TGR5 agonists or their use or manufacture, or (iii) inhibition, activation, regulation or other modulation of TGR5 receptors or the
TGR5 pathway; provided, however, that TGR5 Know-How does not include the TGR5 Patents. 
 “TGR5 License”
means the license set forth in Section 2.2. 
 “TGR5 Patents” means all Patent Rights owned or
Controlled by Satiogen as of the Effective Date or during the term of this Agreement covering (i) the TGR5 Program or any results thereof, (ii) TGR5 agonists or their use or manufacture, or (iii) inhibition, activation, regulation or
other modulation of TGR5 receptors or the TGR5 pathway, including without limitation those Patent Rights listed in Exhibit A. 

“TGR5 Program” means all activities conducted by or on behalf of Satiogen relating to TGR5 agonists or their
use or manufacture, including all research, development, manufacture and other related activities. 
 “Third
Party” means Persons other than the Parties or their Affiliates. 
 “Transaction Agreements” has
the meaning set forth in Section 3.1(a). 
 “Valid Claim” means a claim of an issued and unexpired
patent or a pending patent application included within the Licensed Patents in a country which: (i) has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, which
decision is unappealable or unappealed within the time allowed for appeal, and (ii) has not been cancelled, withdrawn, abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise. 

Article 2 
 GRANT OF
LICENSE 
 2.1      ASBTi License.    Effective automatically
upon the occurrence of the ASBTi Effective Event, and subject to the terms and conditions set forth in this Agreement, Satiogen shall, and it hereby does, grant to Licensee an exclusive (even as to Satiogen and its Affiliates) license, with the
right to grant sublicenses through multiple tiers, under the ASBTi Know-How and the ASBTi Patents to develop, make, have made, use, sell, offer for sale, and import Licensed Products in the Field in the Territory. 

  
 8 

 2.2      TGR5
License.    Effective automatically upon the occurrence of the TGR5 Effective Event, and subject to the terms and conditions set forth in this Agreement, Satiogen shall, and it hereby does, grant to Licensee an
exclusive (even as to Satiogen and its Affiliates) license, with the right to grant sublicenses through multiple tiers, under the TGR5 Know-How and the TGR5 Patents to develop, make, have made, use, sell, offer for sale, and import Licensed Products
in the Field in the Territory. 
 2.3      ASBTi
Exclusivity.    Satiogen shall not grant to any Affiliate or Third Party any license rights in conflict with or otherwise restricting or affecting the license grant in Section 2.1 above during the ASBTi
Exclusivity Period or, if the ASBTi Effective Event has occurred, during the term of this Agreement. During the ASBTi Exclusivity Period Satiogen shall not engage in discussions with or entertain inquiries from any Third Party regarding the grant of
any license or other rights relating to the ASBTi Program. 
 2.4      TGR5
Exclusivity.    Satiogen shall not grant to any Affiliate or Third Party any license rights in conflict with or otherwise restricting or affecting the license grant in Section 2.2 above during the TGR5 Exclusivity Period
or, if the TGR5 Effective Event has occurred, during the term of this Agreement. During the TGR5 Exclusivity Period Satiogen shall not engage in discussions with or entertain inquiries from any Third Party regarding the grant of any license or other
rights relating to the TGR5 Program. 
 2.5      Registration of
Licenses.    Notwithstanding anything to the contrary in Article 6, Licensee may register the licenses granted under this Agreement in any country of the world, following the ASBTi Effective Event or TGR5 Effective Event, as
applicable. Upon request by Licensee, Satiogen agrees promptly to execute any “short form” licenses consistent with the terms and conditions of this Agreement submitted to it by Licensee reasonably necessary to effect the foregoing
registration in such country. 
 2.6      No Implied
Licenses.    No right or license under any Patent Rights or other intellectual property is granted or shall be granted by implication. All such rights are or shall be granted only as expressly provided in the terms of this
Agreement. Without limiting the generality of the foregoing, all rights under the Licensed Patents and Licensed Know-How outside the scope of the license grants in Sections 2.1 and 2.2 (including without limitation any products covered by the
Licensed Patents and/or based on the Licensed Know-How other than Licensed Products) are reserved by Satiogen. 
 Article 3 

CONSIDERATION 

3.1      Equity Issuances upon License Effectiveness. 

(a)        Issuance of Preferred
Stock.    Contemporaneously with the ASBTi Effective Event and the issuance of shares in the Financing (the “Series A-2 Shares”) to the applicable investors (the “Investors”),
(i) Licensee shall issue to Satiogen a number of Series A-1 Shares equal to the Full Allocation of Series A-1 Shares multiplied by a fraction equal to (A) the aggregate purchase price paid by the Investors for the Series A-2

  
 9 

 
Shares on the ASBTi Effective Event (including amounts attributable to the conversion of promissory notes issued by Licensee), divided by (B) $[...***...] (with any resulting
fractional share being rounded down to the nearest whole share), (ii) Satiogen shall execute and deliver, to Licensee and the Investors, customary documents (such as, without limitation, an investor rights agreement and a voting agreement)
containing terms and conditions of the Series A-2 Shares and the Series A-1 Shares, such terms and conditions to be determined by negotiation among Licensee and the Investors (the “Transaction Agreements”), and (iii) Licensee shall
deliver to Satiogen a written notice that the license set forth in Section 2.1 has become effective. 

(b)      Additional Issuance of Preferred Stock.    In the event that
the Investors purchase additional Series A-2 Shares in any subsequent closing of the Financing, Licensee shall issue to Satiogen contemporaneously with such closing an additional number of Series A-1 Shares equal to the Full Allocation of Series A-1
Shares multiplied by a fraction equal to (i) the aggregate purchase price paid by the Investors in the applicable subsequent closing for additional Series A-2 Shares, divided by (ii) $[...***...] (with any resulting fractional share
being rounded down to the nearest whole share); provided, however, that in any event the aggregate number of Series A-1 Shares to be issued by Licensee to Satiogen shall not exceed the Full Allocation of Series A-1 Shares. Notwithstanding the
foregoing, if this Agreement is terminated in its entirety or with respect to the ASBTi License by either Party under Article 9, the foregoing obligation of Licensee to issue additional Series A-1 Shares to Satiogen shall terminate as of the
effective date of such termination of this Agreement. 
 (c)      Issuance of Common
Stock.    Contemporaneously with the ASBTi Effective Event or, if later, the TGR5 Effective Event, Licensee shall issue to Satiogen a number of shares of common stock of Licensee (the “Common Shares”) equal
to the Full Allocation of Common Shares multiplied by a fraction equal to (i) the aggregate purchase price paid by the Investors for the Series A-2 Shares on the ASBTi Effective Event or, if the TGR5 Effective Event is later than the ASBTi
Effective Event, the aggregate purchase price paid on or prior to the TGR5 Effective Event (including amounts attributable to the conversion of promissory notes issued by Licensee), divided by (ii) $[...***...] (with any resulting
fractional share being rounded down to the nearest whole share). 

(d)      Additional Issuance of Common Stock.    In the event that
the TGR5 Effective Event has occurred and the Investors purchase additional Series A-2 Shares in any subsequent closing of the Financing, Licensee shall issue to Satiogen contemporaneously with such closing an additional number of Common Shares
equal to the Full Allocation of Common Shares multiplied by a fraction equal to (i) the aggregate purchase price paid by the Investors in the applicable subsequent closing for additional Series A-2 Shares, divided by
(ii) $[...***...] (with any resulting fractional share being rounded down to the nearest whole share); provided, however, that in any event the aggregate number of Common Shares to be issued by Licensee to Satiogen shall not exceed the
Full Allocation of Common Shares. Notwithstanding the foregoing, if this Agreement is terminated in its entirety or with respect to the TGR5 License by either Party under Article 9, the foregoing obligation of Licensee to issue additional Common

  
 10 

 
Shares to Satiogen shall terminate as of the effective date of such termination of this Agreement. 

3.2      Payments from Licensee to Satiogen. 

(a)      Milestone Payments from Licensee to
Satiogen.    Within [...***...] of Licensee or its Affiliates first achieving a milestone event listed below with respect to any Licensed Product, Licensee will notify Satiogen in writing thereof and pay the
below-specified amounts to Satiogen by wire transfer in immediately available funds to an account designated by Satiogen. 
  

			
	Milestone Event	  	Payment
		
	[...***...]	  	[...***...]

 For the avoidance of doubt, Licensee shall not be required to pay any
milestone fee more than one time, regardless of the number of Licensed Products that achieve any particular milestone, and no milestone fee shall be paid for any milestone that is not achieved. 

(b)      Royalty Payments from Licensee to Satiogen. 

(i)      Royalty Amount.    Subject to the terms and
conditions of this Section 3.2(b), Licensee shall pay to Satiogen a royalty equal to [...***...] of Net Sales of each Licensed Product sold by Licensee and its Affiliates during the Royalty Term for such Licensed Product. 

(ii)     Royalty Accrual in Absence of Issued
Claim.    If the only Valid Claim that, absent the licenses granted in this Agreement, would be infringed by the making, using, selling, offering for sale, or importing of a Licensed Product in a particular country is a claim
of a pending patent application, royalties in respect of such Licensed Product will be accrued for so long as a Discontinuation Event has not occurred, but will not become due and owing under this Agreement unless and until such time as a Licensed
Patent containing such claim issues. Within 

  
 11 

 
[...***...] from the end of the Calendar Quarter in which a Licensed Patent containing such claim issues, Licensee shall make a lump-sum make-up payment to Satiogen equal to the aggregate
of the amounts of the royalties that were accrued as a result of such pending claim. For purposes of this Agreement, “Discontinuation Event” means with respect to a claim of a pending patent application, the earlier of (i) final
cancellation, withdrawal or abandonment, (ii) disallowance without the possibility of appeal or re-filing, or (iii) [...***...] from the earliest priority date to which such claim is entitled. If a Discontinuation Event occurs with
respect to a claim of a pending patent application, then Licensee shall no longer be required to accrue or pay royalties on account of such claim pursuant to this Section 3.2(b)(ii). Notwithstanding anything to the contrary in this Agreement,
royalties accrued, but which do not become due and owing, pursuant to this Section 3.2(b)(ii) prior to termination or expiration of this Agreement shall not survive such termination or expiration. For clarity, Licensee’s sole obligation to
pay royalties based on pending patent applications is as expressly set forth in this Section 3.2(b)(ii). 

(iii)      Payment.    Licensee shall pay
royalties due under this Section 3.2(b) concurrently with the remittance of the royalty report in accordance with Section 3.5. All amounts payable to Satiogen under this Section 3.2(b) shall be paid in U.S. dollars by wire transfer in
immediately available funds to an account designated in writing by Satiogen (unless otherwise instructed by Satiogen in writing). 

3.3      Sublicense Payments. 

(a)      First ASBTi Sublicense Issued Prior to the Initiation of first Phase
III Clinical Trial.    If, prior to the Initiation of the first Phase III Clinical Trial by Licensee or its Affiliate for any Licensed Product covered by the ASBTi Patent Rights and/or based on the ASBTi Know-How, Licensee
grants a sublicense to a Third Party under the ASBTi Patent Rights and/or ASBTi Know-How, then subject to Section 3.3(c), Licensee shall pay to Satiogen [...***...] of the Sublicense Revenues that Licensee actually receives from all of
its sublicensees under all sublicenses under the ASBTi Patent Rights and/or ASBTi Know-How granted by Licensee, regardless of when granted. 

(b)      First ASBTi Sublicense Issued After the Initiation of first Phase
III Clinical Trial.    If, as of the Initiation of the first Phase III Clinical Trial by Licensee or its Affiliate for any Licensed Product covered by the ASBTi Patent Rights and/or based on the ASBTi Know-How, Licensee has
not granted any sublicense to a Third Party under the ASBTi Patent Rights and/or ASBTi Know-How, but Licensee thereafter grants a sublicense to a Third Party under the ASBTi Patent Rights and/or ASBTi Know-How, then Licensee shall pay to Satiogen
[...***...] of the Sublicense Revenues that Licensee actually receives from all of its sublicensees under all sublicenses under the ASBTi Patent Rights and/or ASBTi Know-How granted by Licensee. 

  
 12 

 (c)      ASBTi Sublicense After
the Initiation of a Phase III Clinical Trial.    Notwithstanding anything to the contrary in this Agreement, if, following the grant of a sublicense that is subject to Section 3.3(a), Licensee grants a sublicense to a
Third Party under any ASBTi Patent Rights that cover any Licensed Product for which Licensee or its Affiliate has Initiated a Phase III Clinical Trial, and/or under any ASBTi Know-How on which such Licensed Product is based, then Licensee shall pay
to Satiogen [...***...] of the Sublicense Revenues that Licensee actually receives from such sublicensee under such sublicense. 

(d)      First TGR5 Sublicense Issued Prior to the Initiation of first Phase
III Clinical Trial.    If, prior to the Initiation of the first Phase III Clinical Trial by Licensee or its Affiliate for any Licensed Product covered by the TGR5 Patent Rights and/or based on the TGR5 Know-How, Licensee
grants a sublicense to a Third Party under the TGR5 Patent Rights and/or TGR5 Know-How, then subject to Section 3.3(f), Licensee shall pay to Satiogen [...***...] of the Sublicense Revenues that Licensee actually receives from all of its
sublicensees under all sublicenses under the TGR5 Patent Rights and/or TGR5 Know-How granted by Licensee, regardless of when granted. 

(e)      First TGR5 Sublicense Issued After the Initiation of first Phase III
Clinical Trial.    If, as of the Initiation of the first Phase III Clinical Trial by Licensee or its Affiliate for any Licensed Product covered by the TGR5 Patent Rights and/or based on the TGR5 Know-How, Licensee has not
granted any sublicense to a Third Party under the TGR5 Patent Rights and/or TGR5 Know-How, but Licensee thereafter grants a sublicense to a Third Party under the TGR5 Patent Rights and/or TGR5 Know-How, then Licensee shall pay to Satiogen
[...***...] of the Sublicense Revenues that Licensee actually receives from all of its sublicensees under all sublicenses under the TGR5 Patent Rights and/or TGR5 Know-How granted by Licensee. 

(f)      Subsequent TGR5 Sublicense After the Initiation of a Phase III
Clinical Trial.    Notwithstanding anything to the contrary in this Agreement, if, following the grant of a sublicense that is subject to Section 3.3(d), Licensee grants a sublicense to a Third Party under any TGR5
Patent Rights that cover any Licensed Product for which License or its Affiliate has Initiated a Phase III Clinical Trial, and/or under any TGR5 Know-How on which such Licensed Product is based, then Licensee shall pay to Satiogen [...***...]
of the Sublicense Revenues that Licensee actually receives from such sublicensee under such sublicense. 

(g)      Sublicense Revenues Received as Equity Ownership
Interest.    In the event that Licensee receives Sublicense Revenues in the form of capital stock or other similar equity ownership interest, Licensee shall be permitted, at its sole option and discretion, to make the
applicable payment required pursuant to any of subsections (a) through (f) above either by delivering to Satiogen the applicable percentage of such capital stock or other similar equity ownership interest, or by paying to Satiogen an
amount equal to the applicable percentage of the fair market value of such capital stock or other similar equity ownership interest. 

  
 13 

 (h)      Attribution of
Sublicense Revenues.    Notwithstanding anything to the contrary in this Agreement, under no circumstances shall any consideration that would constitute Sublicense Revenues (without giving effect to clause (ii) of the
definition of “Sublicense Revenues” in Article 1) under any particular sublicense be Attributed to Patent Rights or Know-How licensed to Licensee by Third Parties such that the portion of such consideration payable by Licensee to Satiogen
pursuant to Section 3.3(a) or Section 3.3(d) is less than [...***...] of such consideration, or the portion of such consideration payable by Licensee to Satiogen pursuant to Section 3.3(b), Section 3.3(c),
Section 3.3(e) or Section 3.3(f) is less than [...***...] of such consideration. 

(i)      Sublicense Royalties.    If Licensee
enters into an agreement that grants a sublicense to a Third Party under the ASBTi Patent Rights and/or ASBTi Know-How, and/or under the TGR5 Patent Rights and/or TGR5 Know-How, then Licensee shall pay to Satiogen an amount equal to
[...***...] of the Sublicense Royalties that Licensee actually receives from such sublicensee, provided, however, that such payment obligation shall not in any event exceed an amount equal to [...***...] of the corresponding Net Sales of
Licensed Products sold by such sublicensee. 
 (j)      Sole Payment
Obligation.    For clarity, Licensee has no obligation to pay royalties under Section 3.2(b) above (except where the sublicensee is the end user of the applicable Licensed Product, as contemplated in the definition of
“Net Sales” in Article 1 of this Agreement), or milestone payments under Section 3.2(a) above, in connection with any sublicense. 

3.4      Reimbursement of Patent Prosecution Expenses. 

(a)      ASBTi Patents: Prior to ASBTi Effective
Event.    Prior to the ASBTi Effective Event, Licensee will reimburse Satiogen for [...***...] of all reasonable patent preparing, filing, prosecution and maintenance costs incurred with respect to the ASBTi Patents.

 (b)      ASBTi Patents: Following ASBTi Effective
Event.    Following the ASBTi Effective Event, Licensee will reimburse Satiogen for [...***...] of all subsequent reasonable patent preparing, filing, prosecution and maintenance costs incurred with respect to the ASBTi
Patents. 
 (c)      TGR5 Patents: Prior to TGR5 Effective
Event.    Prior to the TGR5 Effective Event, Licensee will reimburse Satiogen for [...***...] of all reasonable patent preparing, filing, prosecution and maintenance costs incurred with respect to the TGR5 Patents. 

(d)      TGR5 Patents: Following TGR5 Effective
Event.    Following the TGR5 Effective Event, Licensee will reimburse Satiogen for [...***...] of all subsequent reasonable patent preparing, filing, prosecution and maintenance costs incurred with respect to the TGR5
Patents. 

  
 14 

 3.5      Record Retention; Reports and
Payments. 
 (a)      Record
Retention.    Licensee shall keep complete and accurate books and records that are necessary to ascertain Licensee’s compliance with this Agreement including such records as are necessary to verify milestone and royalty
payments owed under Section 3.2, and payments based on Sublicense Revenues and Sublicense Royalties owed under Section 3.3, for a period of [...***...] from the end of the calendar year to which such records relate. Such records
shall be kept in accordance with GAAP and Licensee’s internal practices and procedures, consistently applied. 

(b)      Reports and Payments.    Beginning
with the first Calendar Quarter following the Calendar Quarter in which the earlier of (i) First Commercial Sale of a Licensed Product or (ii) first execution of a sublicense under the Licensed Patents and Licensed Know-How occurs,
Licensee shall furnish Satiogen with a quarterly report on Net Sales of Licensed Products, Sublicense Revenues and Sublicense Royalties within [...***...] after the end of the previous Calendar Quarter. Such report shall include a written
report in reasonable detail of: (a) the Net Sales of Licensed Products for the previous Calendar Quarter, broken down by country, (b) the royalty payment that is due and payable, (c) the basis for calculating such royalty payment;
(d) the Sublicense Revenues received during the previous Calendar Quarter, (e) Satiogen’s share of the Sublicense Royalties due to Satiogen under Section 3.3(i), and (f) if applicable, the basis for how Sublicense Revenues
were Attributed to the applicable Third Party Patent Rights or Know-How. The total amount of payments due to Satiogen, as shown by such report shall be paid by Licensee concurrently with the remittance of such report. 

3.6      Audits.    Satiogen shall have the right, once
annually, and no more than [...***...] with respect to any audited period, to cause an independent, certified public accountant reasonably acceptable to Licensee (the “Auditor”) to audit the books and records of
Licensee described in Section 3.5(a) solely to confirm Net Sales, milestone and royalty payments owed under Section 3.2, and Sublicense Revenues and Satiogen’s share of the Sublicense Royalties owed under Section 3.3, for a
period covering not more than the preceding [...***...]. Such audits may be exercised during normal business hours upon reasonable prior written notice (not to be less than [...***...]) to Licensee. The Auditor will execute a
reasonable written confidentiality agreement with Licensee and will disclose to Satiogen only such information as is reasonably necessary to provide Satiogen with information regarding any actual or potential discrepancies between amounts reported
and actually paid and amounts payable under this Agreement. The Auditor will send a copy of the report to Licensee at the same time it is sent to Satiogen. The report sent to both Parties will include the methodology and calculations used to
determine the results. Satiogen shall bear the full cost of such audit unless such audit discloses an underpayment by Licensee of more than [...***...] of the amount due for any calendar year under this Agreement, in which case, Licensee shall
bear the full cost of such audit and shall promptly remit to Satiogen the amount of any underpayment. If such audit discloses an overpayment by Licensee, then Licensee will deduct the amount of such overpayment from amounts otherwise owed to
Satiogen under this Agreement. If, however, no additional payments are due from Licensee to Satiogen within the next [...***...] under the terms of this Agreement, then, upon request by Licensee, Satiogen will refund such overpayment to
Licensee. Upon the expiration of [...***...] following the end of any calendar year, the calculation of 

  
 15 

 royalties payable with respect to such calendar year will be binding and conclusive upon Satiogen
except with respect to any audit then underway, and except for fraud or misrepresentation, Licensee and its Affiliates will be released from any liability or accountability with respect to royalties for such calendar year. 

3.7       Taxes and Currency.   All payments made under this Agreement shall be
in United States dollars. Any and all taxes levied on any royalty, milestone, or other payments made by Licensee to Satiogen under this Agreement shall be the liability of and paid by Satiogen. If laws or regulations require the withholding of such
taxes by Licensee, the taxes will be deducted by Licensee from the payment and remitted by Licensee to the proper tax authority, provided that Licensee will furnish Satiogen with a copy of the official tax receipt on such withholdings as soon as
practicable after such withholding, and give Satiogen such assistance, at Satiogen’s expense, as may be reasonably necessary to enable or assist Satiogen to claim exemption or take credit therefrom. Proof of payment shall be provided to
Satiogen within [...***...] after payment. Licensee will cooperate, at Satiogen’s expense, in pursuing tax refunds, if such refund is appropriate in Satiogen’s determination. If at any time legal restrictions prevent the prompt
remittance of part or all royalties with respect to any country in the Territory where the Licensed Product is sold, payment shall be made through such lawful means or methods as Satiogen and Licensee reasonably shall agree. With respect to sales of
Licensed Products invoiced in a currency other than United States dollars, all amounts reported and payable under this Agreement shall be calculated based on the domestic currency where such sale is made and converted (as applicable) into the United
States dollar equivalent. The United States dollar equivalent shall be calculated using the average of the exchange rate (local currency per US$1) published in The Wall Street Journal, Western Edition, under the heading “Currency
Trading” on the last business day of each month during the applicable Calendar Quarter. 
 Article 4 

CONDUCT OF DEVELOPMENT 

AND COMMERCIALIZATION OF PRODUCT 

4.1       Transfer of Know-How.   Within [...***...] after the Effective
Date, Satiogen shall disclose to Licensee, at no cost to Licensee, the Licensed Know-How as Controlled by Satiogen as of the Effective Date. Additionally, from time to time on an ongoing basis thereafter during the term of this Agreement, Satiogen
shall disclose to Licensee, at no cost to Licensee, such Licensed Patents and Licensed Know-How as may thereafter become Controlled by Satiogen or its Affiliates. During the time period from the Effective Date until the ASBTi Effective Event or TGR5
Effective Event, as applicable, Licensee shall have the right to use the Licensed Know-How disclosed under the preceding two sentences for research purposes consistent with the scope of the licenses set forth in Sections 2.1 and 2.2. 

4.2       Representatives of the Parties. 

(a)         Designation, Purpose and Decision Making.
  Within [...***...] after the Effective Date, each Party will designate a primary representative for purposes of this Agreement (each, a “Representative”), who shall (i) discuss and manage further development
efforts related to the ASBTi Program and TGR5 Program in the Field in the 

  
 16 

 
Territory, and (ii) manage and facilitate in an orderly manner the transfer of Know-How and transition support. Each Party may replace its Representative at any time upon written notice to
the other Party. The Representatives will strive to reach consensus on any determinations with respect to further development efforts related to the ASBTi Program and TGR5 Program; provided, however, that Licensee shall have final decision-making
authority with respect to such matters. 
 (b)       Meetings.
  The Representatives will meet in person (or participate by telephone where necessary) no less frequently than [...***...] every Calendar Quarter, unless otherwise agreed by the Parties. The Representatives may also meet or be
consulted from time to time by means of telecommunications, videoconferences, electronic mail or correspondence, as deemed necessary or appropriate. Meetings of the Representatives that are held in person will alternate between the offices of the
Parties, or such other place as the Parties may agree. The first meeting of the Representatives will take place at the offices of one of the Parties within [...***...] after the Effective Date. 

(c)       Powers and Duration. The Representatives will have only such
purposes as are specifically stated in this Agreement, and will have no power to amend or interpret this Agreement or waive a Party’s rights or obligations under this Agreement. The Representatives shall conclude their activities on the second
anniversary of the ASBTi Effective Event. 
 4.3       Licensee’s Obligation to
Develop Licensed Products. 
 (a)       ASBTi Diligence
Obligation.     Following the ASBTi Effective Event, Licensee shall use Commercially Reasonable Efforts to develop and commercialize Licensed Products using the ASBTi Patents and ASBTi Know-How and to achieve each milestone
event set forth in Section 3.2(a). If (i) all research, development and commercialization efforts with respect to all Licensed Products related to the ASBTi Patents and ASBTi Know-How, including without limitation all pre-clinical and
clinical trials, cease for a period in excess of [...***...], or (ii) Licensee determines to cease all efforts to develop and commercialize Licensed Products with respect to the ASBTi License at any time, then in either event Licensee
shall provide Satiogen with written notice thereof and Satiogen may elect to terminate this Agreement with respect to the ASBTi License only and such termination shall be deemed a termination by Licensee pursuant to Section 9.4(a). 

(b)       TGR5 Diligence Obligation.   Following the TGR5
Effective Event, Licensee will use Commercially Reasonable Efforts to develop and commercialize Licensed Products using the TGR5 Patents and TGR5 Know-How and to achieve each milestone event set forth in Section 3.2(a). Without limiting the
foregoing, Licensee will use Commercially Reasonable Efforts to identify a lead Licensed Product candidate using the TGR5 Patents and TGR5 Know-How within [...***...] of the TGR5 Effective Event. In addition, if Licensee determines, after the
Effective Date, that a material delay in the performance of the diligence obligations described in this Section 4.3(b) is reasonably likely, Licensee will promptly inform Satiogen thereof and, at Satiogen’s written request, the Parties
shall convene a meeting to discuss the cause of 

  
 17 

 
such delay, the estimated duration of the delay and the possibility of avoiding or mitigating such delay. If (i) all research, development and commercialization efforts with respect to all
Licensed Products related to the TGR5 Patents and TGR5 Know-How, including without limitation all pre-clinical and clinical trials, cease for a period in excess of [...***...], or (ii) Licensee determines to cease all efforts to develop
and commercialize Licensed Products with respect to the TGR5 License at any time, then in either event Licensee shall provide Satiogen with written notice thereof and Satiogen may elect to terminate this Agreement with respect to the TGR5 License
only and such termination shall be deemed a termination by Licensee pursuant to Section 9.4(a). 

(c)      General. 

          (i)       Following the
ASBTi Effective Event and TGR5 Effective Event, as applicable, Licensee shall have sole responsibility and control with respect to all further development and commercialization activities for Licensed Products; provided, however, that Licensee shall
not be responsible for costs and expenses incurred by Satiogen and outstanding prior to such ASBTi Effective Event or TGR5 Effective Event, as applicable. Licensee shall have sole responsibility and control with respect to seeking Regulatory
Approvals to commercialize the Licensed Products, and Licensee or its designees shall hold legal title to all Applications for Marketing Authorizations within the Territory. Licensee will be responsible for all safety and pharmacovigilance
activities under Applicable Laws after the ASBTi Effective Event or TGR5 Effective Event, as applicable. 

          (ii)       Satiogen
acknowledges and agrees that the drug development process is a process of scientific discovery and as such is inherently unpredictable and delays to development of Licensed Products may occur for reasons beyond Licensee’s control as the
Licensed Products are developed, and that the drug development process is subject to a high level of governmental regulation and the requirements of the regulatory process of seeking drug approval may result in delays beyond Licensee’s control
and that such delays or other similar delays, without evidence of some other lack of Commercially Reasonable Efforts, are not a breach of this Section 4.3. 

4.4       Licensee Obligation to Update Satiogen.    At least
[...***...] every year, Licensee shall provide Satiogen with a written summary of the activities conducted during the preceding year with respect to the development and commercialization of Licensed Products (a “Development
Report”). Each Development Report shall include with respect to the applicable one (1) year period a description of the research and development activities conducted both in the United States and outside the United States with respect
to Licensed Products. 
 4.5       Regulatory.    Promptly after
the ASBTi Effective Event, or TGR5 Effective Event, as applicable, Satiogen shall take such actions and execute such documents as are necessary or useful to transfer to Licensee all existing regulatory filings and approvals with respect to the ASBTi
Program, TGR5 Program, and/or Licensed Products, as applicable. 

  
 18 

 Article 5 

INTELLECTUAL PROPERTY 

5.1       Patent Prosecution and Maintenance. 

(a)       General.   Licensed Patents shall be diligently filed, prosecuted
and maintained by Satiogen using patent counsel reasonably acceptable to Licensee. If the Licensed Patents are not being prosecuted by Satiogen in any country where Licensee desires to seek patent protection, Licensee shall have the right to require
Satiogen to file and prosecute Licensed Patents in such country, subject to the provisions of this Article 5. Satiogen shall bear all expenses incurred in filing, prosecuting and maintaining Licensed Patents, except as set forth in Section 3.4.
Satiogen shall keep Licensee informed of the filing, prosecution and maintenance of Licensed Patents, and shall furnish to Licensee copies of all substantive documents (e.g., office actions and responses) relevant to any such efforts in advance with
sufficient time for Licensee to review and provide comments on such documents, and shall in good faith take such comments into account. If Licensee reasonably concludes that any action, including any argument or claim amendment, proposed by Satiogen
would result in a substantive reduction in breadth of claim scope with respect to any Licensed Patent, then Licensee and Satiogen shall review the proposed revisions and following such review Satiogen shall, as appropriate, cause its patent counsel
to modify such proposed action in order to avoid such result. If Satiogen desires to allow any Licensed Patents to lapse or to abandon any Licensed Patents, Satiogen shall notify Licensee in writing not less than [...***...] prior to taking
such action, and Licensee shall have the right to assume the responsibility for and control of the prosecution and maintenance of such Licensed Patents, as applicable, at Licensee’s sole expense. 

(b)       TGR5 Patent Segregation.   Upon Licensee’s request, Licensee
and Satiogen shall meet to review and determine in good faith whether any TGR5 Patents may be segregated by means of continuation or divisional applications into those containing claims that solely or predominantly relate to [...***...] and
those containing claims that solely or predominantly relate to [...***...]. In the event the Parties are unable to agree in good faith on such determination, then patent counsel for each Party shall confer on the best way to proceed, taking
into account the interests of both Parties; provided, however, that Satiogen shall not reject, and shall cause Satiogen’s patent counsel to undertake, any claim segregation requested by Licensee that does not have a material adverse effect on
claim scope that covers any product that is not a Licensed Product. Following segregation of any TGR5 Patent, Licensee may, in its sole discretion, elect to terminate its license with respect to any particular patent application or patent resulting
from such segregation by providing written notice of such termination to Satiogen. In such event, the terminated patent application or patent shall no longer be deemed to be included within the TGR5 Patents or subject to this Agreement and Licensee
shall have no further responsibility for patent prosecution or maintenance costs for such patent application or patent. Licensee shall reimburse Satiogen for all expenses incurred in connection with any such claim segregation request by Licensee.

  
 19 

 5.2       Enforcement of Intellectual Property
Rights. 
 (a)       General.    Licensee and
Satiogen will promptly notify the other of any infringement or misappropriation or suspected infringement or misappropriation that may come to its attention relating to the Licensed Patents or Licensed Know-How, and will provide the other Party with
reasonable information with respect thereto. 
 (b)       Satiogen Sole
Right Prior to ASBTi Effective Event.   Prior to the ASBTi Effective Event, if a Third Party infringes or misappropriates any ASBTi Patent or ASBTi Know-How, Satiogen will have the sole right (but not the obligation), at its own
expense, to pursue any and all injunctive relief, and any or all compensatory and other remedies and relief (collectively, “Remedies”) against such Third Party, and Licensee will have the right to participate in such action in an
advisory capacity at its own expense. In the event that Licensee does not participate in such action, Satiogen shall keep Licensee reasonably informed regarding such action. In the event that the ASBTi Effective Event occurs after Satiogen initiates
action under this Section 5.2(b), upon such occurrence Licensee shall be permitted to take control of such action at its own expense, and the provisions of Section 5.2(d) shall apply as if such action had been initiated after the ASBTi
Effective Event. 
 (c)       Satiogen Sole Right Prior to TGR5 Effective
Event. Prior to the TGR5 Effective Event, if a Third Party infringes or misappropriates any TGR5 Patent or TGR5 Know-How, Satiogen will have the sole right (but not the obligation), at its own expense, to pursue Remedies against such Third
Party, and Licensee will have the right to participate in such action in an advisory capacity at its own expense. In the event that Licensee does not participate in such action, Satiogen shall keep Licensee reasonably informed regarding such action.
In the event that the TGR5 Effective Event occurs after Satiogen initiates action under this Section 5.2(c), upon such occurrence Licensee shall be permitted to take control of such action at its own expense, and the provisions of
Section 5.2(e) shall apply as if such action had been initiated after the TGR5 Effective Event. 

(d)       Licensee First Right after ASBTi Effective Event.
  After the ASBTi Effective Event, if a Third Party infringes or misappropriates any ASBTi Patent or ASBTi Know-How, Licensee will have the first right (but not the obligation), at its own expense, to pursue any and all Remedies against
such Third Party, and Satiogen will have the right to participate in such action at its own expense. Should Licensee determine not to pursue Remedies with respect to any such infringement or misappropriation of ASBTi Patents or ASBTi Know-How within
(a) [...***...] following the notice of alleged infringement or (b) [...***...] before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, then
Satiogen will have the right (but not the obligation), at its own expense, to pursue Remedies against such Third Party, and Licensee shall have the right to participate in such action at its own expense. 

(e)       Licensee First Right after TGR5 Effective Event.
  After the TGR5 Effective Event, if a Third Party infringes or misappropriates any TGR5 Patent or TGR5 

  
 20 

 
Know-How, Licensee will have the first right (but not the obligation), at its own expense, to pursue any and all Remedies against such Third Party, and Satiogen will have the right to participate
in such action at its own expense. Should Licensee determine not to pursue Remedies with respect to any such infringement or misappropriation of TGR5 Patents or TGR5 Know-How within (a) [...***...] following the notice of alleged
infringement or (b) [...***...] before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, then Satiogen will have the right (but not the obligation), at its own
expense, to pursue Remedies against such Third Party, and Licensee shall have the right to participate in such action at its own expense. 

(f)       Assistance and Cooperation; Recoveries.   If a Party
pursues Remedies hereunder with respect to infringement or misappropriation of Licensed Patents or Licensed Know-How, the other Party shall assist and cooperate fully with the Party pursuing such Remedies, including, if required to bring such
action, joining in any action as set forth in this Section 5.2 or providing a power of attorney. Any damages or other amounts collected will be distributed, first, to the Party that pursued Remedies to cover its costs and expenses; and second,
to the other Party to cover its costs and expenses, if any, relating to the pursuit of such Remedies; and any remaining amount will be distributed to the Party that pursued the Remedies, provided, however, that any recovery by Licensee attributable
to lost sales or lost profits shall be deemed Net Sales hereunder, and a royalty shall be paid to Satiogen thereon pursuant to Section 3.2(b); and provided further, however, that any other or additional monetary recovery by Licensee shall be
deemed Sublicense Revenues, and shall be payable pursuant to Section 3.3(a) or Section 3.3(d), as applicable, if as of the date Licensee filed the action, a sublicense under the infringed or misappropriated intellectual property granted by
Licensee on such date would be subject to Section 3.3(a) or Section 3.3(d), or pursuant to Section 3.3(b), Section 3.3(c), Section 3.3(e) or Section 3.3(f), as applicable, if as of the date Licensee filed the action, a
sublicense under the infringed or misappropriated intellectual property granted by Licensee on such date would be subject to Section 3.3(b), Section 3.3(c), Section 3.3(e) or Section 3.3(f). 

(g)       Settlement of Litigation.   No settlement, consent
judgment or other final disposition of an action for infringement or validity or misappropriation may be entered into as to any Licensed Patent or Licensed Know-How without the prior written consent of both Parties, which consent shall not be
unreasonably withheld. 
 5.3       Infringement of Third Party Rights.   If
a Third Party institutes a patent, trade secret or other infringement or misappropriation suit against Licensee during the term of this Agreement, alleging that the manufacture, marketing, sale, use or importation of the Licensed Products infringes
or misappropriates one or more patent or other intellectual property rights held by such Third Party, then Licensee will have the sole right (but not the obligation), at its sole expense, to assume direction and control of the defense of such
claims. At Licensee’s request, Satiogen will provide reasonable assistance in connection with the defense of such claims, and Licensee will reimburse Satiogen for all documented reasonable expenses incurred by Satiogen in connection therewith.

  
 21 

 5.4       Ownership of Inventions. 

(a)       Inventorship.   Inventorship of inventions and
discoveries conceived and reduced to practice during the term of this Agreement shall be determined in accordance with the rules of inventorship under United States patent laws. Satiogen shall solely own and, except as set forth in Section 3.4,
shall bear all expenses incurred in preparing, filing, prosecuting and maintaining all patent applications and patents that encompass all such inventions and discoveries that are solely invented by Satiogen. Licensee shall solely own and shall bear
all expenses incurred in preparing, filing, prosecuting and maintaining all patent applications and patents that encompass all such inventions and discoveries that are solely invented by Licensee. 

(b)       Assignment of Certain Joint Inventions; Related Licenses. 

(i)       Ownership and Assignment.   Licensee shall solely
own all right, title and interest in, and shall bear all expenses incurred in preparing, filing, prosecuting and maintaining all patent applications and patents that encompass, all Joint Inventions that relate to Licensed Products or the manufacture
or use thereof (collectively “Licensee Inventions”). Each party will promptly, but in no event later than [...***...] from invention, creation or conception, inform the other party of all Licensee Inventions. Information
provided with respect to such Licensee Inventions will be in reasonable detail but in no circumstance less than would be sufficient to permit an understanding of the nature of such Licensee Inventions by a practitioner reasonably skilled in the
relevant technical or scientific area. Satiogen hereby irrevocably, unconditionally, and without encumbrance of any kind assigns, forever waives, and agrees never to assert, and shall cause its Affiliates, employees and contractors to irrevocably,
unconditionally, and without encumbrance of any kind assign to Licensee, and forever waive and agree never to assert, its joint right, title, and interest in Licensee Inventions as necessary to give effect to the provisions of this
Section 5.4(b). Each Party agrees to execute any documents and take any other actions reasonably requested by any other Party (and shall cause its Affiliates, employees and contractors to do likewise) in order to give effect to the provisions
of this Section 5.4(b). 
 (ii)       License to Satiogen.
  Licensee shall, and hereby does, grant to Satiogen a fully paid-up, non-exclusive, perpetual and irrevocable license with the right to grant sublicenses through multiple tiers, under Licensee Inventions to develop, make, have made, use,
sell, offer for sale, and import products other than Licensed Products, in the Field in the Territory; provided, however, that the foregoing license shall not include the right to conduct or have conducted any activities with respect to
(a) ASBT inhibitors or their use or manufacture, or (b) inhibition, activation, regulation or other modulation of the ASBT pathway, including without limitation with respect to any compound or any product containing any compound
(i) the manufacture, use, sale or import of which is covered by the ASBTi Patents, or (ii) which is based on the ASBTi Know-How (such activities, the “ASBTi Activities”). 

  
 22 

 (iii)       Research License to
Satiogen.   Licensee shall, and hereby does, grant to Satiogen a fully paid-up, non-exclusive, perpetual and irrevocable license without the right to grant sublicenses, under Licensee Inventions solely for internal research purposes in
the Field in the Territory; provided, however, that the foregoing license shall not include (i) the right to conduct or have conducted any ASBTi Activities or (ii) the right to sell, offer for sale or otherwise commercialize, or have any
of the foregoing done with respect to, any Licensed Product. 
 (iv)
      Licensee Invention Improvements.   All inventions, discoveries and Know-How conceived, reduced to practice, made or developed by, on behalf of or for Satiogen or by, on behalf of or for its
sublicensees (to the extent such inventions, discoveries or Know-How are Controlled by Satiogen) under the licenses set forth in subsections (ii) and (iii) above during the term of this Agreement and which fall within the definitions of
Licensed Patents or Licensed Know-How hereunder (“Licensee Invention Improvements”) are automatically deemed to constitute ASBTi Patents, ASBTi Know-How, TGR5 Patents or TGR5 Know-How, as applicable, for all purposes under this
Agreement, including without limitation the license grants set forth in Sections 2.1 and 2.2. For clarity, with respect to inventions, discoveries and Know-How conceived, reduced to practice, made or developed by, on behalf of or for Satiogen’s
sublicensees, such inventions, discoveries and Know-How shall be deemed to constitute Licensee Invention Improvements (and ASBTi Patents, ASBTi Know-How, TGR5 Patents or TGR5 Know-How, as applicable), and the rights and licenses granted by Satiogen
in this Agreement will apply with respect thereto, in each case to the greatest extent that is consistent with the applicable agreement under which Satiogen obtained Control with respect to such inventions, discoveries and Know-How. For example, if
Satiogen is entitled to grant only non-exclusive rights and licenses with respect to such inventions, discoveries or Know-How, then such inventions, discoveries or Know-How shall be included in the license grants set forth in Sections 2.1 and 2.2 on
a non-exclusive basis. Notwithstanding the foregoing, Licensee shall not have any obligation to make any payments pursuant to Section 3.2 or 3.3 on the basis of or with respect to any Licensee Invention Improvements. 

(c)       Other Joint Inventions.   Except as set forth in
Section 5.4(b) above, Joint Inventions shall be owned jointly by Licensee and Satiogen, and all Patent Rights containing a claim covering any Joint Inventions shall be jointly owned by the Parties. Subject to the rights granted under this
Agreement, including without limitation the exclusive licenses granted under Section 2.1 and Section 2.2, each Party shall have the right to practice and exploit Joint Inventions and jointly owned Patent Rights without any obligation to
account to the other for profits, or to obtain any approval of the other Party to license, assign, or otherwise exploit Joint Inventions and jointly owned Patent Rights, by reason of joint ownership thereof, and each Party hereby waives any right it
may have under the laws of any jurisdiction to require any such approval or accounting; and to the extent there are any applicable laws that prohibit such a waiver, each Party will be 

  
 23 

 
deemed to so consent. Each Party agrees to be named as a party, if necessary, to bring or maintain a lawsuit involving a Joint Invention or jointly owned Patent Rights. 

(d)       Assistance of Dr. Slava Gedulin.   As soon as
practicable after the Effective Date, Licensee and Dr. Slava Gedulin, a consultant of Satiogen, intend to enter into an agreement, pursuant to which Dr. Gedulin would become engaged as an employee or consultant of Licensee. If Licensee and
Dr. Gedulin enter into such an agreement, then notwithstanding anything to the contrary in subsections (a), (b) or (c) of this Section 5.4, Licensee shall solely own all right, title and interest in all inventions and discoveries
conceived or reduced to practice, and in all Know-How made or developed, by Dr. Gedulin during the term of her engagement by Licensee to the full extent provided under the applicable agreement between Licensee and Dr. Gedulin (each a
“Gedulin Invention” and collectively, “Gedulin Inventions”). To the extent a particular Gedulin Invention relates to Licensed Products or the manufacture or use thereof or otherwise relates to the inventions covered
by the Licensed Patents or to the Licensed Know-How, such Gedulin Invention shall be deemed to be a Licensee Invention solely for the purposes of rights, licenses and obligations set forth in Sections 5.4(b)(ii), 5.4(b)(iii), 5.4(b)(iv) and 9.3(b).
In the event that any right, title and interest in any Gedulin Invention (other than the rights under Sections 5.4(b)(ii), 5.4(b)(iii), 5.4(b)(iv) and 9.3(b) of this Agreement) vests in Satiogen, Satiogen hereby irrevocably, unconditionally, and
without encumbrance of any kind assigns, forever waives, and agrees never to assert, and shall cause its Affiliates, employees and contractors to irrevocably, unconditionally, and without encumbrance of any kind assign to Licensee, and forever waive
and agree never to assert, any such right, title, and interest in Gedulin Inventions as necessary to give effect to the provisions of this Section 5.4(d). Each Party agrees to execute any documents and take any other actions reasonably
requested by any other Party (and shall cause its Affiliates, employees and contractors to do likewise) in order to give effect to the provisions of this Section 5.4(d). 

5.5       Patent Reporting.   Within [...***...] after each Calendar
Year, Satiogen shall provide Licensee with a written report describing the status of all Licensed Patents, including the patent country, patent and application numbers, filing date, issue date, expiration date, and any other relevant information
requested by Satiogen. 
 5.6       Trademarks.   Licensee will own and be
responsible for all trademarks related to its marketing of Licensed Products and will be responsible, in its sole discretion, with respect to registering, defending and maintaining such trademarks. 

5.7       Patent Cooperation.   Each Party hereby agrees to make its employees,
agents and consultants reasonably available to the other Party (or the other Party’s authorized attorneys, agents or representatives) at the other Party’s expense, to the extent reasonably necessary to enable the Party responsible for
prosecuting the Licensed Patents to undertake preparation, filing, prosecution and maintenance of the Licensed Patents. 

5.8       Patent Term Extensions.   Licensee shall have the right to prepare
and file, or to cause Satiogen to prepare and file, a patent term extension or supplementary protection certificate application with respect to any applicable Licensed Patent upon regulatory approval

  
 24 

 
of a Licensed Product (the making, using, selling, offering for sale, or importing of which would infringe such Licensed Patent), and the Parties will cooperate with each other and use
reasonable efforts to obtain all available extensions and supplementary protection certificates for any such Licensed Patent applicable to such Licensed Product. Each Party shall be permitted to assist and provide comments to the other Party, and to
provide the regulatory timeline, diligence and regulatory period calculations required as part of the application, to complete the application(s) for such extensions or supplementary protection certificates and to assist in any other matters related
to preparation of the application(s) for such extensions or supplementary protection certificates, and each Party will fully cooperate, in preparing and filing such a patent term extension or supplementary protection certificate application with
respect to any such Licensed Patent within the limited time set for filing such application. All term extensions under this Section 5.8 shall be owned by Satiogen. 

Article 6 

CONFIDENTIALITY 

6.1       Confidential Information.   The Parties agree that, unless the
Receiving Party obtains the prior written consent of the Disclosing Party, at all times during the term of this Agreement and for a [...***...] period following its expiration or earlier termination, the Receiving Party will keep completely
confidential, will not publish or otherwise disclose and will not use directly or indirectly for any purpose other than as contemplated by this Agreement any Confidential Information of the Disclosing Party, whether such Confidential Information was
received by the Receiving Party prior to, on or after the Effective Date. Confidential Information exchanged under the Nondisclosure Agreement dated October 31, 2010 shall also be included in this Section 6.1. 

6.2       Limited Disclosure Permitted.   Each Party may disclose Confidential
Information of the Disclosing Party to the extent that such disclosure is: 
 (a)
      required by Applicable Laws, in the opinion of legal counsel to the Receiving Party; provided, however, that the Receiving Party will first have given reasonable notice to the Disclosing Party (if practicable) and
given the Disclosing Party a reasonable opportunity to obtain a protective order or confidential treatment requiring that the Confidential Information and documents that are the subject thereof be held in confidence by the recipient or, if
disclosed, be used only for purposes required by such law; provided further, however, that if a protective order is not obtained, the Confidential Information so disclosed will be limited to that information that is legally required to be disclosed
as required by Applicable Laws; 
 (b)       made by the Receiving
Party to a governmental or regulatory authority, including FDA, as required to conduct clinical trials or obtain or maintain Regulatory Approval for the Licensed Product; 

(c)       made by Licensee to a Third Party or sublicensee as may be
necessary or useful in connection with the manufacture, development and commercialization of any Licensed Product, provided that Licensee will in each case obtain from the proposed 

  
 25 

 
Third Party or sublicensee recipient a written confidentiality agreement containing confidentiality and non-use obligations no less protective than those set forth in this Agreement in any
material respect; 
 (d)       made solely with respect to the TGR5
Patents and/or TGR5 Know-How by Satiogen to a Third Party licensee or proposed licensee thereunder as may be necessary or useful in connection with the manufacture, development and commercialization of any product that is not a Licensed Product,
provided that Satiogen will in each case obtain from the Third Party a written confidentiality agreement containing confidentiality and non-use obligations no less protective than those set forth in this Agreement in any material respect; 

(e)       made by the Receiving Party to a United States or foreign tax
authority; 
 (f)       made by the Receiving Party to its
representatives or to Third Parties in connection with financing activities of the Receiving Party, or in connection with the transfer or sale of all or substantially all of the business of the Receiving Party to which this Agreement relates to a
Third Party, whether by merger, sale of stock, sale or transfer of assets or otherwise; provided, however, that: (i) each such representative or Third Party has, in the reasonable determination of the Receiving Party, a need to know such
Confidential Information and has an obligation to maintain the confidentiality of such information, (ii) the Receiving Party informs each representative or Third Party receiving Confidential Information of its confidential nature, and
(iii) the Receiving Party will be responsible for any breach of this Article 6 by any of its representatives or such Third Parties to the same extent as if the breach were by the Receiving Party; 

(g)       made by a Receiving Party or any representative of the
Receiving Party in the filing or prosecution of the Licensed Patents or any patent claiming any invention owned by such Party pursuant to this Agreement, to the extent such disclosure in the filing or publication of the patent or patent application
is, reasonably necessary for support of the patent or patent application; or 
 (h)
      made by a Receiving Party in order to comply with applicable securities law disclosure requirement or any disclosure requirements of any applicable stock market or securities exchange. 

6.3       Disclosure of Agreement.   The Parties agree that the material terms
of this Agreement shall be considered Confidential Information of both Parties, subject to the special authorized disclosure provisions set forth below in this Section 6.3 (in lieu of the authorized disclosure provisions set forth in
Section 6.2, to the extent of any conflict) and without limiting the generality of the definition of Confidential Information set forth in Article 1. The Parties will mutually agree the text of a press release announcing the execution of this
Agreement. Thereafter, if either Party desires to make a public announcement concerning the terms of this Agreement, such Party shall give reasonable prior advance notice of the proposed text of such announcement to the other Party for its prior
review and approval, such approval not to be unreasonably withheld. A Party shall not be required to seek the permission of the other Party to repeat or disclose any information as to the terms of this Agreement that has already been

  
 26 

 
publicly disclosed by such Party in accordance with the foregoing or by the other Party, or any similar or comparable information. Either Party may disclose the terms of this Agreement to such
Party’s existing investors, lenders, directors and professional advisors and to potential investors, lenders, acquirors or merger partners and their professional advisors who are bound by written or professional obligations of non-disclosure
and non-use that are at least as stringent as those contained in this Article 6 or are customary for such purpose. Licensee also may disclose the relevant terms of this Agreement to potential sublicensees who agree to be bound by obligations of
non-disclosure and non-use at least as stringent as those contained in this Article 6 in all material respects. 

6.4      Scientific Publications.    Prior to making any
formal scientific publication relating to the ASBTi Program or the TGR5 Program (a “Scientific Publication”) after the Effective Date, each Party (the “Publishing Party”) agrees to provide the other
Party (the “Reviewing Party”) the opportunity to review: (a) any proposed Scientific Publication comprising a formal scientific paper for publication in any peer reviewed journal at least [...***...] prior to its intended
publication, and (b) any proposed Scientific Publication comprising a formal scientific abstract or poster at least [...***...] prior to its intended publication. The Reviewing Party shall have the right (i) to request in good faith
a delay in the Scientific Publication in order to protect patentable information; and (ii) to require the Publishing Party to remove from the Scientific Publication the Reviewing Party’s Confidential Information. If the Reviewing
Party requests a delay pursuant to clause (i) of the preceding sentence, the Publishing Party shall delay the Scientific Publication for a period of [...***...] from such request to enable patent applications to be filed protecting each
Party’s rights in such information. Upon the expiration of the applicable period specified above in this Section 6.4, the Publishing Party shall be free to proceed with the Scientific Publication as transmitted to the Reviewing Party,
except to the extent that the Reviewing Party has exercised its rights under clause (i) or (ii) of the second preceding sentence. The foregoing shall not apply to the following Scientific Publications that may be submitted or
resubmitted for publication after the Effective Date without Licensee having any rights regarding thereto as a Reviewing Party: (x) [...***...], and (y) a proposed Scientific Publication by [...***...]; provided,
however, that Satiogen agrees to provide Licensee the opportunity to review and comment upon the proposed Scientific Publication in clause (y) above for a period of [...***...], such period to begin at least [...***...] prior to
its intended submission for publication, and Satiogen shall not unreasonably reject Licensee’s comments thereto. 
 Article 7

 REPRESENTATIONS, WARRANTIES, COVENANTS, AND DISCLAIMERS 

7.1      No Litigation.    Each Party represents and warrants to the
other Party that, to the best of its knowledge as of the Effective Date, there is no litigation, proceeding or investigation pending or threatened against or involving such Party in any court or before any agency or

  
 27 

 
regulatory body which could adversely affect such Party’s ability or right to carry out the transactions contemplated by this Agreement. 

7.2      Compliance with Applicable Laws; No Debarment.    During the
term of this Agreement, each Party shall comply with all Applicable Laws. In addition to the foregoing, each Party represents and warrants to the other that it will comply at all times with the provisions of the Generic Drug Enforcement Act of 1992
and upon request each Party will certify in writing to the other Party that neither such Party, its employees, nor any Person providing services for such Party under this Agreement has been debarred under the provisions of such Act. 

7.3      Corporate Existence.    As of the Effective Date,
each Party represents and warrants to the other that it is a company duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is formed. 

7.4      Authority to Execute and Perform.    As of the Effective
Date, each Party represents and warrants to the other that it: 

(a)      has the power and authority and the legal right to enter into
this Agreement and perform its obligations hereunder; 
 (b)      has
taken all necessary company action on its part required to authorize the execution and delivery of this Agreement; and 

(c)      has duly executed and delivered the Agreement, which constitutes
a legal, valid, and binding obligation of it and which is enforceable against it in accordance with the Agreement’s terms. 

7.5      Representations and Warranties Regarding Securities Issuances. 

(a)      Licensee Representations and
Warranties.    Licensee represents and warrants to Satiogen that the Series A-1 Shares and the Common Shares, when issued, sold and delivered in accordance with the terms and conditions set forth in this Agreement,
will be validly issued, fully paid and non-assessable, and free of restrictions on transfer other than restrictions on transfer under the Transaction Agreements, applicable state and federal securities laws and liens or encumbrances created by or
imposed by Satiogen. 
 (b)      Satiogen Representations and
Warranties.    Satiogen represents and warrants to Licensee that: 

(i)      Purchase Entirely for Own Account.    The
Series A-1 Shares and the Common Shares to be acquired by Satiogen will be acquired for investment for Satiogen’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and Satiogen has no
present intention of selling, granting any participation in, or otherwise distributing the same. Satiogen does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participations to such
Person or to any third Person, with respect to any of the Series A-1 Shares or the Common Shares. 

  
 28 

 (ii)      Disclosure of
Information.    Satiogen has had an opportunity to discuss Licensee’s business, management, financial affairs and the terms and conditions of the offering of the Series A-1 Shares and the Common Shares with
Licensee’s management. 
 (iii)     Restricted
Securities.    Satiogen understands that the Series A-1 Shares and the Common Shares have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), by reason
of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of Satiogen’s representations as expressed herein. Satiogen
understands that the Series A-1 Shares and the Common Shares are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, Satiogen must hold such shares indefinitely unless they are
registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. Satiogen acknowledges that Licensee has no obligation to register or
qualify the Series A-1 Shares or the Common Shares, or any shares into which such shares may be converted, for resale except as set forth in the Transaction Agreements. Satiogen further acknowledges that if an exemption from registration or
qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Series A-1 Shares and the Common Shares, and on requirements relating to Licensee which
are outside of the Satiogen’s control, and which Licensee is under no obligation and may not be able to satisfy. 

(iv)      No Public Market.    Satiogen understands
that no public market now exists for the Series A-1 Shares or the Common Shares, and that Licensee has made no assurances that a public market will ever exist for such shares. 

(v)      Legends.    Satiogen understands that the
stock certificates for the Series A-1 Shares and the Common Shares and any securities issued in respect of or exchange for such shares, may bear one or all of the following legends 

(1)      “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION
STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.” 

(2)      Any legend set forth in, or required by, the other Transaction
Agreements. 

  
 29 

 (3)      Any legend
required by the securities laws of any state to the extent such laws are applicable to such shares represented by the certificate so legended. 

(vi)      Accredited Investor.    Satiogen is an
accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. 

7.6      Additional Satiogen Representations, Warranties and
Covenants.    Satiogen represents, warrants and covenants to Licensee that: 

(a)      Satiogen owns all right, title and interest in and to the
Licensed Patents on Exhibit A, free and clear of all encumbrances, security interests, options and licenses, and Satiogen has the authority to direct the prosecution and maintenance of such Licensed Patents. The Licensed Patents listed on
Exhibit A include all of the Patent Rights owned or Controlled by Satiogen or its Affiliates related to the Programs. The Licensed Patents have been prosecuted and maintained in accordance with all Applicable Laws, and Satiogen is not aware
of any prior art, prior disclosure or other event or circumstance that would reasonably be expected to adversely affect the patentability, validity or enforceability thereof; 

(b)      To Satiogen’s knowledge, the practice of the Licensed
Patents and Licensed Know-How as contemplated under this Agreement will not infringe the Patent Rights or other intellectual property rights of any Third Party. Neither Satiogen nor any of its Affiliates has received notice from any Third Party
claiming that the practice of the Licensed Patents or development, manufacture, use, sale, offer for sale or import of any Licensed Product infringes the Patent Rights or other intellectual property rights of any Third Party. During the term of this
Agreement, Satiogen shall promptly notify Licensee in writing upon learning of any such claim; 

(c)      To Satiogen’s knowledge, there is no use, infringement or
misappropriation of the Licensed Patents or Licensed Know-How in derogation of the rights granted to Licensee under this Agreement; 

(d)      To Satiogen’s knowledge there are no investigations,
inquiries, actions or other proceedings pending before the FDA with respect to the ASBTi Program, TGR5 Program or Licensed Products, and Satiogen has not received written notice threatening any such investigation, inquiry, action or other
proceeding. During the term of this Agreement, Satiogen shall promptly notify Licensee in writing upon learning of any such actual or threatened investigation, inquiry, action or proceeding; 

(e)      Satiogen has not withheld any information related to the ASBTi
Program, TGR5 Program, or Licensed Products, including, but not limited to, preclinical and clinical data, regulatory filings and regulatory communications, that would reasonably be expected to be material to Licensee’s decision to enter into
this Agreement; 
 (f)      Satiogen has not granted to any Third Party
or Affiliate any license or other right with respect to the Licensed Patents or Licensed Know-How. During the term of this Agreement, Satiogen shall not grant any rights inconsistent with the rights and

  
 30 

 
licenses granted herein, and Satiogen shall not assign the Licensed Patents or Licensed Know-How except to a permitted assignee of this Agreement pursuant to Section 10.10; and 

(g)      Satiogen has obtained the assignment of all interests and all
rights of any and all Third Parties (including employees and independent contractors) and Affiliates involved in the creation of the Licensed Patents and Licensed Know-How, and Satiogen has taken reasonable measures to protect the confidentiality of
the Licensed Know-How. 
 7.7      No Implied Warranties.    Except
as expressly set forth in this Agreement, neither Party makes any representation or warranty, express or implied, with respect to the subject matter hereof or the transactions contemplated hereby. 

Article 8 

INDEMNIFICATION 

8.1      Indemnification. 

(a)      Licensee’s Obligation.    Except
to the extent such Damages are due to gross negligence or willful misconduct or breach of any representation, warranty or covenant in this Agreement by Satiogen, its Affiliates or their officers, directors, employees or agents, Licensee shall
defend, indemnify and hold harmless Satiogen and its Affiliates and their officers, directors, employees and agents against any and all Damages incurred by any of them resulting from or arising out of: 

(i)      any gross negligence, willful misconduct or breach of any
representation, warranty or covenant made by Licensee in this Agreement; or 

(ii)     the handling, possession, development, manufacturing, marketing,
distribution, promotion, sale or use of Licensed Products or any other use of the Licensed Patents or Licensed Know-How by Licensee or its Affiliates or sublicensees. 

(b)      Satiogen’s Obligation.    Except to the
extent such Damages are due to gross negligence or willful misconduct or breach of any representation, warranty or covenant in this Agreement by Licensee, its Affiliates or their officers, directors, employees or agents, Satiogen shall defend,
indemnify and hold harmless Licensee, its Affiliates and their officers, directors, employees and agents against any and all Damages incurred by any of them resulting from or arising out of: 

(i)      any gross negligence, willful misconduct or breach of any
representation, warranty or covenant made by Satiogen in this Agreement; 

(ii)     the handling, possession, development, manufacturing, marketing,
distribution, promotion, sale or use of Licensed Products or any other use of the Licensed Patents or Licensed Know-How by Satiogen or its Affiliates; and 

  
 31 

(iii)      any activities conducted under any license
granted to Satiogen under Section 5.4(b). 
 8.2      Notice and Opportunity to
Defend. 
 (a)      Notice.    Promptly
after receipt by a Party hereto of notice of any claim which could give rise to a right to indemnification pursuant to Section 8.1, such Party (the “Indemnitee”) will give the other Party (the
“Indemnifying Party”) written notice describing the claim in reasonable detail. The failure of an Indemnitee to give notice in the mariner provided herein will not relieve the Indemnifying Party of its obligations under this Article
8, except to the extent that such failure to give notice materially prejudices the Indemnifying Party’s ability to defend such claim. 

(b)      Defense of Action.    In case any
action that is subject to indemnification under this Article 8 shall be brought against an Indemnitee and it shall give written notice to the Indemnifying Party of the commencement thereof, the Indemnifying Party shall be entitled to participate
and, if it so desires, to assume the defense with counsel reasonably satisfactory to such Indemnitee. After notice from the Indemnifying Party to the Indemnitee of its election to assume the defense, the Indemnifying Party shall not be liable to
such Indemnitee under this Article 8 for any fees of other counsel or any other expenses, in each case subsequently incurred by such Indemnitee in connection with the defense. 

(c)      Indemnitee’s Separate
Counsel.    Notwithstanding the foregoing, the Indemnitee shall have the right to employ separate counsel and to participate in the defense of such action, and the Indemnifying Party shall bear the reasonable fees, costs and
expenses of such separate counsel if: (i) the use of counsel chosen by the Indemnifying Party to represent the Indemnitee would present such counsel with a conflict of interest, and the Indemnifying Party does not elect to engage new counsel
without such a conflict; (ii) the Indemnifying Party shall not have employed counsel reasonably satisfactory to the Indemnitee to represent the Indemnitee within a reasonable time after notice of the institution of such action; or
(iii) the Indemnifying Party shall authorize the Indemnitee in writing to employ separate counsel at the Indemnifying Party’s expense. 

(d)      Settlement.    If an Indemnifying Party
assumes the defense of such action, no compromise or settlement thereof may be effected by the Indemnifying Party without the Indemnitee’s written consent, which consent shall not be unreasonably withheld or delayed, unless there is no finding
or admission of any violation of law or any violation of the rights of the Indemnitee and no effect on any other claims that may be made against the Indemnitee. In any event, the Indemnitee and the Indemnifying Party may participate, at their own
expense, in the defense of such asserted claim. The Indemnifying Party shall not be liable for any settlement amounts if the settlement is effectuated by the Indemnitee without the Indemnifying Party’s prior written consent, which consent shall
not be unreasonably withheld or delayed. 

  
 32 

 (e)      Conduct of
Defense.    Notwithstanding anything to the contrary in this Section 8.2, the Party conducting the defense of a claim will (1) keep the other Party informed on a reasonable and timely basis as to the status of the
defense of such claim (but only to the extent such other Party is not participating jointly in the defense of such claim), and (2) conduct the defense of such claim in a prudent manner. 

8.3      Non-Waiver of Indemnification Rights.    Each Indemnified
Party’s rights under this Article 8 will not be deemed to have been waived or otherwise affected by such Indemnified Party’s waiver of the breach of any representation, warranty, agreement or covenant contained in or made pursuant to this
Agreement, unless such waiver expressly and in writing also waives any or all of the Indemnified Party’s right under this Article 8. 

Article 9 
 TERM AND
TERMINATION 
 9.1      Term.    The term of this Agreement
will begin upon the Effective Date and, unless sooner terminated under this Article 9, will continue in full force and effect until the expiration of the last-to-expire Valid Claim of the Licensed Patents. Upon expiration of this Agreement, Licensee
will have a fully paid up, perpetual, irrevocable license under the ASBTi Know-How and TGR5 Know-How, as applicable. 

9.2      Termination by Either Party for Material
Breach.    Upon any material breach of this Agreement by either Party, the non-breaching Party may, at its option, terminate this Agreement upon ninety (90) days written notice to the breaching Party. Such
termination shall become effective at the end of such ninety (90) day period unless the breaching Party cures such breach or violation during such ninety (90) day period; provided, however, in the case of a breach or violation that cannot
be cured within such ninety (90) day period, the non-breaching Party may terminate this Agreement following such ninety (90) day period only if the breaching Party shall have failed to commence substantial remedial actions within such
ninety (90) day period and to use best efforts to pursue the same (any failure to cure such breach or violation under this Section 9.2 shall be deemed an “Uncured Breach”). Any right to terminate under this
Section 9.2 shall be stayed and the cure period tolled in the event that, during any cure period, the breaching Party shall have initiated dispute resolution in accordance with Section 10.14 with respect to the alleged breach, which stay
and tolling shall last so long as the breaching Party diligently and in good faith cooperates in the prompt resolution of such dispute resolution proceedings. Each Party shall be entitled to offset, against amounts payable to the other Party under
this Agreement, any amounts of Damages determined, in a final decision by the applicable court action or other legal proceeding, to be owed to such Party by the other Party based on the other Party’s material breach of this Agreement. 

Notwithstanding the foregoing, to the extent a material breach of this Agreement by Licensee affects Licensee’s
performance and Satiogen’s rights under this Agreement as it relates to one or more countries, but not all countries, Satiogen may only terminate this Agreement in accordance with this Section 9.2 as to the affected country or countries only,
and in such case this Agreement will remain in full force and effect with respect to the countries that are not terminated. Further, to the extent a material breach of this Agreement by Licensee affects 

  
 33 

 
Licensee’s performance and Satiogen’s rights under this Agreement as it relates to one of the Licenses but not the other, Satiogen may only terminate this Agreement in accordance with
this Section 9.2 as to the affected one of the Licenses in the affected country, and in such case this Agreement will remain in full force and effect with respect to the non-affected one of the Licenses that is not terminated in such country.

 9.3      Rights upon Termination by Satiogen.    If Satiogen
terminates this Agreement under Section 9.2, or Licensee terminates this Agreement under Section 9.4(a), then the following will take effect upon the effective date of such termination: 

(a)      Reversion of Licensed Patents and Licensed Know-How and Assignment
of Sublicenses.    All rights under the Licensed Patents and the Licensed Know-How granted by Satiogen to Licensee pursuant to Article 2 will terminate and all rights granted therein will immediately revert to Satiogen;
provided, however, that if the termination relates only to a specific country or a specific one of the Licenses in a specific country, then only the license pertaining to such country or specific one of the Licenses, as applicable, in such country
will revert to Satiogen hereunder. Any sublicense granted by Licensee hereunder shall survive such termination and automatically convert to a direct license between Satiogen and the sublicensee, provided such sublicense is consistent with, and not
in conflict with, the terms of this Agreement in any material respect. 

(b)      License to Licensee Improvements and Licensee
Inventions.    Subject to the immediately following sentence, Licensee will grant to Satiogen a world-wide license, with the right to sublicense, under Licensee Improvements and Licensee Inventions (in each case solely
to the extent Controlled by Licensee as of the effective date of such termination) to develop, make, have made, use, offer to sell, sell and import Licensed Products in the Field solely in the country or countries in which Licensee’s rights to
Licensed Products were so terminated and solely with respect to one of the ASBTi License or TGR5 License, as applicable, in such country or countries for which Licensee’s rights were so terminated. The Parties shall negotiate in good faith
reasonable compensation and other terms, including without limitation exclusivity (or non-exclusivity) and a reasonable a royalty amount, from Satiogen to Licensee for such license. 

9.4      Additional Termination by Licensee. 

(a)      Licensee may terminate this Agreement, or the provisions of this
Agreement with respect to one of the Licenses, but not the other, or with respect to both Licenses, for any reason or no reason upon [...***...] written notice to Satiogen. 

(b)      If Licensee terminates this Agreement under Section 9.4(a),
then the terms of Section 9.3 shall apply. 
 9.5      Partial Termination Following
Expiration of Exclusivity.    Either Party may terminate this Agreement with respect to the ASBTi License or the TGR5 License, as applicable, by providing written notice to the other Party (with immediate effect) if: 

  
 34 

 (a)      with respect to the
ASBTi License, the ASBTi Exclusivity Period expires without occurrence of the ASBTi Effective Event; or 

(b)      with respect to the TGR5 License, the TGR5 Exclusivity Period
expires without occurrence of the TGR5 Effective Event. 
 Upon the effectiveness of any such termination, each Party’s
obligations with respect to the terminated Program or License (including applicable ASBTi Patents, TGR5 Patents, ASBTi Know-How and TGR5 Know-How) under this Agreement shall cease and be of no further force and effect. 

9.6      Residual Obligations upon Termination. 

(a)      Termination of this Agreement (including any partial termination
as to one or the other of the Licenses) for any reason will not relieve either Party of any obligation or liability accruing prior thereto and will be without prejudice to the rights and remedies of either Party with respect to any antecedent breach
of the provisions of this Agreement. Without limiting the generality of the foregoing or the rights upon termination set forth in Section 9.3, no termination of this Agreement, whether by lapse of time or otherwise, will serve to terminate the
rights and obligations of the Parties hereto with respect to this Agreement as it relates to the Licenses or jurisdiction(s) for which this Agreement has not been terminated. The provisions of Sections 2.6, 3.5(a), 3.6, 3.7, 5.3, 5.4 (provided that
no Gedulin Inventions conceived, reduced to practice, made or developed after the date of termination or expiration shall be considered Licensee Inventions for any purpose) and 7.7 and Articles 1 (to the extent required to enforce other surviving
rights and/or obligations), 6 (excluding Section 6.4), 8, 9 and 10 are intended to and shall survive termination or expiration of this Agreement in accordance with the terms of such Articles or Sections. 

(b)      Within [...***...] following the termination or expiration
of this Agreement, each Party shall deliver to the other Party any and all Confidential Information of the other Party in its possession, except that the terminating Party may retain such Confidential Information to the extent necessary or useful
for the practice of its surviving license(s) hereunder (if any), and except for one (1) copy of each item of the other Party’s Confidential Information which may be retained in confidential files solely for record purposes. 

9.7      Certain Remedies for Satiogen Uncured Breach.    In the
event of an Uncured Breach by Satiogen of Satiogen’s obligations set forth in Section 5.2(f), the royalties with respect to all Licensed Products and amounts payable by Licensee under Section 3.3(i) each immediately shall be reduced
by [...***...] of the amounts otherwise owed by Licensee under this Agreement until such time as Satiogen has cured such Uncured Breach. For clarity, such reduction shall be cumulative with, and shall not limit the application of, any other
reduction or offset to which Licensee is or may be entitled under this Agreement. Without limiting the foregoing or any other remedy to which Licensee may be entitled, in the event Licensee takes action to enforce Section 7.6(f) of this
Agreement on account of an Uncured Breach thereof by Satiogen and Licensee prevails with respect to such enforcement (in a final decision by the 

  
 35 

 
applicable court action or other legal proceeding, or by settlement or otherwise), Satiogen shall pay all reasonable out-of-pocket costs and expenses of Licensee and its Affiliates, including
attorneys’ fees, incurred in connection with such enforcement. Without limiting any other remedy to which it may be entitled, upon notice to Satiogen specifying in reasonable detail the basis for such offset, Licensee may, following such time
as Licensee prevails with respect to such enforcement (in a final decision by the applicable court action or other legal proceeding, or by settlement or otherwise), offset any amount to which it is entitled under this Section 9.7 against
amounts otherwise payable by Licensee to Satiogen pursuant to Section 3.2 or Section 3.3. 

9.8      Bankruptcy Code.    All licenses granted under this
Agreement will be deemed licenses of rights to intellectual property for purposes of Section 365(n) of the United States Bankruptcy Code and a licensee under this Agreement will retain and may fully exercise all of its rights and elections
under the United States Bankruptcy Code. 
 9.9      Additional
Remedies.    The remedies set forth in this Article 9 or elsewhere in this Agreement will be in addition to, and will not be to the exclusion of, any other remedies available to the Parties at law, in equity or under
this Agreement. 
 Article 10 

MISCELLANEOUS 

10.1      Independent Contractor.    It is understood and agreed that
the Parties shall have the status of an independent contractor under this Agreement and that nothing in this Agreement shall be construed as creating any partnership, joint venture or employer-employee relationship between the Parties or as
authorization for either Licensee or Satiogen to act as agent for the other. 

10.2      No Benefit to Others.    The representations, warranties,
covenants and agreements contained in this Agreement are for the sole benefit of the Parties and their legal representatives, successors and assigns, and they shall not be construed as conferring any rights to any Third Party. 

10.3      Force Majeure.    Each Party shall be excused from
liability for the failure or delay in performance of any obligation under this Agreement (other than payment obligation) by reason of any event beyond such Party’s reasonable control including Acts of God, fire, flood, explosion, earthquake, or
other natural forces, war, civil unrest, acts of terrorism, accident, destruction or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, any strike or labor disturbance, or any other
event similar to those enumerated above. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur.
Notice of a Party’s failure or delay in performance due to force majeure must be given to the other Party within [...***...] after its occurrence. All delivery dates under this Agreement that have been affected by force majeure shall be
tolled for the duration of such force majeure. In no event shall any Party be required to prevent or settle any labor disturbance or dispute. 

  
 36 

10.4      Amendment.    This Agreement may not be amended,
supplemented, or otherwise modified except by an instrument in writing signed by authorized representatives of the Parties. 

10.5      Entire Agreement.    This Agreement constitutes the entire
agreement and understanding relating to the subject matter of this Agreement and supersedes all previous communications, proposals, representations and agreements, whether oral or written, relating to the subject matter of this Agreement, including
the Nondisclosure Agreement dated October 31, 2010. 

10.6      Severability.    If any provision of this Agreement is held
to be illegal, invalid, or unenforceable under present or future laws effective while this Agreement remains in effect, the legality, validity and enforceability of the remaining provisions will not be affected thereby; provided,
however, that, if the absence of such provision causes a material adverse change in either the risks or benefits of this Agreement to either Party, the Parties shall negotiate in good faith a commercially reasonable substitute or replacement for
the invalid or unenforceable provision. 
 10.7      Waiver.    Any
term or provision of this Agreement may be waived at any time by the Party entitled to the benefit thereof only by a written instrument executed by such Party. No delay on the part of Satiogen or Licensee in exercising any right, power or privilege
hereunder will operate as a waiver thereof, nor will any waiver on the part of either Satiogen or Licensee of any right, power or privilege hereunder operate as a waiver of any other right, power or privilege hereunder nor will any single or partial
exercise of any right, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, power or privilege hereunder. 

10.8    Notices.    All notices required or permitted to be given under
this Agreement shall be in writing and shall be deemed given upon receipt if delivered personally or by facsimile transmission (receipt verified), telexed, mailed by registered or certified mail (return receipt requested), postage prepaid, or sent
by prepaid express courier service, to the Parties at the following addresses (or at such other address for a Party as shall be specified by the notice; provided, that notices of a change of address shall be effective only upon receipt
thereof): 
  

			
	For Licensee:	  	Lumena Pharmaceuticals, Inc.
		  	c/o A.M. Pappas & Associates, LLC
		  	P.O. Box 110287
		  	Research Triangle Park, NC 27709
		  	Attention: Michael Grey
	
	With a copy to:
		  	A.M. Pappas & Associates, LLC
		  	P.O. Box 110287
		  	Research Triangle Park, NC 27709
		  	Attention:  Ford S. Worthy

  
 37 

			
	With a further copy to:
		 	Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan LLP
		 	P.O. Box 2611
		 	Raleigh, NC 27601
		 	Attention: Christopher Capel
		
	For Satiogen:	 	Ted Greene
		 	277 Crystal Drive
		 	Frankfort, MI 49635
	
	With a copy to:
		 	Rob Ayling
		 	3924 Henry Street
		 	San Diego, CA 92103

 10.9     Governing Law.   This Agreement shall be
governed by, and construed in accordance with, the laws of the State of Delaware, United States, excluding any choice of law rules that may direct the application of the law of any other jurisdiction. However, the scope, validity and enforceability
of any patents encompassed within the scope of this Agreement shall be determined in accordance with the Applicable Laws of the countries in which such patents have issued. 

10.10   Assignability.  Except as expressly provided hereunder, neither this Agreement nor any
rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided, however, that either Party may assign this
Agreement and its rights and obligations hereunder without the other Party’s consent: (a) to the transferee or successor entity to such Party upon the transfer or sale of all or substantially all of the business of such Party to which this
Agreement relates to a Third Party, whether by merger, sale of stock, sale or transfer of assets or otherwise; or (b) to an Affiliate, provided that the assigning Party shall remain liable and responsible to the non-assigning Party hereto for
the performance and observance of all such duties and obligations by such Affiliate; provided, however, in either case that such transferee, successor entity or Affiliate (as applicable) shall deliver to the non-assigning Party a
written instrument agreeing to be bound by this Agreement. The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a Party
appearing herein will be deemed to be replaced with the name of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this section. For clarity, and without limiting the foregoing, the obligations of
Licensee under this Agreement shall be binding upon any successors and permitted assignee of Licensee, and the name of Licensee appearing herein will be deemed to be replaced with the name of Licensee’s successor or permitted assignee to the
extent necessary to carry out the intent of this section. Any assignment not in accordance with this Agreement shall be void. 

10.11   Jointly Prepared.  This Agreement will be deemed to have been drafted by both Satiogen and
Licensee and will not be construed against either Party as the draftsperson hereof. 

  
 38 

 10.12   Headings, Gender and Number.  All section and
article titles or captions contained in this Agreement and in any exhibit, schedule or certificate referred to herein or annexed to this Agreement are for convenience only, will not be deemed a part of this Agreement and will not affect the meaning
or interpretation of this Agreement. Words used herein, regardless of the number and gender specifically used, shall be deemed and construed to include any other number, singular or plural, and other gender, masculine, feminine, or neuter, as the
context requires. 
 10.13   Interpretation. All references to days in this Agreement shall mean calendar
days, unless otherwise specified. The words “include,” “includes” and “including” shall be deemed to be followed by the phrase “but not limited to” unless expressly stated otherwise. 

10.14   Dispute Resolution. 

(a)   General.   If any dispute arises relating to this Agreement, prior to instituting any
lawsuit or other dispute resolution process on account of such dispute, the Parties will attempt in good faith to settle such dispute first by negotiation and consultation between themselves, including referral of such dispute to the Chief Executive
Officer of Licensee and the Chief Executive Officer of Satiogen. If such executives are unable to resolve such dispute or agree upon a mechanism to resolve such dispute within [...***...] of the first written request for dispute resolution
under this Section 10.14, then at the request of either Party the dispute shall be submitted to non-binding mediation before a mutually acceptable mediator chosen by agreement of the parties. If disputes are not resolved through such mediation,
then either Party may seek any remedy, at law or in equity, which may be available. This provision shall not preclude any Party from seeking immediate injunctive relief in the event such Party believes that irreparable harm will occur. 

(b)   Attribution of Sublicense Revenues.   If Satiogen reasonably disputes how Licensee has
Attributed any payment on account of Sublicense Revenues, then within [...***...] of Satiogen’s receipt of the report pursuant to Section 3.5(b) describing such Attribution, Satiogen shall provide written notice of such dispute to
Licensee and the Parties shall attempt in good faith to settle such dispute first by negotiation and consultation between themselves, including referral of such dispute to the Chief Executive Officer of Licensee and the Chief Executive Officer of
Satiogen. If such executives are unable to resolve such dispute or agree upon a mechanism to resolve such dispute within [...***...] the Parties shall submit the matter to expert intervention to be resolved by one expert, to be mutually
selected by the Parties. If the Parties fail to agree on the expert within [...***...] of the written dispute notice, then the individuals nominated by each Party to serve as expert shall select a third individual to act as the expert. The
expert shall be an industry consultant with expertise and experience in product and intellectual property valuations in the human pharmaceutical industry, and shall not be an employee, director, shareholder or agent of either Party or an Affiliate
of either Party, or otherwise involved (whether by contract or otherwise) in the affairs of either Party. The intervention shall be conducted in San Diego, California. The expert shall provide a written rationale for its decision.
The expert’s decision shall be final and the Attribution determined by the expert (which shall be in compliance with Section 3.3(h)) immediately shall be binding upon the Parties under this Agreement. The intervention shall be
completed within [...***...] of selection of the expert. The costs of the intervention (exclusive of the expense of a Party in preparing for and 

  
 39 

 
participating in the intervention, all of which shall be borne by such Party) shall be shared equally by the Parties. 

10.15   Counterparts.   This Agreement may be executed in one or more counterparts, each of which
shall be an original, but all of which taken together shall constitute one and the same agreement. It shall not be necessary in making proof of this Agreement or any counterpart hereof to produce or account for any of the other counterparts. 

10.16   Schedules, Exhibits and Attachments.   Except with respect to Exhibit B, which
provisions shall not be effective unless and until set forth separately in a writing signed by the Parties in connection with the Financing, all schedules, exhibits and attachments referred to herein are intended to be and hereby are specifically
made part of this Agreement. However, if there is a conflict between a term or condition of such schedules, exhibits and attachments and this Agreement, the terms and conditions of this Agreement shall prevail. 

10.17   Further Assurances.   At any time during the term of this Agreement, Satiogen and Licensee
each will, at the request of the other Party, use reasonable efforts to (a) deliver to the other Party such records, data or other documents, consistent with the provisions of this Agreement, (b) execute, deliver or cause to be delivered,
all such assignments, consents, documents or further instruments of transfer or license, and (c) take or cause to be taken all such other actions, as a Party reasonably may deem necessary or desirable in order for such Party to obtain the full
benefits of this Agreement and the transactions contemplated hereby. 
 [signature page to follow] 

  
 40 

 [Signature Page to License Agreement] 

IN WITNESS WHEREOF, the Parties by their respective authorized
representatives, have executed this Agreement. 
  

			
	SATIOGEN PHARMACEUTICALS, INC.

 
			
		
	By:	 	 /s/ Howard E. Greene

			
		
	Printed:	 	Howard E. Greene, Jr.
		
	Title:	 	Chairman of the Board
	
	LUMENA PHARMACEUTICALS, INC.

 
			
		
	By:	 	 /s/ M G Grey

 
			
		
	Printed:	 	 M G Grey

 
			
		
	Title:	 	 President & CEO

 EXHIBIT A 

LICENSED PATENTS 

ASBTi Patents: 
  

					
	  

Patent Application No.
  
	  	  

Filing Date
  
	  	  

Title
  

	 [ ...***...]

 
  
	  	 [...***...]

 
	  	
[...***...]
  

 TGR5 Patents: 
  

					
	  

Patent Application No.
  
	  	  

Filing Date
  
	  	  

Title
  

	 [...***...]

 
  
	  	[...***...]	  	[...***...]

 EXHIBIT B 

CERTAIN TERMS OF SERIES A-1 SHARES 

Protective Provisions 

(i)         At any time when Series A-1 Shares are outstanding, Licensee shall
not, without the consent of the holders of a majority of the outstanding Series A-1 Shares, voting together as a separate class, amend Licensee’s Certificate of Incorporation or Bylaws if the proposed amendment would alter or change the powers,
preferences, or special rights of the Series A-1 Shares so as to affect them adversely; provided, however, that if any proposed amendment would alter or change the powers, preferences or special rights of one or more series of Licensee’s
preferred stock, including the Series A-1 Shares, so as to affect them adversely, then the shares of the series of preferred stock so affected by the amendment, including the Series A-1 Shares, shall vote together as a single class on the proposed
amendment and the Series A-1 Shares shall not be entitled to vote as a separate class on such proposed amendment, unless otherwise required by the Delaware General Corporation Law. 

Information and Board Observer Rights. 

(ii)       Delivery of Financial Statements.  As long as Satiogen owns not less
than fifty percent (50%) of the Series A-1 Shares it is receiving under this Agreement (or an equivalent amount of Common Stock issued upon conversion thereof), Licensee shall deliver to Satiogen: annual and quarterly financial statements, and
other financial information as determined by Licensee’s Board of Directors (the “Board”) and as received by any other stockholders, such as budgets and capitalization information; provided, however, that Licensee shall not be
obligated under this Section to provide information (a) that Licensee reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to
Licensee) or (b) the disclosure of which would adversely affect the attorney-client privilege between Licensee and its counsel. Notwithstanding the foregoing, Licensee may cease providing the information set forth in this Section during the
period starting with the date sixty (60) days before Licensee’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the United States Securities and Exchange
Commission rules applicable to such registration statement and related offering; provided that Licensee’s obligations under this Section shall be reinstated at such time as Licensee is no longer actively employing its commercially reasonable
efforts to cause such registration statement to become effective. 
 (iii)       Board
Observer Rights.  If Ted Greene is not a member of the Board, and as long as Satiogen owns not less than fifty percent (50%) of the Series A-1 Shares it is receiving under this Agreement (or an equivalent amount of Common Stock
issued upon conversion thereof), Licensee shall invite a representative of Satiogen to attend all meetings of its Board in a nonvoting observer capacity and, in this respect, shall give such representative copies of all notices, minutes, consents,
and other materials that it provides to its directors; provided, however, that such representative shall agree in form acceptable to Licensee to hold in confidence and trust and to act in a fiduciary manner with respect to all information so
provided; and provided further, that Licensee reserves the right to withhold any information and to exclude 

 
such representative from any meeting or portion thereof if access to such information or attendance at such meeting could adversely affect the attorney-client privilege between Licensee and its
counsel or result in disclosure of trade secrets or a conflict of interest. (Note: Board observer rights also to include so-called pay-to-play provision whereby right terminates if Satiogen does not fund any commitment under the Financing; to be
conformed to Transaction Agreements.) 
 (iv)       Termination of Information and Board
Observer Rights.  The covenants set forth in Section (ii) and Section (iii) shall terminate and be of no further force or effect (a) when Licensee first becomes subject to the periodic reporting requirements of
Section 12(g) or 15(d) of the Securities Exchange Act of 1934, as amended, or successor provisions or (b) upon a Deemed Liquidation Event, as such term (or comparable term) is defined in Licensee’s Certificate of Incorporation,
whichever event occurs first. 
 (v)       Confidentiality.  Satiogen agrees
that it will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in Licensee) any confidential information obtained from Licensee pursuant to the terms of this Agreement (including
information obtained pursuant to Sections (ii) and (iii) above, and notice of the Licensee’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general
(other than as a result of a breach of this Section by Satiogen), (b) is or has been independently developed or conceived by Satiogen without use of Licensee’s confidential information, or (c) is or has been made known or disclosed to
Satiogen by a third party without a breach of any obligation of confidentiality such third party may have to Licensee; provided, however, that Satiogen may disclose confidential information (w) to its attorneys, accountants, consultants, and
other professionals to the extent necessary to obtain their services in connection with monitoring its investment in Licensee; (x) to any prospective purchaser from Satiogen of capital stock of Licensee, if such prospective purchaser agrees in
form acceptable to Licensee to be bound by the provisions of this Section (unless Licensee determines that such disclosure may result in disclosure of trade secrets or a conflict of interest, or if the receiving party is a competitor of Licensee);
(y) to any Affiliate, partner, member, stockholder, or wholly owned subsidiary of Satiogen in the ordinary course of business, provided that Satiogen informs such Person that such information is confidential and directs such Person to maintain
the confidentiality of such information; or (z) as may otherwise be required by law, provided that Satiogen promptly notifies Licensee of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]